

PALM INTRANETKu
Day : WednesdayDate: 8/9/2006
Time: 15:11:39**Inventor Information for 10/809637**

Inventor Name	City	State/Country
FENG, JUN	CARLSBAD	CALIFORNIA
GWALTNEY, STEPHEN L.	SAN DIEGO	CALIFORNIA
KALDOR, STEPHEN W.	SAN DIEGO	CALIFORNIA
STAFFORD, JEFFREY A.	SAN DIEGO	CALIFORNIA
WALLACE, MICHAEL B.	SAN DIEGO	CALIFORNIA
ZHANG, ZHIYUAN	SAN DIEGO	CALIFORNIA

[Appn Info](#) [Contents](#) [Petition Info](#) [Atty/Agent Info](#) [Continuity/Reexam](#) [Foreign](#) [Help](#) [Logout](#)

Search Another: Application# or Patent#
 PCT / / or PG PUBS #
 Attorney Docket #
 Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L3	1630	544/292, 544/283, 544/284, 544/286	US-PGPUB; USPAT	OR	OFF	2006/08/09 15:07

10/809,637 Page 3

containing 1 : 13 :

(2)


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

Narrow
Search Jan-86



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 13:38:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1745 TO ITERATE

100.0% PROCESSED 1745 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 32395 TO 37405
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 13:38:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 34990 TO ITERATE

100.0% PROCESSED 34990 ITERATIONS 76 ANSWERS
SEARCH TIME: 00.00.05

L3 76 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL

Habte

08/09/2006

FULL ESTIMATED COST	ENTRY	SESSION
	166.94	167.15

FILE 'CAPLUS' ENTERED AT 13:38:27 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006 (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 24 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006142762 CAPLUS
 DOCUMENT NUMBER: 144:233087

TITLE: Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands.

INVENTOR(S): Lin, Chu-Chung; Chen, Hong-Chuan; Lee, Kuang-Yuan;

Huang, Ying-Huey; Fan, Yang-Ping; Xiang, Yibin

PATENT ASSIGNEE(S): Taigen Biotechnology, Taiwan

SOURCE: U.S. Pat. Appl. Publ., 60 pp.

CODEN: USXICO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006036093	A1	20060316	US 2005-204792	20050816
WO 2006023381	A1	20060302	WO 2005-0628679	20050811


W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EO, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MU, MM, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ,
 CP, CG, CI, CM, GA, GN, GO, GW, GU, MR, NB, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-601776P P 20040816

OTHER SOURCE(S): MARPAT 144:233087

GI

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



II

AB Title compds. [I]: A = aryl, heteroaryl; X = S, NR1; L1 = CRb1Rb2, alkylene, heteroalkylene, null; L2 = CRc1, null; L3, L4 = CO, SO2, CO2, COCH2, SO2CH2, alkylene, heteroalkylene, etc.; L3L4N, L1L3N = atoms

to form 5-membered ring; R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R2 = R1, etc.; R2L2 = null; R3, R4 = R1, halo, cyano, amidino, guanidino, ureido, etc.; R1, Rb1, Rb2, Rc1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, etc.). were prepared

Thus, title compound (II) was prepared in 7 steps from anthranilic acid, propionyl chloride, 4-ethoxyaniline, BocNHCH2CH2NH2, 3,4-dichlorophenylacetic acid, and (Me2S)2C=NCN. 138 I inhibited activation of CXCR3 using a Delphi GTP binding kit with IC50 < 1 μM.


IT 876014-72-1 876015-29-1P 876015-32-6P
 876015-33-7P 876015-44-OP 876015-45-1P
 876015-77-9P 876015-78-OP 876015-79-1P
 876015-95-1P 876016-03-4P 876016-08-9P
 876016-21-6P 876016-37-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)


RN 876014-72-1 CAPLUS

CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876015-29-1 CAPLUS
 CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 876015-32-6 CAPLUS
 CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-3,4-dichloro-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 876015-33-7 CAPLUS
 CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876015-44-0 CAPLUS
 CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-45-1 CAPLUS
 CN Benzenecacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quiazolinyl]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876015-77-9 CAPLUS
CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-78-0 CAPLUS
CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-79-1 CAPLUS


L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876016-08-9 CAPLUS
CN Benzeneacetamide, N-[3-amino-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3,4-dichloro-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 876016-21-6 CAPLUS
CN Benzeneacetamide, N-[3-amino-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876016-37-4 CAPLUS
CN Benzeneacetamide, N-[2-amino-2-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2-aminoethyl)-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876015-95-1 CAPLUS
CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 876016-03-4 CAPLUS
CN Decanamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 876016-71-6P 876016-75-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)

RN 876016-71-6 CAPLUS

CN Carbamic acid, ((3R)-3-amino-3-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876016-75-0 CAPLUS

CN Benzeneacetamide, N-[3-amino-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-

-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006132072 CAPLUS
 DOCUMENT NUMBER: 144:128993
 TITLE: Preparation of fused pyrimidine derivatives as CXCR3 receptor modulators for prevention and treatment of inflammatory and immuno regulatory conditions
 INVENTOR(S): Fu, Zice; Johnson, Michael G.; Li, An-Rong; Marcus, Andrew P.; Medina, Julio C.; Bergeron, Philippe; Chen, Jason; Xiaoqi; Deignan, Jeffrey; Du, Xiaohui; Duquette, A.; Gustin, Darin; Mihalic, Jeffrey T.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004915	A1	20060112	WO 2005-US23251	20050628
M: AB, AG, AL, AM, AT, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006069099	A1	20060330	US 2005-168005	20050627
PRIORITY APPLN. INFO.: US 2004-583901P P 20040628				
OTHER SOURCE(S): MARPAT 144:128993 GI				

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compd. I [A1, A4 = independently CH and derive., N; Q = a bond, hetero/alkylene, CO, CH₂CO, etc.; L = a bond, alkylene; X = CH₂, SO₂, CO; Ra = H, OH and derivs., halo, etc.; n = 0-4; R1 = hetero/aryl; R2 = H, halo, hetero/alkyl, etc.; or R2 may be combined with L to form a 5- to 8-membered ring containing 1-3 heteroatoms; R3 = absent, H, SRS, NH₂O₂R₅, piperidin-4-yl, etc.; R3 may be combined with R2 to form a 4- to 8-membered ring containing 1-3 heteroatoms; R5 = hetero/alkyl, hetero/aryl; R4 = hetero/alkyl, hetero/aryl, etc.; and their pharmaceutically acceptable salts and prodrugs] were prepared as chemokine receptor CXCR3 modulators (no data).

Two biol. assays are given. Thus, reductive amination of 1-isopropylpiperazine-4-carboxaldehyde with 2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)-(3H)-quinazolinone, and acylation of the amine intermediate with [4-fluoro-3-(trifluoromethyl)phenyl]acetic acid gave quinazolinone II. I are useful for the treatment of inflammatory and immune disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, psoriasis,


and inflammatory bowel disease (no data). IT 873191-29-8P, [(R)-2-Amino-2-[3-(4-ethoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intermediate; preparation of fused pyrimidine derive. as CXCR3 receptor modulators for prevention and treatment of inflammatory and immune disorders and diseases)

IT 873191-29-8P, [(R)-2-Amino-2-[3-(4-ethoxyphenyl)-4-oxo-3,4-dihydro-4-oxo-2-(quinazolinyl)ethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Habte

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 473720-85-3 873191-38-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of fused pyrimidine derivs. as CXCR3 receptor modulators for prevention and treatment of inflammatory and immune disorders and diseases)
 RN 473720-85-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminoethyl]-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 873191-38-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminoethyl]-3-[(4-(2,2,2-trifluoroethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS FORMAT


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1329696 CAPLUS
 DOCUMENT NUMBER: 144:45525
 TITLE: Methods for treating mast cell disorders
 INVENTOR(S): Hayflick, Joel S.; Pefaur, Noah; Puri, Kamal D.; Tino, William
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120511	A1	20051222	WO 2005-US19558	20050604
MW: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MM, MW, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, GU, HR, NE, SN, TD, TO	PRIORITY APPLN. INFO.: US 2004-576947P	P 20040604	


OTHER SOURCE(S): MARPAT 144:45525
 AB The invention provides methods of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase delta (PI3K δ). The invention also provides methods for treating or preventing a condition associated with undesirable mast cell activity in an individual comprising administering an effective amount of a selective PI3K δ inhibitor.
 IT 871585-37-4 871585-74-9 871585-75-0
 871585-80-7
 RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods for treating mast cell disorders)
 RN 871585-37-4 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[5-amino-1-(6-(dimethylamino)-9H-purin-9-yl)methyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-74-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[5-amino-1-(6-(dimethylamino)-9H-purin-9-yl)methyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-75-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[5-amino-1-[(2-amino-1H-purin-6-yl)amino]pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-80-7 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[4-amino-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1259353 CAPLUS
DOCUMENT NUMBER: 144:22759


TITLE: Preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
INVENTOR(S): Fowler, Kerry W.; Huang, Danwen; Kesicki, Edward A.; Ooi, Hua Chee; Oliver, Amy R.; Ruan, Puqiang; Treisberg, Jennifer
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 247 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113556	A1	20051201	WO 2005-016778	20050512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZR				
RM: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CH, GA, GH, GO, GW, ML, MR, NE, SN, TD, TG				
WO 2005113554	A2	20051201	WO 2005-016661	20050512
WO 2005113554	A3	20060406		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZR				
RM: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CH, GA, GH, GO, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-570784P P 20040513

OTHER SOURCE(S): MARPAT 144:22759
G1

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB: Quinazolinone derivs. of formula I [X, Y = N, (substituted) CH; Z = NH, O; R1-R3 = H, halo, alkyl; R4 = H, halo, OH, alkoxy, CN, acyl, etc.; R5 = alkyl, Ph, CH2C(=O)bond.CH, etc.; R6 = H, halo, (substituted) NH2; R7 = alkyl, halo, CF3, etc.; R8 = alkylene] are prepared that inhibit PI3Kδ activity, and methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compds. also are disclosed.

Thus, I was prepared, and had EC50 value of 1.6 nM in human B lymphocyte assay.

IT: 870281-25-7P 870281-26-6P 870281-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN: 870281-25-7 CAPLUS

CN: 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN: 870281-26-8 CAPLUS
CN: 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-[(2-amino-1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN: 870281-32-6 CAPLUS
CN: 4(3H)-Quinazolinone, 2-[(1S)-4-amino-1-[(2-amino-1H-purin-6-ylamino)butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT: 870282-58-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN: 870282-58-9 CAPLUS

CN: 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




IT: 870280-87-8P 870281-80-4P 870281-86-0P
870281-97-3P 870282-35-2P 870282-41-0P
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN: 870280-87-8 CAPLUS


CN: 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 870281-80-4 CAPLUS
 CN Carbamic acid, [(1S)-4-amino-1-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-86-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-97-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminooethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:857326 CAPLUS
 DOCUMENT NUMBER: 141:309639
 TITLE: Dipeptidyl peptidase inhibitors
 INVENTOR(S): Feng, Jun; Gwaltney, Stephen L.; Kaldor, Stephen W.; Stafford, Jeffrey A.; Wallace, Michael B.; Zhang, Zhiyuan
 PATENT ASSIGNEE(S): Syrrx, Inc., USA
 SOURCE: PCT Int. Appl., 244 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087053	A2	20041014	WO 2004-US9217	20040324
WO 2004087053	C1	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MM, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, QO, GW, ML, MR, NE, SN, TD, TG				
CA 2518465	AA	20041014	CA 2004-2518465	20040324
US 2004242568	A1	20041202	US 2004-809636	20040324
US 2004242566	A1	20041202	US 2004-809638	20040324
US 2004259870	A1	20041223	US 2004-809637	20040324
US 2005004117	A1	20050106	US 2004-809635	20040324
EP 1608317	A2	20051228	EP 2004-758366	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.:			US 2003-457785P	P 20030325
		WO 2004-US9217		W 20040324

OTHER SOURCE(S): MARPAT 141:309639
 GI




AB Dipeptidyl peptidase IV inhibitors I [Q = CO, SO, SO2, C:NR5; R1 = 2R6; Z = moiety providing 1-6 atom separation between R6 and ring; R2 = (substituted)3-7-membered ring; R3,R4 = taken together form a (substituted)5-6-membered ring; R5 = H, (substituted)alkyl, cycloalkyl,

Habte


08/09/2006

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 870282-35-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-amino-3-butynyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 870282-41-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


IT 22126-97-2 CAPLUS

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc.; R6 = (substituted)C3-7-cycloalkyl or aryl] are disclosed. Thus, 2-[2-(3-aminopiperidin-1-yl)-6,7-dimethoxy-4-oxo-4H-quinazolin-3-ylmethyl]benzonitrile (I; R1 = 2-cyanophenylmethyl; R2 = 3-aminopiperidin-1-yl; R3,R4 = dimethoxyphenyl) was synthesized. This compd. exhibited enhanced stability in rat liver microsomes.


IT 22126-97-2 CAPLUS
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (dipeptidyl peptidase inhibitors)
 RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 80096-35-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 769157-99-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 769158-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003-1006962 CAPLUS
 DOCUMENT NUMBER: 140:59652
 TITLE: Preparation of fused-ring pyrimidin-4(3H)-one derivatives as LXR modulators
 INVENTOR(S): Kaneko, Satoru; Watanabe, Taeiyo; Oda, Kozo; Mohan, Raju; Schweiger, Edwin J.; Martin, Richard
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan; X-Ceptor Therapeutics, Inc.
 SOURCE: PCT Int. Appl., 465 pp.
 CODEN: PIIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106435	A1	20031224	WO 2003-JP7677	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003238157	A1	20031231	AU 2003-238157	20030617
PRIORITY APPLN. INFO.:			US 2002-389662P	P 20020618
			WO 2003-JP7677	W 20030617

OTHER SOURCE(S): MARPAT 140:59652
 G1



AB The title compds. [I; A = aryl or heteroaryl; R1-R3 = H, OH, NO2, CN, etc.; or R1 and R2 together = alkyleneoxy; R4, R5 = H, OH, NH2, halo, etc.; X = H, OH, halo, alkoxy, haloalkoxy; Y = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl] which can modulate LXR function and as a result show excellent

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 anti-atherosclerotic and anti-inflammatory activity, were prepnd. and formulated. Thus, reacting anthranilic acid with phenylacetic acid in the presence of PPh3 in pyridine followed by addn. of 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol afforded 76% 2-benzyl-3-[4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl]-4(3H)-quinazolinone. The compds. I showed excellent binding affinity against LXR (biol. data were given).
 IT 637345-78-9
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused-ring pyrimidin-4(3H)-one derivs. as LXR modulators)
 RN 637345-78-9 CAPLUS
 CN 4(3H)-Quinazolinone,
 2-(amino phenylmethyl)-3-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003-737738 CAPLUS
 DOCUMENT NUMBER: 139:261313
 TITLE: Quinazolinone amide compounds as modulators of nuclear receptors, particularly farnesoid X receptor (FXR) and/or orphan nuclear receptors, and their preparation, pharmaceutical compositions, and methods of use
 INVENTOR(S): Martin, Richard; Kahl, Jeffery Dean; Platt, Brenton Todd; Griffith, Ronald X-Ceptor Therapeutics, Inc., USA
 PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076418	A1	20030918	WO 2003-US6793	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003228283	A1	20030922	AU 2003-228283	20030304
EP 1521746	A1	20050413	EP 2003-726031	20030304
R: AT, BE, CH, DE, DK, ES, PR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-363132P	P 20020307
			WO 2003-US6793	W 20030304


OTHER SOURCE(S): MARPAT 139:261313
 G1




L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB Compds., pharmaceutical compns., and methods for modulating the activity of nuclear receptors are provided. In particular, amide-containing quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors. The disclosed compds. include I ($n = 0-4$; R1 = H, (un)substituted alk(en/y)nyl, (heteroaryl), cycloalkyl(alkyl), (hetero)aralkyl, heterocyclyl(alkyl) (preceding groups designated as group A), OH or derivs., NH2 or derivs.; R2, R6 = (independently) group A, or R2R6 = (un)substituted alkylene; R4, R5 = (independently) group A, OH or derivs., NH2 or derivs., various acyl, sulfinyl, sulfonyl, or phosphoryl groups, etc.; or R4R5 (un)substituted alkylene, alkenylene, alkenylenedioxy, thioalkylenoxy, alkenylenedithioxy; including stereoisomers, racemates, mixts., and pharmaceutically acceptable derivs.; with one exception compound]. Over 300 specific compds. were prepared and claimed by name. Ten of the most preferred compds. are named. The compds. are useful for treating diseases and disorders selected from: hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, lipodystrophy, hyperglycemia, diabetes mellitus, dyslipidemia, atherosclerosis, gallstone disease, acne vulgaris, acneiform skin conditions, diabetes, Parkinson's disease, cancer, Alzheimer's disease, inflammation, immunol. disorders, lipid disorders, obesity, conditions characterized by a perturbed epidermal barrier function, hyperlipidemia, cholestasis, peripheral occlusive disease, ischemic stroke, obesity, disease states associated with elevated cholesterol levels, conditions of disturbed differentiation or excess proliferation of the epidermis or mucous membrane, and cardiovascular disorders. For instance, Me anthranilate was N-amidated with 2-chloropropionyl chloride (97%), followed by saponification of the ester (97%), and amidation/cyclocondensation of the resultant acid using p-anisidine and PC13 (72%), to give 2-(1-chloroethyl)-3-(4-methoxyphenyl)-3H-quinazolin-4-one. This intermediate chloride was aminated with methylamine in THF (99%), and the obtained secondary amine was sulfonylated with 4-tert-butylbenzenesulfonyl chloride and TEA in DCM (92%), to give preferred invention compound II.

In an FRET assay for binding to human FXR (ligand-binding domain, fused to glutathione-S-transferase), II had an EC50 of about 300 nM. In an FXR/ECRE7 co-transfection assay using African green monkey kidney cells, II had an efficacy of 190% relative to high control (chenodeoxycholic acid).
 IT 602318-88-7P, 3-(4-Methoxyphenyl)-2-methylaminomethyl-3H-quinazolin-4-one 602318-95-6P, 2-Aminomethyl-3-(4-methoxyphenyl)-3H-quinazolin-4-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate and drug candidate; prepn. of quinazolinone amides as farnesoid X and/or orphan nuclear receptor modulators)
 RN 602318-88-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 602318-95-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS FORMAT

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:833514 CAPLUS

DOCUMENT NUMBER: 137:337912

TITLE: Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): ICOS Corp., USA
 SOURCE: U.S. Pat. Appl. Publ. 86 pp., Cont.-in-part of U.S. Ser. No. 841,341.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161014	A1	20021031	US 2001-27591	20011019
US 6667300	B2	20031223		
US 6518277	B1	20030211	US 2001-841341	20010424
CA 2463294	AA	20030501	CA 2002-2463294	20020827
WO 200305075	A1	20030501	WO 2002-US27240	20020827
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, RU, ID, IL, IN, JP, KS, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UK, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, LG, ZM, BE, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1438052	A1	20040721	EP 2002-757407	20020827
R: AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IR, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1606444	A	20050413	CN 2002-825687	20020827
JP 2005509635	T2	20050414	JP 2003-537642	20020827
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
US 2003195211	A1	20031016	US 2003-337192	20030106
US 6800620	B2	20040105		
US 2004266780	A1	20041230	US 2003-697912	20031030
US 6949535	B2	20050927	US 2005-110204	20050420
US 2005261317	A1	20051124	US 2000-199655P	P 20000425
PRIORITY APPLN. INFO.:			US 2000-238057P	P 20001005
			US 2001-841341	A2 20010424
			US 2001-27591	A 20011019
			WO 2002-US27240	W 20020827
			US 2003-697912	A1 20031030

OTHER SOURCE(S): MARPAT 137:337912
 GI


L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB A method of decreasing leukocyte function comprises administration of title compds. [I; X = C(Rb)2, CH2CRb, CH:CRb; Rb = H, alkyl, aryl, heteroaryl, aralkyl, etc.; Y = null, S, SO2, NH, O, CO, CO2, NHCOCH2S; R, RI = H, alkyl, aryl, heteroaryl, halo, etc.; R1 = atoms to form a 3-4 membered alkyne, alkenylene chain; R2 = H, (substituted) alkyl, cycloalkyl, heterocycloalkyl, alkenylencycloalkyl, alkenyl, alkenylarynl, aryl, heteroaryl, etc.; A = (substituted) mono- or bicyclic ring system containing 22 N atoms and in which ≥1 ring is aromatic]. Thus, dose-dependent decrease in histamine release from basophiles when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; S connected to 6-position of purine ring; preparation given).


IT 371244-07-4P, 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- 3-(2-chlorophenyl)-5-fluoro- 371244-09-6P, 4(3H)-Quinazolinone, 2-(1-aminomethyl)-3-(2-methylphenyl)- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta)

RN 371244-07-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371244-08-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371244-09-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)- (9CI)
 (CA INDEX NAME)



L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 2002:813938 CAPLUS
 DOCUMENT NUMBER: 137:337907
 TITLE: Preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions
 INVENTOR(S): Medina, Julio C.; Johnson, Michael G.; Li, An-Rong; Liu, Jiwenn; Huang, Alan Xi; Zhu, Liusheng; Marcus, Andrew P.
 PATENT ASSIGNEE(S): Tularik Inc., USA
 SOURCE: PCT Int. Appl., 205 pp.
 CODEN: PIIXDZ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083143	A1	20021024	WO 2001-US47850	20011211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CV, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TG, BP, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2431553	AA	20021024	CA 2001-2431553	20011211
US 2002169159	A1	20021114	US 2001-15532	20011211
US 6964967	B2	20051115		
EP 1243505	A1	20030917	EP 2001-273533	20011211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR				
JP 2004536796	T2	20041209	JP 2002-580947	20011211
CN 1575177	A	20050202	CN 2001-822596	20011211
BR 2001016096	A	20051018	BR 2001-16096	20011211
US 2003069234	A1	20030410	US 2002-164690	20020606
US 6794379	B2	20040921		
US 2003055054	A1	20030220	US 2002-231895	20020829
US 7053215	B2	20060630		
ZA 2003004342	A	20050509	ZA 2003-4342	20030603
NO 2003002612	A	20030805	NO 2003-2612	20030610
US 2005075333	A1	20050407	US 2004-946935	20040921
US 7067662	B2	20060627		
US 2006116388	A1	20060601	US 2006-332054	20060113
PRIORITY APPLN. INFO.:			US 2000-255241P	P 20001211
			US 2001-296499P	P 20010606
			US 2001-15532	A1 20011211
			WO 2001-US47850	W 20011211
			US 2002-164690	A1 20020606

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2002-231895 A1 20020829OTHER SOURCE(S): MARPAT 137:337907
GI

AB Title compds. I (wherein X = a bond, CO, CR5R6, CR5:, SO, SO₂, or N: ; Z = a bond, N, O, S, NR17, or CR7: ; with the proviso that X and Z are not both a bond; L = CO-alkylene or (hetero)alkylene; Q = (hetero)alkylene, CO, OCO, NR8CO, CH2CO, CH2SO, or CH2SO2; or NR9 = heterocyclyl; R1 and R2 = independently H, (hetero)alkyl, or (hetero)aryl; or CR1R2 = (hetero)cyclol; or CR2L1 heterocyclol; R3 = OH, alkoxy, NH₂, (di)alkylamino, heteroalkyl, heterocyclol, acylaminoamidino, guanidino, ureido, CN, heteroaryl, carbamoyl, or carboxy; R4 = (hetero)alkyl, (hetero)aryl, etc.; R5 and R6 = independently H, (hetero)alkyl, or (hetero)aryl; or CR5R6 = a ring; R7 and R8 = independently H, (hetero)alkyl, or (hetero)aryl; Y1 and Y2 = independently CR12: N:, O, S, or NR13; Y3 = N or C, wherein C shares a double bond with either Z or Y4; Y4 = NR14, CR14:, N:, NR14CR15R16; R12 = H, halo, OH, NH₂, (di)alkylamino, (hetero)alkyl, or (hetero)aryl, with provisos; R13 = H, (hetero)alkyl, (hetero)aryl, etc.; R14 = (hetero)alkyl, (hetero)aryl, etc.; R15 and R16 = independently H or (hetero)alkyl; R17 = H, (hetero)alkyl, (hetero)aryl, etc.; with provisos) were prepared as chemokine receptor modulators, in particular CXCR3 antagonists. For example, anthranilic acid was acylated with propionyl chloride and the amide cyclized using acetic anhydride to give 2-ethylbenzo[d][1,3]oxazine-4-one. Treatment with 4-fluoroboranimine, followed by ethylene glycol and NaOH afforded 2-ethyl-3-(4-fluorophenyl)-3H-quiazolin-4-one. Bromination and stepwise addition of 1-amino-2-methoxyethane and decanoyl chloride produced the decanoic acid (quinazolinylethyl)(methoxyethyl)amide II. Approx. one third of the 101 invention compds. tested in a CXCR3 binding assay displayed activity with


Habte

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IC₅₀ values of < 1 μM. I are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, and type I diabetes (no data).


IT 473720-85-4P
 473721-09-4P
 RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473720-87-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-(1R)-1-aminoethyl)-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473720-87-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 473720-88-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-iodophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 473721-09-4 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:798224 CAPLUS
 DOCUMENT NUMBER: 135:357937
 TITLE: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sodhi, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 278 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081346	A2	20011101	WO 2001-US13315	20010424
WO 2001081346	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CI, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2406278	AA	20011101	CA 2001-2406278	20010424
EP 1278748	A2	20030129	EP 2001-928855	20010424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR			
BR 2001010371	A	20030617	BR 2001-10371	20010424
JP 2003531209	T2	20031021	JP 2001-578436	20010424
NZ 522076	A	20050826	NZ 2001-522076	20010424
NO 2002005104	A	20031210	NO 2002-5104	20021024
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
	PRIORITY APPLN. INFO.: US 2000-199655P		US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			WO 2001-US13315	W 20010424

OTHER SOURCE(S): MARPAT 135:357937
 GI

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are claimed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compsd. are provided that inhibit PI3Kδ activity, including compds. that selectively inhibit PI3Kδ activity. The compds. claimed are all quinazolin-4-one derive., including I (Y = null, S, NH; R = H, halo, OH, OMe, Me, CF₃; R1

H, OMe, halo; R2 together with C-6 and C-7 of quinazoline ring define a 5- or 6-membered aromatic ring optionally containing ≥ 1 O, N or S; R2 = C1-6 alkyl, Ph, halophenyl, alkylphenyl, biphenyl, PhCH₂, pyridinyl, 4-methylpiperasinyl, CO₂Et, morpholinyl, R3 = NH₂, halo, Cl-3 alkyl, S(C1-3 alkyl), OH, NH(C1-3 alkyl), N(C1-3 alkyl)₂, NH(C1-3 alkylenephenyl); q = 1, 2) and pharmaceutically acceptable salts and solvates thereof. Methods of using PI3Kδ inhibitory compds. to inhibit cancer cell growth or proliferation are also provided.

Accordingly, the invention provides methods of using PI3Kδ inhibitory compds. to inhibit PI3Kδ-mediated processes in vitro and in vivo. Thus, in an example, dose-dependent decrease in histamine release from basophile when stimulated with anti-IgE was 100% at 1.000 nM,


with an EC₅₀ of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC₆H₄,

R3 = H; S connected to 6-position of purine ring; preparation given).


IT 371244-07-4P 371244-08-5P 371244-09-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)

(preparation and substitution reaction of, with chloropurine derivs.)
 RN 371244-07-4 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371244-08-5 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(1-aminoethyl)-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371244-09-6 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:208250 CAPLUS
 DOCUMENT NUMBER: 134:54352
 TITLE: Preparation of 3-aryl-2-arylureidoalkylquinoxolin-4-ones and related compounds as mediators of hedgehog signaling pathways.
 INVENTOR(S): Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Olivia M.; Price, Stephen; Rubin, Lee D.
 PATENT ASSIGNEE(S): Curis, Inc., USA
 SOURCE: PCT Int. Appl. 177 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019800	A2	20010322	WO 2000-US25461	20000915
WO 2001019800	A3	20011206		
WO 2001019800	C2	20021003		
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GM, ML, MR, NE, SN, TD, TG				
CA 2385736	AA	20010322	CA 2000-2385736	20000915
EP 1216234	A2	20020626	EP 2000-963551	20000915
EP 1216234	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003059414	T2	20030311	JP 2001-523380	20000915
US 6545005	B1	20030408	US 2000-663835	20000915
AT 286033	E	20050115	AT 2000-963551	20000915
EP 1516876	A1	20050323	EP 2004-28252	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AU 780846	B2	20050421	AU 2000-74948	20000915
ES 2234662	T3	20050701	ES 2000-963551	20000915
US 2005080138	A1	20050414	US 2004-953601	20040929
AU 2005220214	A1	20051103	AU 2005-220214	20051006
PRIORITY APPLN. INFO.:			US 1999-154526P	P 19990916
			US 1999-159412P	P 19991014
			US 1999-162899P	P 19991101
			AU 2000-74948	A 20000915
			EP 2000-963551	A3 20000915
			US 2000-663835	A2 20000915


L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:552517 CAPLUS
 DOCUMENT NUMBER: 131:310612
 TITLE: Novel quinoxolinones from 2-cyanomethyl-3-phenyl-4(3H)quinoxolinone
 AUTHOR(S): El-Feky, S. A.
 CORPORATE SOURCE: Dept. of Organic Pharmaceutical Chemistry, Faculty of Pharmacy, Zagazig Univ., Zagazig, Egypt
 SOURCE: Bollettino Chimico Farmaceutico (1998), 137(7), 286-289
 CODEN: BCPAAI; ISSN: 0006-6648
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB: The title compound was converted to several other quinoxolinones, e.g., I, II, III, and IV. The new compds. were characterized by elemental analyses, ¹H-NMR and IR spectra, and alternative syntheses in certain cases.
 IT 220460-17-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and conversion to oxadiazole derivative)
 RN 220460-17-3 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(benzoyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NO 2000-US25461 W 20000915
 US 2000-687800 B2 20001013
 US 2000-711343 B2 20001109
 US 2000-724277 A1 20001128

OTHER SOURCE(S): MARPAT 134:252352
 AB R1X1Y1Z1L2Y2Z1R2 (R1, R2 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; L = null, alkyl, alkenyl, alkynyl, (CH₂)_n(CH₃)p, etc.; n, p = 0-10; X1, X2 = NR₂, O, S, Se, N=N, ON:CH, heterocycl, bond, etc.; Y1, Y2 = CO, CS, SO₂, SO, C(:CN), heteroaryl, bond, etc.; Z1, Z2 = NR₂, O, S, Se, N=N, ON:CH, heterocycl, bond, etc.; R₁ = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl, etc.) were prepared. Thus, triphosgene in EtOAc was added to reflux. The mixture was concentrated, dissolved in CHCl₃, and treated with 3-(4-fluorophenyl)-2-(1-methylethoxyethyl)-4-oxo-3,4-dihydroquinazoline in CHCl₃ to give 97% 1-(1-(3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-3-(3-trifluoromethyl-4-nitrophenyl)-1-methylurea. The latter inhibited sonic hedgehog-induced Gli transcription activity with IC₅₀ < 5 μM.
 IT 330796-23-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-aryl-2-arylureidoalkylquinoxolin-4-ones and related compds. as mediators of hedgehog signaling pathways)
 RN 330796-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 220460-11-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)
 RN 220460-11-7 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(acetoxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

IT 220460-09-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, acetylation, and conversion to oxadiazole derivative)
 RN 220460-09-3 CAPLUS
 CN 2-Quinazolineethanimidamide, 3,4-dihydro-N-hydroxy-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

IT 220460-09-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, acetylation, and conversion to oxadiazole derivative)
 RN 220460-09-3 CAPLUS
 CN 2-Quinazolineethanimidamide, 3,4-dihydro-N-hydroxy-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:800426 CAPLUS
 DOCUMENT NUMBER: 130:168315
 TITLE: Novel quinazolinones from
 2-cyanomethyl-3-phenyl-4-(3H)-
 quinazolinone
 AUTHOR(S): El-Feky, Said A.
 CORPORATE SOURCE: Dep. organic Pharmaceutical Chemistry, Faculty
 Pharmacy, Zagazig University, Zagazig, Egypt
 SOURCE: Chinese Pharmaceutical Journal (Taipei) (1998),
 50(5).
 305-312
 CODEN: CPHJEP; ISSN: 1016-1015
 PUBLISHER: Pharmaceutical Society of Republic of China
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 2-[{[(4-Chlorophenylthio)-ciano(methylene)-3-phenyl-1,2,3,4-tetrahydroquinazolin-4-one, 2-amino-4-phenylpyrazolo[1,5-a]quinazolin-5(4H)-one, and 2-[5-methyl- or phenyl-1,2,4-oxadiazol-3-yl)methyl]-3-phenyl-4-(3H)-quinazolinone were prepared from 2-(cyanomethyl)-3-phenyl-4-(3H)-quinazolinone via its *a*-bromo and amide oxime derivs. The new compds. were characterized by elemental anal., ¹H NMR, IR, and alternative synthesis in same cases.
 IT 220460-09-3P 220460-11-7P 220460-17-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phenylquinazolinones from (cyanomethylphenylquinazolinone)
 RN 220460-09-3 CAPLUS
 CN 2-Quinazolineethanimidamide, 3,4-dihydro-N-hydroxy-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:352629 CAPLUS
 DOCUMENT NUMBER: 129:27954
 TITLE: Quinazolinone derivatives as cholecystokinin (CCK) ligands
 INVENTOR(S): Padia, Janak Khimchand
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 287,454.
 CODEN: USXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5756502	A	19980526	US 1995-500436	19950710
US 5869665	A	19990209	US 1997-826843	19970408
PRIORITY APPLN. INFO.:			US 1994-287454	A2 19940808

US 1995-500436 A3 19950710

OTHER SOURCE(S): CASREACT 129:27954; MARPAT 129:27954

GI




AB The title compds. [I; M, X, Y, Z = CR₃, CR₄, CR₅, N, etc.; M = O, S; B = bond or (un)substituted alkylene; A = R₁NCO(CH₂)_n, CONR₁₁(CH₂)_n, etc.; n = 0, 1; R₁, R₂ = C₁₋₆ alkyl, (un)substituted aryl, etc.; R₃-R₆ = H, OH, alkoxy, etc.; R₁₁ = H, lower alkyl] are prepared I with good binding affinity for the CCK-A and CCK-B receptors are useful agents to suppress appetite, reduce gastric acid secretion, and the like. Thus, 2-(aminomethyl)-3-[3-(methylethoxy)phenyl]-4-(3H)-quinazoline (preparation given) was reacted with 3-methylphenyl isocyanate to give 50% the title compound (II), which showed CCK-A and CCK-B receptor binding affinities (K_i) of 1637 and 879 nm resp.
 IT 205064-38-6P 207978-52-7P


Habte

08/09/2006

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220460-17-3 CAPLUS
 CN 2-Quinazolineethanimidamide, N-(benzoyloxy)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


FORMAT

L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (quinazolinone derivs. as cholecystokinin (CCK) ligands)

RN 205064-38-6 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(aminomethyl)-3-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 207978-52-7 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-(2-aminoethyl)-3-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

FORMAT

L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:169718 CAPLUS
 DOCUMENT NUMBER: 128:238969

TITLE: Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists
 AUTHOR(S): Padie, Janak K.; Field, Mark; Hinton, Joanna;
 Meecham, Ken; Pablo, Julius; Pinnock, Rob; Roth, Bruce D.;
 Singh, Lakhbir; Suman-Chauhan, Nirmala; Trivedi,
 Bharat K.; Webdale, Louise
 CORPORATE SOURCE: Departments of Chemistry and of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Medicinal Chemistry (1998), 41(7), 1042-1049
 PUBLISHER: CODEN: JMCCHAR; ISSN: 0022-2623
 DOCUMENT TYPE: American Chemical Society
 LANGUAGE: Journal English
 GI




AB Urea-linked quinazolines [I; R = (un)substituted Ph, cyclohexyl; R1 = (un)substituted Ph, 3-pyridyl, 1-naphthyl] were prepared as selective orally active CCK-B antagonists. Thus, thioxoquinazolines II (prepared from anthranilic acid and the requisite isothiocyanate) were treated with hydrazine to give the 2-hydrazino compds. which were then treated with an isocyanate to give I. Representative compds. of this series were tested in the functional assay, i.e., guinea pig stomach strip assay, and showed pure antagonist profiles. I [R = 3-(tert-butoxycarbonyl)phenyl, R1 = 3-isopropoxypyhenyl] and I [R = 3-cyanophenyl, R1 = 3-(dimethylamino)phenyl] (III) were orally active in the elevated rat

X-maze test and showed dose-dependent anxiolytic-like action. These compds. were also evaluated for their pharmacokinetic profile. The absolute oral bioavailability of III was 22% in rats.

IT 205064-38-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of urea-linked quinazolinones as selective CCK-B receptor antagonists)


RN 205064-38-6 CAPLUS

L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-[3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:510992 CAPLUS
 DOCUMENT NUMBER: 117:110992
 TITLE: Electroreduction of some potential antimicrobial thiomericarbazide derivatives of quinazolin-4(3H)-one
 AUTHOR(S): Ismail, Mohamed I.
 CORPORATE SOURCE: Fac. Sci., Univ. Ain Shams, Cairo, Egypt
 SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1992), (4), 585-9
 DOCUMENT TYPE: CASREACT 117:110992
 LANGUAGE: English
 OTHER SOURCE(S): English
 AB Polarog. data for a series of 3-phenyl-2-substituted thiocarbamoylhydrazonemethylquinazolin-4(3H)-ones (with antimicrobial activity), in 50% ethanolic aqueous buffers covering a wide range of pH are reported and discussed. A mechanism interpreting the electrode process, in both acidic and alkaline media, is proposed and confirmed via the identification of CPE products. Hammett's σ -El/2 relation and pKa determination
 IT 22126-97-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by electroredund. of formylphenylquinazolinone thiomericarbazide)
 RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:497416 CAPLUS
 DOCUMENT NUMBER: 105:97416
 TITLE: Synthesis and biological activities of certain derivatives of 3-aryl-4(3H)-quinazolinones. Part II
 AUTHOR(S): Rao, A. Devender; Shankar, C. Ravik; Reddy, P.
 Bhagavan; Reddy, V. Malli
 CORPORATE SOURCE: Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009, India
 SOURCE: Journal of the Indian Chemical Society (1985), 62(3), 234-7
 DOCUMENT TYPE: CASDEA 105:97416
 LANGUAGE: English
 OTHER SOURCE(S): English
 AB Polarg. data for a series of 3-phenyl-2-substituted thiocarbamoylhydrazonemethylquinazolin-4(3H)-ones (with antimicrobial activity), in 50% ethanolic aqueous buffers covering a wide range of pH are reported and discussed. A mechanism interpreting the electrode process, in both acidic and alkaline media, is proposed and confirmed via the identification of CPE products. Hammett's σ -El/2 relation and pKa determination
 IT 22126-97-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by electroredund. of formylphenylquinazolinone thiomericarbazide)
 RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)






AB 3-Arylquinazolinones I [R = H, Br; R1 = 4-MeC6H4, 2-MeC6H4, 4-O2NC6H4, 2-O2NC6H4; R2 = NMe2, NEt2, N(CH2CH2OH)2, piperidino, morpholino, 4-AcNHIC6H4SO2, etc.] were prepared from I (R2 = Cl), which were obtained by cyclocondensation of N-chloroacetylanthranilic acids with R1NH2 in the presence of PCl3. I are fungual agents, I (R = H, R1 = 4-O2NC6H4, R2 = 4-AcNHIC6H4SO2) giving total control of Curvularia lunata and Fusarium oxyphorum at 80 μ g/ml.
 IT 80096-33-9P 103952-91-6P 103952-92-7P
 103952-93-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and condensation of, with acetamidobenzenesulfonyl chloride)
 RN 80096-33-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 103952-91-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methylphenyl)- (9CI)

L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
(CA INDEX NAME)

(Continued)

RN 103952-92-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)RN 103952-93-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-nitrophenyl)- (9CI) (CA INDEX NAME)L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983-72038 CAPLUS

DOCUMENT NUMBER: 98:72038

TITLE: Studies on side-chain bromination and oxidation of 6-bromo-2-methyl-3-phenyl-4(3H)-quinazolinone and related compounds

AUTHOR(S): El-Sherief, H. A. H.; El-Naggar, G. M.; Mahmoud, A. M.; Alaf, H.; Abdel-Hamed, K.


CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt

SOURCE: Bulletin of the Faculty of Science, Assiut University (1982), 11(1), 49-60

DOCUMENT TYPE: CODEN: ISAUDW; ISSN: 0366-4740

LANGUAGE: Journal English

GI

AB: Bromination of the quinazolinone I ($R = Me$) gave I ($R = CH_2Br, CHBr_2$). I ($R = CH_2Br$) reacted with nucleophiles to give I ($R = CH_2NHMe, CH_2SCH_2CO_2H, CH_2SPh, CH_2SC_6H_4Me-2$). I ($R = Me$) was oxidized to I ($R = CHO$) which was converted to various anilines. I ($R = CH_2CHO, CH_2C_6H_4OMe-4$) were brominated to I ($R = CHBrCHBrPh, CHBrCHBrC_6H_4OMe-4$). The latter compound was treated with nucleophiles to give I ($R = CHBrCH_2C_6H_4OMe-4; R_1 = OMe, OEt, NH_2, OAc$).


IT 84546-37-2

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 84546-37-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-(2-amino-1-bromo-2-(4-methoxyphenyl)ethyl)-6-bromo-3-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HBr

L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982-6679 CAPLUS

DOCUMENT NUMBER: 96:6679

TITLE: Quinazolinones. 2. Syntheses and some reactions of 2-azidomethyl-3-aryl-4-quinazolinones

AUTHOR(S): Domanig, Rainer
CORPORATE SOURCE: Inst. Org. Pharm. Chem., Univ. Innsbruck, Innsbruck, Austria


SOURCE: Monatshefte fuer Chemie (1981), 112(10), 1195-202

DOCUMENT TYPE: CODEN: MOCHB7; ISSN: 0026-9247

LANGUAGE: German

OTHER SOURCE(S): CASREACT 96:6679

GI

AB: Starting with the chloromethyl compds. I ($R = Cl; R_1 = H, 2-Me, 2-MeO, 2-NO_2, 3-MeO, 3,5-(MeO)_2, 4-Cl, 5-NO_2$), the new 2-azidomethyl-3-aryl-4-quinazolinones I ($R = N_3$) were prepared, some of which were reduced to the corresponding amines I ($R = NH_2$) by H₂S in good yield. As a first example of the capability of the azides to undergo 1,3-dipolar cycloaddn., II ($R = 2-Me, 3-MeO, 4-Cl$) were prepared by reacting I ($R = N_3$) with MeO₂C-tpbonds-COO₂Me.


IT 22126-97-2B 80096-33-9P 80096-34-0P

80096-35-1P


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 22126-97-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)

RN 80096-33-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 80096-34-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 80096-35-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:175028 CAPLUS
 DOCUMENT NUMBER: 94:175028
 TITLE: Reactions of 2,3-disubstituted 4(3H)-quinazolinones and related compounds

AUTHOR(S): Badr, M. Z. A.; El-Neggar, G. M.; El-Sherief, H. A.

H.
 CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(10), 925-6


DOCUMENT TYPE: CODEN: IJSDBD; ISSN: 0376-4699
 LANGUAGE: Journal
 English
 OTHER SOURCE(S): CASREACT 94:175028
 GI



AB The arylidenequinazolines I (R1 = bond, R2 = p-MeO, H, m-NO2, p-NO2) were brominated with Br2 to give I (R = R1 = Br). I (R = R1 = Br, R2 = p-MeO) underwent substitution reactions to give I (R = Br, R1 = AcO, MeO, EtO; R = R1 = H2N, piperidino, morpholino, PhO, PhS; R2 = p-MeO). I (R1 = bond, R2 = p-MeO) was also obtained as an elimination product.

IT 77143-54-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 77143-54-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1,2-diamino-2-(4-methoxyphenyl)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1974:463563 CAPLUS

DOCUMENT NUMBER: 81:63563

TITLE: Chemistry of heterocycles. LVII. Synthesis and transformation of

4H-3,1-benzoxazin-4-one-2-carboxylic

acid amides

AUTHOR(S): Petyunin, P. A.; Bulgakov, V. A.; Petyunin, G. P.

CORPORATE SOURCE: Khar'k. Farm. Inst., Kharkov, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1974), (5), 609-12

CODEN: KGSSAO; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB Benzoxazinecarboxamides I (R = H, Cl-7 alkyl, CH2:CHCH2, PhCH2) were obtained in 40-87% yields by cyclization of o-HO2C6H4NHCOONHR in boiling Ac2O for 10 min. Quinazolinecarboxamides II (R = Me, H; R1 = H, Cl-5 alkyl, CH2CH2Cl, CH2CO2Et, Ph, o-MeC6H4, o-C10C6H4,

o-, m-, p-MeOC6H4, o-, m-, p-HO2C6H4, cyclohexyl, p-H2NCO2C6H4, 2-pyridyl, 1-quinolyl) were obtained in 53-93% yields by


amination of I with R1NH2.

IT 53115-39-2P 53115-40-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 53115-39-2 CAPLUS

CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 53115-40-5 CAPLUS
 CN Benzoic acid, 4-(2-(aminocarbonyl)-4-oxo-3(4H)-quiazolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1973:16128 CAPLUS

DOCUMENT NUMBER: 78:16128

TITLE: 4-Quinazolinones. II. 2-(Aminomethyl)-3-aryl-4-quinazolinones

AUTHOR(S): Kozhevnikov, Yu. V.; Pilat, N. V.

CORPORATE SOURCE: USSR
 SOURCE: Tr. Perm. Sel.-Khoz. Inst. (1971), No. 79, 66-72

DOCUMENT TYPE: From: Ref. Zh., Khim. 1972, Abstr. No. 92h404

LANGUAGE: Journal

Russian

GI For diagram(s), see printed CA Issue.

AB The appropriate 3-(substituted phenyl)-2-(chloromethyl)quinazolinone, K phthalimide, and DMP refluxed 1 hr gave the following I (R = phthalimido) (R1 and % yield given): H, 80.6; p-Me, 62.7; p-MeO, 85.5; p-NO2, 65.3; m-Br, 60; p-Br, 75.8; and o-Cl, 53.6. Then refluxed with NaBH4·H2O in alc., then with 6N HCl gave the following I·HCl (R = NH2) (R1 and % yield given): H, 40.6; o-Me, 30.3; p-Me, 1a, 50.8; p-MeO, 45.6; m-Br, 42; p-Br, 57.4; and o-Cl, 39.5. 1a heated with ClCH2COCl in HOAc gave 58.5% II (R2 = Cl), which refluxed 2 hr with Et2NH in PhMe gave 62% II (R1 = Et2N). Similarly prepared III were (R2 and % yield given): morpholino, 60.8; piperidino, 72.3; phenylpiperazino, 63.7; p-tolylpiperazino, 64.5; and o-tolylpiperazino, 56.8.

IT 22126-93-4P 39070-42-3P 39070-43-4P


39070-44-5P 39070-45-6P 39070-46-7P

39070-47-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 22126-93-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)




• HCl

RN 39070-42-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 39070-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 39070-44-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 39070-45-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(3-bromophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 39070-46-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-bromophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 39070-47-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:76386 CAPLUS
 DOCUMENT NUMBER: 74:76386
 TITLE: Heterocyclic chemistry. LI. Reaction of ethoxacylanthranil with amines
 AUTHOR(S): Petyunin, P. A.; Chernykh, V. P.; Petyunin, G. P.; Kozhevnikov, Yu. V.
 CORPORATE SOURCE: Khar'k. Farm. Inst., Khar'kov, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (11), 1575-8
 CODEN: KGSSAO; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB The title compound (I, Z = O) reacted with 28 aromatic amines (RNH₂) in DMP, yielding the corresponding I (Z = NR). The latter underwent amidation with NH₃, N₂H₄, and R₁C₆H₄NH₂ (R₁ = H, 3-, 4-Br, 3-Me, 4-MeO), and saponification in the usual manner.
 IT 30689-32-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 30689-32-8 CAPLUS
 CN 2-Quinazolinonecarboxamide, 3,4-dihydro-4-oxo-3-(p-sulfamoylphenyl)- (8CI) (CA INDEX NAME)




L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1969:87715 CAPLUS
 DOCUMENT NUMBER: 70:87715
 TITLE: 4-Quinazolones. II. Synthesis of some imidazo[1,5-a]quinazolin-5(4H)-ones
 AUTHOR(S): Singh, Buddha D.; Chaudhury, D. N.
 CORPORATE SOURCE: Bihar Univ., Muzaffarpur, India
 SOURCE: Journal of the Indian Chemical Society (1969), 46(1), 21-5
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The synthesis of 4-phenylimidazo[1,5-a]quinazolin-5(4H)-one and its 1-substituted analogs is described.
 IT 22126-93-8P 22126-97-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 22126-93-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

RN 22126-97-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



10/809,637 Page 2

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:21:12 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10809637gh.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N
G2 Ak,C,S,N,CH2,A

Structure attributes must be viewed using STN Express query preparation.

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
----------------------	------------	-------

Habte

08/08/2006


2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

G2 Ak,C,S,N,CH2,A

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:41:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 33621 TO ITERATE

5.9% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 661461 TO 683379
 PROJECTED ANSWERS: 852 TO 1836

L2 4 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:41:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 673691 TO ITERATE

100.0% PROCESSED 673691 ITERATIONS
 SEARCH TIME: 00.00.13

1134 ANSWERS

L3 1134 SEA SSS FUL L1

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
166.94	167.15

FILE 'CAPLUS' ENTERED AT 10:41:59 ON 08 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 72 L3

=> d ibib abs hitstr tot



L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2006142762 CAPLUS
DOCUMENT NUMBER: 144:233087
TITLE: Preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands.
INVENTOR(S): Lin, Chu-Chung; Chen, Hong-Chuan; Lee, Kuang-Yuan; Huang, Ying-Huey; Fan, Yang-Ping; Xiang, Yibin
PATENT ASSIGNEE(S): TaiGen Biotechnology, Taiwan
SOURCE: U.S. Pat. Appl. Publ., 60 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060316093	A1	20060216	US 2005-204792	20050816
WO 200623381		20060302	WO 2005-US28679	20050816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, IU, ID, IL, IN, JP, JK, KE, KG, KM, KP, KR, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, SM, ZV				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, GU, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BY, CZ, CF, CG, CI, CO, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, MW, NZ, NA, SD, SI, SL, SZ, TZ, UG, 2M, ZW, AM, AZ, KG, KZ, MD, RU, TJ, TM				
PRIORITY APRIL 1, 2004			US 2004-6017765	P 20040816

PRIORITY APPLN. INFO.: US 2004-601776P P 20040816
OTHER SOURCE(S): MARPAT 144:233087
GI

61

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. [I]: A = aryl, heteroaryl; X = S, NR1; L1 = CRb1Rb2, alkylene, heteroalkylene, null; L2 = CR1, null; L3 = CO, SO2, COO, COCH2, SO2CH2, alkylene, heteroalkylene, etc.; L3L4N, L1L3N, L1L4N = atoms to form 5-7 membered ring; R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R2 = R1, etc.; R2L2 = null; R3, R4 = R1, halo, cyano, amidino, guanidino, heteroacyl, etc.; R1, Rb1, Rb2, R2, L1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, etc.), were prepared thus, title compound (II) was prepared in 7 steps from anthranilic acid, propionyl chloride, 4-ethoxyaniline, BocNHCH2CH2NH2, 3,4-dichloropropionic acid, and (Me2S)2C:NCN. 138 I inhibited activation of CXCR3 using a Delfia GTP binding kit with IC50 < μ M.


IT 82 CCRs using a 3611A binding kit
876015-89-3P 876015-91-7P 876016-09-0P
876016-11-4P 876016-12-5P 876016-13-6P
876016-14-7P 876016-15-8P 876016-16-9P
876016-17-0P 876016-18-1P 876016-22-7P
876016-23-8P 876016-24-9P 876016-25-0P
876016-26-1P 876016-27-2P 876016-28-3P

876016-26-1P 876016-27-2P 876016-28-3P
876016-30-7P 876016-31-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(preparation of fused pyrimidinones as chemokine CXCR3 receptor ligands)
 RN 876015-89-3 CAPLUS
 CN Neaceanacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinoxolinyl]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl) (9CI) [CA INDEX NAME]

L4 ANSWER 1 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876015-91-7 CAPLUS
CN Benzenecacetamide, N-[1-(3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 876016-09-0 CAPLUS
CN Benzenecacamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl]-3-fluoro-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876016-11-4 CAPLUS
CN Benzenacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 876016-12-5 CAPLUS
CN Benzenacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinolinyl]-3-(4-piperidinylamino)propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-13-6 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[3-[(1-ethyl-4-piperidinyl)amino]-1-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinylpropyl] - (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-14-7 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl] - (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876016-15-8 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-(4-piperidinylamino)propyl] - (9CI) (CA INDEX NAME)


PAGE 2-A

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-17-0 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(1-ethyl-4-piperidinyl)amino]propyl] - (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A



PAGE 2-A



RN 876016-16-9 CAPLUS
 CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl) - (9CI) (CA INDEX NAME)

Habte



08/08/2006

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A





RN 876016-18-1 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[2-(dimethylamino)ethyl]-N-[1-(3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)-3-(4-piperidinylamino)propyl]- (9CI) (CA INDEX NAME)

RN 876016-22-7 CAPLUS

CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-N-[3-[(1-ethyl-4-piperidinyl)amino]-1-(3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

||
O



RN 876016-23-8 CAPLUS

CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-(3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)-3-[(1-(1-methylethyl)-4-piperidinyl)amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 876016-24-9 CAPLUS

CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-(3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A

||
O


PAGE 2-A

RN 876016-25-0 CAPLUS

08/08/2006


Habte

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-thiopyran-4-yl)amino]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-A



RN 876016-26-1 CAPLUS
 CN Benzeneacetamide, N-[3-[(1-acetyl-4-piperidinyl)amino]-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 2-A

RN 876016-27-2 CAPLUS
 CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(1-methylethyl)-4-piperidinyl]amino]propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 2-A

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A

L4 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876016-30-7 CAPLUS
 CN Benzeneacetamide, N-[3-[(1-ethyl-4-piperidinyl)amino]-1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-3-fluoro-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 876016-28-3 CAPLUS
 CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]propyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



PAGE 2-A




RN 876016-31-8 CAPLUS
 CN Benzeneacetamide, 3-fluoro-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-3-[(1-methylethyl)-4-piperidinyl]amino]propyl]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:32072 CAPLUS
 DOCUMENT NUMBER: 144:128993
 TITLE: Preparation of fused pyrimidine derivatives as CXCR3 receptor modulators for prevention and treatment of inflammatory and immunoregulatory conditions
 INVENTOR(S): Fu, Zilce; Johnson, Michael G.; Li, An-Rong; Marcus, Andrew P.; Medina, Julio C.; Bergeron, Philippe; Chen, Xiaocui; Deignan, Jeffrey; Du, Xiaohui; Duquette, Jason A.; Gustin, Darin; Mihalic, Jeffrey T.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004915	A1	20060112	WO 2005-US23251	20050626
W:	AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006069099	A1	20060330	US 2005-168005	20050627
PRIORITY APPLN. INFO.:			US 2004-583901P	P 20040628
OTHER SOURCE(S):	MARPAT 144:128993			
GI				



AB Title compds. I [A1, A4 = independently CH and derivs., N; Q = a bond, hetero/alkylene, CO, CH₂CO, etc.; L = a bond, alkylene; X = CH₂, SO₂, CO; R_a = H, OH and derivs., halo, etc.; n = 0-4; R₁ = hetero/aryl; R₂ = H, halo, hetero/alkyl, etc.; or R₂ may be combined with L to form a 5- to 8-membered ring containing 1-3 heteroatoms; R₃ = absent, H, SRS, NH₂OSR₅, piperidin-4-yl, etc.; R₃ may be combined with R₂ to form a 4- to 8-membered ring containing 1-3 heteroatoms; R₅ = hetero/alkyl, hetero/acyl]

R4 - hetero/alkyl, hetero/aryl, etc., and their pharmaceutically acceptable salts and prodrugs] were prepared as chemokine receptor CXCR3 modulators (no data). Two biol. assays are given. Thus, reductive amination of 1-isopropylpiperidine-4-carboxaldehyde with 2-((1*R*)-1-aminoethyl)-3-(4-ethoxyphenyl)-4(3H)-quinazolinone, and acylation of the amine intermediate with [4-fluoro-3-(trifluoromethyl)phenyl]acetic acid gave quinazolinone II. I are useful for the treatment of inflammatory and immune disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease (no data).

IT 873191-60-7? RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of fused pyrimidine derivs. as CXCR3 receptor

modulators for prevention and treatment of inflammatory and immune disorders and diseases)

RN 873191-60-7 CAPLUS

CN Benzenesacetamide, N-((1*R*)-1-[3-(4-cyanophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl)-4-fluoro-N-(tetrahydro-2*H*-thiopyran-4-yl)-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 20051329696 CAPLUS

DOCUMENT NUMBER: 144:45525


TITLE: Methods for treating mast cell disorders
INVENTOR(S): Haylick, Joel S.; Pefaur, Noah; Puri, Kamal D.; Tino, William
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXK02

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005120511	A1	20051222	WO 2005-US19558	20050604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SZ, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RV: BW, GH, GH, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2004-576947P	P	20040604
OTHER SOURCE(S): MARPAT 144:45525				
AB	The invention provides methods of inhibiting mast cell activity by administering a selective inhibitor of phosphoinositide 3-kinase delta (PI3KB). The invention also provides methods for treating or preventing a condition associated with undesirable mast cell activity in an individual comprising administering an effective amount of a selective PI3K inhibitor.			
IT	371243-12-8 371243-13-9 371243-14-0 371243-15-1 371243-17-3 371243-22-0 371243-23-1 474012-90-3 474012-93-6 474012-96-9 474012-98-1 474013-01-9 845527-57-3 845527-58-4 845527-59-5 845527-60-8 845527-61-9 845527-62-0 845527-63-1 845527-64-2 845527-65-3 845527-66-4 845527-67-5 845527-68-6 845527-69-7 845527-70-8 845527-71-1 845527-72-2 845527-73-3 845527-74-4 870282-36-3 870282-37-7 871585-40-9 871585-41-0 871585-42-1 871585-43-2 871585-44-3 871585-45-4 871585-46-5 871585-47-6 871585-48-7 871585-49-8 871585-50-1 871585-51-2 871585-52-3 871585-53-4 871585-54-5 871585-55-6 871585-56-7 871585-57-8 871585-58-9 871585-59-0 871585-60-3 871585-62-5 871585-63-6 871585-64-7 871585-65-8			


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-14-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 371243-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

871585-66-9 871585-67-0 871585-68-1

871585-69-2 871585-70-5 871585-71-6

871585-72-7 871585-73-8 871585-74-9

871585-75-0 871585-76-1 871585-77-2

871585-78-3 871585-79-4 871585-80-7

871585-81-8 871585-82-9 871585-83-0

871585-84-1 871585-85-2 871585-86-3

871585-87-4 871585-88-5 871585-89-6

871585-90-9 871585-91-0 871585-92-1

871585-93-2 871585-94-3 871585-95-4

871585-96-5 871585-97-6 871585-98-7

871585-99-8 871586-00-4 871586-01-5

871586-02-6 871586-03-7 871586-04-8

871586-05-9 871586-06-0 871586-07-1

871586-08-2 871586-09-3 871586-10-6

871586-11-7 871586-12-8 871586-13-9

871586-14-0 871586-15-1 871586-16-2

871586-17-3 871586-18-4 871586-19-5

871586-20-8 871586-21-9 871586-22-0

871586-23-1 871586-24-2 871586-25-3

871586-26-4 871586-27-5 871586-28-6

871586-29-7 871586-30-8 871586-31-1 871586-32-2 871586-33-3 871586-34-4

871586-35-5 871586-36-6 871586-37-7

871586-38-8 871586-39-9 871586-40-2

871586-41-3 871586-42-4 871586-43-5

871586-44-6 871586-45-7 871586-46-8

871586-47-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods for treating mast cell disorders)

RN 371243-12-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


RN 371243-13-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 371243-17-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 371243-22-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-90-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-93-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-96-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474013-01-9 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(phenylimethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-57-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME

RN 845527-59-5 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]-
 (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-69-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(2-[(diethylamino)ethyl]methylamino)phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-70-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-71-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-72-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 870282-37-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871585-40-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 871585-41-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]ethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-42-1 CAPLUS
 Habte


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 870282-36-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1-[(2-amino-1H-purin-6-yl)amino]-3-butynyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-43-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1-[(2-amino-1H-purin-6-yl)amino]ethyl)-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 871585-44-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[(1-[(2-fluoro-1H-purin-6-yl)amino]ethyl)-5-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 871585-45-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871585-46-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-47-6 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-pyrido[2,3-d]pyrimidin-4-ylamino)propyl]- (9CI) (CA INDEX NAME)



RN 871585-48-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-((2-fluoro-1H-purin-6-yl)amino)propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-49-8 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-50-1 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 871585-51-2 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-52-3 CAPLUS


CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[2-(phenylmethoxy)-1-(1H-pyrido[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-53-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-((2-fluoro-1H-purin-6-yl)amino)-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-54-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-55-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(4-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-56-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-57-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino]ethyl- (9CI) (CA INDEX NAME)




RN 871585-58-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-pyrazolo[2,3-d]pyrimidin-4-

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-59-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]ethyl-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-60-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino]ethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-62-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-hydroxy-1H-purin-6-yl)amino]ethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-63-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(phenyl(1H-purin-6-yl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 871585-64-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]phenylmethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-65-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]phenylmethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-66-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(phenyl(1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 871585-67-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]ethyl-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-68-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-69-2 CAPLUS
 CN Carbamic acid, [5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-5-(1H-purin-6-ylamino)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 871585-70-5 CAPLUS
 CN Carbamic acid, [5-[(2-amino-1H-purin-6-yl)amino]-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 871585-71-6 CAPLUS
 CN Carbamic acid, [4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-4-(1H-purin-6-ylamino)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 871585-72-7 CAPLUS
 CN Carbamic acid, [4-[(2-amino-1H-purin-6-yl)amino]-4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-73-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-74-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-75-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[5-amino-1-[(2-amino-1H-purin-6-yl)amino]pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-76-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dimethylphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-77-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dimethylphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 871585-78-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-(4-morpholinylmethyl)-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-79-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-80-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[4-amino-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-81-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-6-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-82-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-(1,1-dimethylethoxy)-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-83-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(3-methylphenyl)-2-[1-(1H-purin-6-

ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]-2-hydroxyethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-84-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 871585-87-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 871585-85-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-88-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871585-86-3 CAPLUS
 Habte

08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-89-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-90-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871585-91-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871585-92-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871585-93-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871585-94-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-(2,6-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 871585-95-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)



RN 871585-96-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)



RN 871585-97-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)butyl]- (9CI) (CA INDEX NAME)




RN 871585-98-7 CAPLUS


08/08/2006

Habte

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871585-99-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-00-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinylmethyl)phenyl]-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 871586-03-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-2-[1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 871586-04-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-05-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-(2-hydroxy-1-(1H-purin-6-ylamino)ethyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-06-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-

Habte


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-01-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(3-(4-morpholinylmethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 871586-02-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ylamo)propyl]- (9CI) (CA INDEX NAME)



RN 871586-07-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-08-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-




RN 871586-09-3 CAPLUS

08/08/2006

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-[1-((5-bromo-1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino)ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-10-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[1-[(5-methyl-1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 871586-11-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-((2-amino-1H-purin-6-yl)amino)propyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6,7-difluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-14-0 CAPLUS


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 5-fluoro-2-[1-((2-fluoro-1H-purin-6-yl)amino)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 871586-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-16-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[3,3,3-trifluoro-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 871586-18-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-19-5 CAPLUS

L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-20-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[2-[2-(dimethylamino)ethoxy]phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-21-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[3-(cyclopropylmethoxy)phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 871586-22-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-[3-(2-propynyl)phenyl]-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-23-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 871586-24-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-3-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-25-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-3-[3-(cyclopropylmethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-26-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-5-methyl-3-[3-(2-propynyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 871586-27-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[3-ethynylphenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-28-6 CAPLUS
 CN Benzonitrile, 3-[5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-29-7 CAPLUS
 CN Benzanamide, 3-[5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-30-0 CAPLUS
CN 4 (3H)-Quinazolinone, 3-(3-acetylphenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-31-1 CAPLUS
CN Acetamide, 2-[3-(5-methyl-4-oxo-2-[1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 871586-32-2 CAPLUS
CN 4 (3H)-Quinazolinone, 5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]-3-[3-(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 871586-33-3 CAPLUS
CN 4 (3H)-Quinazolinone, 3-[3-(2-methoxyethoxy)phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-34-4 CAPLUS
CN 4 (3H)-Quinazolinone, 6-fluoro-2-[1-(1H-purin-6-ylamino)ethyl]-3-[3-(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 871586-35-5 CAPLUS
CN 4 (3H)-Quinazolinone, 3-[3-(dimethylamino)propoxy]phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 871586-37-7 CAPLUS
CN Benzonitrile, 3-[2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-38-8 CAPLUS
CN Benzamide, 3-[2-[1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-methyl-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 871586-36-6 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(ethynylphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-39-9 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[1-(1H-purin-6-yloamino)ethyl]-(9CI) (CA INDEX NAME)




RN 871586-40-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-5-methyl-3-[3-(4-morpholinyl)phenyl]-(9CI) (CA INDEX NAME)




RN 871586-41-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-3-[3-(2-methoxyethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-42-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-3-[3-(2-dimethylamino)ethoxyphenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 871586-43-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}propyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871586-44-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}ethyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 871586-45-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-6-fluoro-2-[1-(1H-purin-6-yloamino)ethyl]-(9CI) (CA INDEX NAME)



RN 871586-46-8 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2,6-difluorophenyl)-2-[1-(1H-purin-6-yloamino)propyl]-(9CI) (CA INDEX NAME)



RN 871586-47-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-{(2-amino-1H-purin-6-yl)amino}propyl]-5-chloro-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 20051313884 CAPLUS
DOCUMENT NUMBER: 14432213
TITLE: Methods using phosphoinositide 3-kinase 5 inhibitors for treating and/or preventing aberrant proliferation of hematopoietic cells
INVENTOR(S): Hayflick, Joel S.; Bouscary, Didier; Lacombe, Catherine; Mayeux, Patrick
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117889	A1	20051215	WO 2004-US37860	20041112
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GH, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LA, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NL, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, RW: BG, GH, GM, KE, LS, MW, MZ, NA, SD, SZ, TZ, UG, ZM, ZU, AM, AZ, BY, KG, KZ, MD, RU, TZ, TH, AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CL, CH, GA, GN, GO, GW, HL, MA, ME, SN, TD, TG				
US 2006106038	A1	20060518	US 2005-137901	20050525
PRIORITY APPLN. INFO.:			US 2004-574481P	P 20040525
			US 2004-578683P	P 20040609

OTHER SOURCE(S): MARPAT 144:32213
AB The invention discloses methods for treating and/or preventing aberrant proliferation of hematopoietic cells. More particularly, the invention discloses methods for treating and/or preventing aberrant proliferation of hematopoietic cells comprising selectively inhibiting phosphoinositide 3-kinase 5 (PI3K5) activity in hematopoietic cells. The methods may be used to treat any indication involving aberrant proliferation of hematopoietic cells.
IT 371243-12-8 371243-13-9 371243-14-0
371243-15-1 371243-17-3 371243-22-0
371243-23-1 474012-90-3 474012-93-6
474012-96-9 474012-98-1 474013-01-9
845527-52-8 845527-59-4 845527-59-5
845527-60-8 845527-61-9 845527-62-0
845527-63-1 845527-64-2 845527-65-3
845527-66-4 845527-67-8 845527-68-6
845527-69-7 845527-70-0 845527-71-1
845527-72-2 845527-73-3 845527-74-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphoinositide 3-kinase 5 inhibitors for treating and/or preventing aberrant proliferation of hematopoietic cells)
RN 371243-12-8 CAPLUS

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
CN 4 (3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-15-1 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-(1-(1H-purin-6-ylamino)ethyl)- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-(1-(1H-purin-6-ylamino)propyl)- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-


L4 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-
 (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(3,5-
 difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 845527-66-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[(2-(diethylamino)ethyl)methylamino]phenyl-5-
 methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS

Habte


08/08/2006




RN 845527-70-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-72-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



RN 845527-73-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 845527-74-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]ethyl-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005126655 CAPLUS
 DOCUMENT NUMBER: 144-612
 TITLE: Phosphoinositide 3-kinase δ selective inhibitors for inhibiting angiogenesis
 INVENTOR(S): Hallahan, Dennis; Hayflick, Joel S.; Sadhu, Chanchal
 PATENT ASSIGNEE(S): Vanderbilt University, USA; Icos Corporation
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2005112935	A1	20051201	WO 2004-US29561	20040909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MX, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZV RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		US 2006079538	A1	20060413	US 2005-129006	20050512
PRIORITY APPLN. INFO.: US 2004-570688P						P 20040513
OTHER SOURCE(S): MARPAT 144-612						

AB The invention discloses methods for inhibiting angiogenesis. The methods comprise selectively inhibiting phosphoinositide 3-kinase delta (PI3K δ) activity in endothelial cells. The methods may comprise administration of one or more cytotoxic therapies including but not limited to radiation, chemotherapeutic agents, photodynamic therapies, radiofrequency ablation, anti-angiogenic agents, and combinations thereof. Inhibitors of the invention include quinazolin-4-one derivs.

IT 371243-12-8 371243-13-3 371243-14-0

371243-15-1 371243-17-3 371243-22-0

371243-23-1 474012-90-3 474012-93-6

474012-96-9 474012-98-1 474013-01-9

845527-52-8 845527-53-9 845527-54-0

845527-57-3 845527-58-4 845527-59-5

845527-60-8 845527-61-9 845527-62-0

845527-63-1 845527-64-2 845527-65-3

845527-66-4 845527-67-5 845527-68-6


845527-69-7 845527-70-0 845527-71-1

845527-72-2 845527-73-3 845527-74-4


RL: PAC (Pharmacological activity); USES (Uses)
 (Biological study); THU (Therapeutic use); BIOL
 (phosphoinositide 3-kinase δ inhibitors for angiogenesis inhibition)

RN 371243-12-8 CAPLUS


CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
CN 4 (3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 371243-22-0 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1-[(2-fluoro-1H-purin-6-yl)amino]ethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Habte




RN 474012-93-6 CAPLUS
CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1-[(2-fluoro-1H-purin-6-yl)amino]propyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 474012-98-1 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-57-3 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-53-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[(1-(2-fluoro-1H-purin-6-ylamino)ethyl)-5-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-60-6 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-(9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]-(9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]-(9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]-(9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]-(9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[2-[(2-diethylamino)ethyl]methylamino]phenyl]-5-




RN 845527-70-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[1-(1H-purin-6-ylamino)methyl]-(9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)methyl]-(9CI) (CA INDEX NAME)




RN 845527-72-2 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-yloamino)methyl]- (9CI) (CA INDEX NAME)



RN 845527-73-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-yloamino)methyl]- (9CI) (CA INDEX NAME)



RN 845527-74-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 20051259353 CAPLUS
DOCUMENT NUMBER: 144:22759
TITLE: Preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
INVENTOR(S): Fowler, Kimberly W.; Huang, Danwen; Kesicki, Edward A.; Ooi, Hua Chia; Oliver, Amy R.; Ruan, Fuqiang; Tseng, Jennifer
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIIX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113556	A1	20051201	WO 2005-US16778	20050512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GV, ML, MR, NE, SN, TD, TG				
WO 2005113554	A2	20051201	WO 2005-US16661	20050512
WO 2005113554	A3	20060406		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GV, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-570764P P 20040513
OTHER SOURCE(S): MARPAT 144:22759
GI




AB Quinazolinone derivs. of formula I [X = N, (substituted) CH; Z = NH, O; R1-R3 = H, halo, alkyl; R4 = H, halo, OH, alkoxy, CN, acyl, etc.; RS = alkyl, Ph, CH2C(=O)R, etc.; R5 = H, halo, (substituted) NH2; R7 = alkyl, halo, CF3, etc.; ZRS = alkylene] are prepared that inhibit PI3K α activity. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K δ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K δ plays a role in leukocyte function, using the compds. also are disclosed. Thus, II was prepared, and had EC50 value of 1.6 nM in human B lymphocyte assay.

IT 870280-58-1P 870281-20-2P 870281-21-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)


RN 870280-59-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1R)-2-(phenylmethoxy)-1-(1H-purin-6-yloamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-20-2 CAPLUS
CN Carbanic acid, [(5S)-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinolinyl)-1-(1H-purin-6-yloamino)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 870281-21-3 CAPLUS
CN Carbanic acid, [(5S)-5-[(2-amino-1H-purin-6-yl)amino]-5-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-23-5 CAPLUS
CN Carbanic acid, [(4S)-4-[(2-amino-1H-purin-6-yl)amino]-4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 870282-26-1P 870282-27-2P 870282-29-4P
870282-30-7P 870282-31-8P 870282-32-9P
870282-36-3P 870282-37-4P 870282-42-1P
870282-43-2P 870282-44-3P 870282-45-4P
870282-46-5P


RL: PAC (Pharmacological activity); SPA (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)

RN 870280-85-6 CAPLUS


CN 4 (3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870280-88-9 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870280-89-0 CAPLUS

Habte


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 870280-85-6P 870280-88-9P 870280-89-0P
870280-90-3P 870280-91-4P 870280-92-5P
870280-93-7P 870280-94-7P 870280-95-8P
870280-96-9P 870280-97-0P 870280-99-2P
870281-01-9P 870281-02-0P 870281-03-1P
870281-04-2P 870281-05-3P 870281-06-4P
870281-07-5P 870281-08-6P 870281-09-7P
870281-10-0P 870281-12-2P 870281-13-3P
870281-14-4P 870281-15-5P 870281-16-6P
870281-17-7P 870281-18-8P 870281-19-9P
870281-22-4P 870281-24-6P 870281-25-7P
870281-26-8P 870281-27-9P 870281-28-0P
870281-30-4P 870281-31-5P 870281-32-6P
870281-34-8P 870281-36-0P 870281-38-2P
870281-40-6P 870281-42-8P 870281-43-9P
870281-44-0P 870281-45-1P 870281-46-2P
870281-47-3P 870281-48-4P 870281-49-5P
870281-50-8P 870281-51-9P 870281-52-0P
870281-53-1P 870281-54-2P 870281-55-3P
870281-56-4P 870281-57-5P 870281-58-6P
870281-59-7P 870281-61-1P 870281-62-2P
870281-63-3P 870281-64-4P 870281-65-5P
870281-66-6P 870281-67-7P 870281-68-8P
870281-69-9P 870281-70-2P 870281-71-3P
870281-72-4P 870281-73-5P 870281-74-6P
870281-75-7P 870281-76-8P 870281-77-9P
870281-78-0P 870281-79-1P 870281-82-6P
870281-88-2P 870281-89-3P 870281-90-6P
870281-91-7P 870281-92-8P 870281-93-9P
870281-94-0P 870282-00-1P 870282-01-2P
870282-02-3P 870282-03-4P 870282-04-5P
870282-06-7P 870282-07-8P 870282-08-9P
870282-09-0P 870282-12-5P 870282-14-7P
870282-16-9P 870282-17-0P 870282-18-1P
870282-19-2P 870282-20-5P 870282-22-7P
870282-23-8P 870282-24-9P 870282-25-0P


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4 (3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-90-3 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-91-4 CAPLUS
CN 4 (3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-92-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-94-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-95-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-fluoro-1H-purin-6-yl)amino)propyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-97-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)aminoethyl)-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870280-98-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-((2-amino-1H-purin-6-yl)amino)-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1R)-2-(phenylmethoxy)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-02-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-[(2-fluoro-1H-purin-6-yl)amino]-2-(phenylmethoxy)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-03-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-04-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(4-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-05-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-06-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-07-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-08-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-09-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-10-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-12-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-2-hydroxy-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-13-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(S)-1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-14-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(S)-[(2-amino-1H-purin-6-yl)amino]phenylmethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-15-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(S)-[(2-fluoro-1H-purin-6-yl)amino]phenylmethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-16-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(S)-phenyl(1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-17-7 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(S)-1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-18-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-19-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-22-4 CAPLUS
 CN Carbamic acid, [(4S)-4-(3,4-dihydro-5-methyl-4-oxo-3-phenyl-2-quinazolinyl)-4-(1H-purin-6-ylamino)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-24-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-25-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-(1H-purin-6-ylamino)pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-26-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-5-amino-1-[(2-amino-1H-purin-6-yl)amino]pentyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-27-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dimethylphenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-28-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dimethylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-30-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-(4-morpholinylmethyl)-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-31-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-32-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-4-amino-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-34-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-36-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-6-fluoro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-38-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-2-(1,1-dimethylethoxy)-1-(1H-purin-6-ylamino)ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-40-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(3-methylphenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-42-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-43-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 870281-44-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-45-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1R)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-hydroxyethyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-46-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-47-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1R)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-48-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-49-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(3-fluorophenyl)-2-[(1S)-1-(1H-purin-6-yloamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 870281-50-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-51-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-(1H-purin-6-yloamino)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-52-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-53-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(2,6-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-54-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-dichlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-55-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-dichlorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-56-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(2,6-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-57-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-58-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-chloro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-59-7 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-61-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-62-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-63-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[(3-(4-morpholinylmethyl)phenyl)amino]ethyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-64-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[(3-(4-morpholinylmethyl)phenyl)amino]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-65-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(5-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-66-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-2-[(1S)-1-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-67-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(5-fluoro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-68-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-2-hydroxy-1-(1H-purin-6-ylamino)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-69-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-70-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-71-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-72-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(5-bromo-1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-73-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-5-methyl-2-[(1S)-1-(5-methyl-1H-pyrazolo[2,3-d]pyrimidin-4-yl)amino]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-74-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-75-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-76-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]propyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-77-9 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-difluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-78-0 CAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-79-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(1S)-4-(diethylamino)-1-(1H-purin-6-ylamino)butyl]-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-82-5 CAPLUS

CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-88-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-89-3 CAPLUS

CN 4(3H)-Quinazolinone, 5-fluoro-2-[(1S)-1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-90-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-fluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870281-91-7 CAPLUS

CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-92-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870281-93-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-methyl-5-phenyl-2-[(1S)-3,3-trifluoro-1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870281-94-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-00-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-01-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(2-(dimethylamino)ethoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-02-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[3-(cyclopropylmethoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-03-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-methyl-5-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-04-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-(3-hydroxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-06-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-07-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-(3-cyclopropylmethoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-08-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(2-propynyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-09-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-ethynylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-12-5 CAPLUS
 CN Benzonitrile, 3-[5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-14-7 CAPLUS
 CN Benzamide, 3-[5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 870282-16-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-acetylphenyl)-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-17-0 CAPLUS
 CN Acetamide, 2-[3-(5-methyl-4-oxo-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3(4H)-quinazolinyl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-18-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3-[3-(tetrahydro-2H-pyran-4-yl)oxy]phenyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-19-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[3-(2-methoxyethoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-20-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]-3-[3-(tetrahydro-2H-pyran-4-yl)oxy]phenyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-22-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[3-(3-(dimethylamino)propoxy)phenyl]-5-methyl-2-[(1S)-1-(1H-purin-6-ylamino)ethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-23-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl]-3-[3-(ethoxymethyl)phenyl]-5-methyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-24-9 CAPLUS
CN Benzonitrile, 3-[2-((1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-methyl-4-oxo-3(4H)-quinazolinyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870282-25-0 CAPLUS
CN Benzamide, 3-[2-((1S)-1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-methyl-4-oxo-3(4H)-quinazolinyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-26-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[3-acetylphenyl]-2-[(1S)-1-(2-amino-1H-purin-6-ylamino)ethyl]-5-methyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 870282-27-2 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[(1S)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-29-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-methyl-3-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-30-7 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-[3-(2-methoxyethoxy)phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 870282-31-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)ethyl]-3-[3-(2-dimethylamino)ethoxyphenyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-32-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[(1H-purin-6-ylamino)-3-butynyl]- (9CI) (CA INDEX NAME)




RN 870282-36-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]-3-butynyl-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 870282-37-4 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[(1H-purin-6-ylamino)-3-butynyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 870282-42-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)propyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-43-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)ethyl]-5-chloro-3-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-44-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-6-fluoro-2-[(1S)-1-(1H-purin-6-yloamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-45-4 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-(2,6-difluorophenyl)-2-[(1S)-1-(1H-purin-6-yloamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-46-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-((2-amino-1H-purin-6-yl)amino)propyl]-5-chloro-3-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 870282-21-6 870282-55-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)
RN 870282-21-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-(3-hydroxyphenyl)-2-[(1S)-1-[(9-[(2-trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]aminoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870282-55-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-6-fluoro-2-[(1R)-2-(1,1-dimethylethoxy)-1-(1H-purin-6-yloamino)ethyl]-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 870281-99-4P 870281-99-5P 870282-05-6P
870282-10-3P 870282-11-4P 870282-13-6P
870282-15-6P 870282-26-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of purine quinazolinones as inhibitors of human phosphatidylinositol 3-kinase δ)
RN 870281-99-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-hydroxyphenyl)-5-methyl-2-[(1S)-1-[(9-[(2-trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]aminoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870281-99-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-methoxyphenyl)-5-methyl-2-[(1S)-1-[(9-[(2-trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]aminoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-05-6 CAPLUS
CN Imidodicarboxylic acid, [6-[(1S)-1-[3,4-dihydro-3-(3-hydroxyphenyl)-5-methyl-4-oxo-2-quinazolinyl]ethyl]amino]-9-[(2-(trimethylsilyl)ethoxy)methyl]- bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.

RN 870282-10-3 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-[5-methyl-4-oxo-2-[(1S)-1-[(9-[(2-trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-11-4 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-2-[(1S)-1-[(9-[(2-(trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]amino]ethyl]-3-[3-(trimethylsilyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 870282-13-6 CAPLUS
CN Benzonitrile, 3-[5-methyl-4-oxo-2-[(1S)-1-[(9-[(2-(trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 870282-15-8 CAPLUS
CN Benzanamide, 3-[5-methyl-4-oxo-2-[(1S)-1-[(9-[(2-(trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]amino]ethyl]-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870282-28-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-[3-(4-morpholinyl)phenyl]-2-[(1S)-1-[(9-[(2-(trimethylsilyl)ethoxy]methyl)-9H-purin-6-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1124613 CAPLUS

DOCUMENT NUMBER: 144:22885

TITLE: Synthesis and microbiological evaluation of N'-3-(4-(4-chlorophenyl)thiazol-2-yl)quinazolin-4(3H)-ones

AUTHOR(S): Pattan, S. R.; Reddy, V. V. K.; Pattan, J. S.; Venkataraman, N. V.; Prajapati, P. N. R. Bhat, A. R.; Hemashettar, B. M.

CORPORATE SOURCE: Dept. of Medicinal Chemistry, K.L.E.S's College of Pharmacy, Belgaum, 590 010, India

SOURCE: Indian Journal of Heterocyclic Chemistry (2005), 15(1), 79-80

CODEN: IJCHEI; ISSN: 0971-1627

PUBLISHER: Prof. R. S. Varma

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:22885


AB N'-3-(4-(4-Chlorophenyl)thiazol-2-yl)-2-aminomethyl)quinazolin-4(3H)-ones were synthesized. The prepared compds. were screened for the antimicrobial activity. Some of these showed promising antifungal and antibacterial activity.

IT 870539-32-5P 870539-33-6P 870539-34-7P
870539-35-8P 870539-36-9P 870539-37-0P
870539-39-2PRL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and microbial evaluation of (chlorophenyl)thiazolyquinazolin-


4(3H)-ones)

RN 870539-32-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl]-3-[4-(4-chlorophenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 870539-33-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[(4-fluorophenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 870539-34-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[(4-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 870539-35-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[(4-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 870539-36-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[(4-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 870539-37-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[4-(4-chlorophenyl)-2-thiazolyl]-2-[(pyrazinylamino)methyl- (9CI) (CA INDEX NAME)



RN 870539-39-2 CAPLUS
CN Benzoic acid, 4-[[3-[4-(4-chlorophenyl)-2-thiazolyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino-2-hydroxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:960102 CAPLUS
DOCUMENT NUMBER: 143:248418
TITLE: Preparation of heterocycle-substituted acetic acid esters or acetanilides
INVENTOR(S): Sugino, Motoaki; Iwamoto, Ryohei; Katakura, Toshie;
Sugita, Shuichi
PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JPOXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005232041	A2	20050902	JP 2004-41049	20040218
PRIORITY APPLN. INFO.:			JP 2004-41049	20040218
OTHER SOURCE(S):	HARPAT	143:248418		
GI				


L4 ANSWER 8 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 863318-29-0 CAPLUS
CN Benzoic acid, 4-chloro-3-[[3,4-dihydro-4-oxo-3-(2-pyridinyl)-2-quinazolinyl]-1H-imidazol-1-ylacetyl]amino-, dodecyl ester (9CI) (CA INDEX NAME)



AB The esters or acetanilides I (A = OR1, NHAr; R2 = alkyl, aryl, heterocyclic; Q1 = 5-7-membered ring-forming nonmetallic atom. group; R1 = alkyl, aryl; Ar = aryl; L1 = H, substituent), useful as intermediates for yellow photog. couplers, etc., are prepared by reacting I (R2 = H; Q1, R1, L1 same as above) with R2X (R2 = alkyl, aryl, heterocyclic; X = halo, OSO2R3; R3 = alkyl, aryl). Thus, BuLi was added dropwise to a mixture of MeCN, benzopyrimidinylacetate II (R2 = H), and Et3N, previously stirred at 40° for 1 h, over 1 h and the reaction mixture was further refluxed for 4 h to give 93% II (R2 = Bu).
IT 863318-29-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycle-substituted acetate esters or acetanilides by introducing alkyl, aryl, or heterocyclic to N with halides or sulfonates)

Habte


08/08/2006



AB The esters or acetanilides I (A = OR1, NHAr; R2 = alkyl, aryl, heterocyclic; Q1 = 5-7-membered ring-forming nonmetallic atom. group; R1 = alkyl, aryl; Ar = aryl; L1 = H, substituent), useful as intermediates for yellow photog. couplers, etc., are prepared by reacting I (R2 = H; Q1, R1, L1 same as above) with R2X (R2 = alkyl, aryl, heterocyclic; X = halo, OSO2R3; R3 = alkyl, aryl). Thus, BuLi was added dropwise to a mixture of MeCN, benzopyrimidinylacetate II (R2 = H), and Et3N, previously stirred at 40° for 1 h, over 1 h and the reaction mixture was further refluxed for 4 h to give 93% II (R2 = Bu).
IT 863318-29-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycle-substituted acetate esters or acetanilides by introducing alkyl, aryl, or heterocyclic to N with halides or sulfonates)

L4 ANSWER 9 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:822709 CAPLUS
 DOCUMENT NUMBER: 143:238608
 TITLE: Silver halide color photographic material and area gradation image-forming method
 INVENTOR(S): Tanaka, Shigeo; Ishidai, Hiroshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 97 pp.
 CODEN: JPOXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2005221902 A2 20050818 JP 2004-31458 20040209
 PRIORITY APPLN. INFO.: JP 2004-31458 20040209
 OTHER SOURCE(S): MARPAT 143:238608
 GI

L4 ANSWER 9 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a Ag halide color photog. material which comprises on a support ≥ 1 yellow coupler-containing Ag halide emulsion layer, ≥ 1 magenta coupler-containing Ag halide emulsion layer, and ≥ 1 cyan coupler-containing Ag halide emulsion layer and has a AgCl content ≥ 95 mol% in the all Ag halide emulsion layers, wherein the yellow, magenta, and cyan couplers are represented by I (B, R = substituent; Z = atomic group forming 6-7-membered ring; and A = leaving group), II (R1,12 = substituent; Y1 = leaving group), and III (R1 = H, substituent; R2 = substituent; m = integer; Z = nonmetallic atomic group forming N-containing 5-membered ring; and X1 = leaving group), resp. Further, ≥ 1 of said Ag halide emulsion contains a metal complex having Group V-X element central metal and nitroso or thionitroso ligand and a sp. inorg. S compound, and is sensitized by Au chalcogenide. Also disclosed is a process using a developer comprising an aromatic primary amino compound, a hydroxylamine derivative, and a compound represented by IV (R11,12 = H, substituent; R13,14 = H, alkyl, etc.; R15,16 = substituent; Rw = substituent; and M = H, alkali metal, alkali earth metal, etc.).
 IT 840524-02-9
 RL: NUU (Other use, unclassified); USES (Uses)
 (silver halide color photog. material and area gradation image-forming method)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:673090 CAPLUS
 DOCUMENT NUMBER: 143:166655
 TITLE: Phosphoinositide 3-kinase δ -selective inhibitors for treating and preventing hypertension and hypertension-related disorders
 INVENTOR(S): Watts, Stephanie W.; Northcott, Carrie A.
 PATENT ASSIGNEE(S): Michigan State University, USA
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PI0X02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2005067901 A2 20050728 WO 2005-US677 20050107
 WO 2005067901 A3 20051201
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW, SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, SQ, GV, ML, MR, NE, SN, TD, TG
 US 2005239809 A1 20051027 US 2005-31477 20050107
 PRIORITY APPLN. INFO.: US 2004-535412P P 20040108
 US 2004-547107P P 20040224
 US 2004-548620P P 20040227
 OTHER SOURCE(S): MARPAT 143:166655
 GI


L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 p110S subunit of PI-3-K to the development of hypertension and hypertension-related conditions by showing that it is localized to the vascular smooth muscle cells, up-regulated in both activity and expression, and pharmacol. responsive to specific inhibitors as evidence by changes in spontaneous tone. Thus, compds. that selectively inhibit phosphoinositide 3-kinase (PI-3-K) p110S expression activity can be used to treat hypertension and hypertension-related disorders. Inhibitors of expression include ribozymes, antisense oligonucleotides, and siRNA, while inhibitors of activity may include aptamers and small mols. In particular, 2-(6-aminopurin-9-ylmethyl)-5-methyl-3-o-tolyl-3H-quinazolin-4-one (I) is provided as a selective PI-3-K δ inhibitor for the treatment of hypertension.

IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474013-01-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphoinositide 3-kinase δ -selective inhibitors for treating and preventing hypertension and hypertension-related disorders)
 RN 371243-12-8 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


AB The present invention is based on the discovery that the δ isoform of phosphoinositide 3-kinase (PI-3-K) plays a role in arterial spontaneous tone, and specifically the p110S subunit in the mesenteric resistance arteries. The data emphasize the critical importance of the Habte




RN 371243-14-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-93-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-



RN 474012-96-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 474013-01-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-(2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 2005:302468 CAPLUS
 DOCUMENT NUMBER: 142:382086
 TITLE: Silver halide photographic paper showing improved color reproducibility, storage stability, color fading balance, and fast processability
 INVENTOR(S): Sugita, Shuichi; Sugino, Motoaki; Iwamoto, Ryohji
 PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 92 pp.
 CODEN: JPOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2005091679 A2 20050407 JP 2003-324246 20030917
 PRIORITY APPLN. INFO.: JP 2003-324246
 OTHER SOURCE(S): MARPAT 142:382086
 GI



AB The title photog. paper comprises at least a red-sensitive Ag halide emulsion layer, a green-sensitive Ag halide emulsion layer, and a red-sensitive Ag halide emulsion layer on a support, wherein the blue-sensitive Ag halide emulsion layer contains a yellow coupler represented by I ($\text{R}^1 = \text{substituent}; \text{X}^1 = \text{aryl, heterocycl}; \text{Z}^1 = \text{atoms for forming 6-membered ring}$) and the green-sensitive Ag halide emulsion layer contains a magenta coupler represented by II ($\text{Y}^{11} = \text{H, halo, alkyl, aryl, cycloalkyl, heterocycl, alkox, arylox}; \text{R}^{11}, \text{R}^{13} = \text{substituent}; \text{L}^{11} = -\text{NR}^{14}-, -\text{O}-, \text{R}^{12}, \text{R}^{14} = \text{alkyl, cycloalkyl, alkenyl, heterocycl, aryl}; \text{m}11 = 1, 2; \text{n}11 = 0-4; \text{X}^1 = \text{H group capable of leaving upon reaction with color development agent oxide}$). The photog. paper may contain the above yellow coupler in the red-sensitive Ag halide emulsion layer and a specified cyan coupler in the red-sensitive Ag halide layer. The above coupler combinations improved the color reproduction as well as the

L4 ANSWER 11 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 2005:302464 CAPLUS
 DOCUMENT NUMBER: 142:382083
 TITLE: Silver halide photographic paper containing specific surfactant and specific photographic yellow coupler
 INVENTOR(S): Nakamura, Takeshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
 CODEN: JPOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2005091649 A2 20050407 JP 2003-323808 20030917
 PRIORITY APPLN. INFO.: JP 2003-323808
 OTHER SOURCE(S): MARPAT 142:382083
 GI




AB The title film has light-sensitive layers containing photog. emulsions on a support, wherein surfactant $\text{R}-(\text{CF}_2)_m\text{CH}_2\text{CH}_2-\text{Y}-\text{L}^1-\text{COOX}$ ($\text{R} = \text{H, F}; m = \text{integer } 3-16; \text{Y} = \text{S, SO}_2, \text{SO}, \text{O}; \text{L}^1 = 2\text{-valent C23 compound X, cation}$) and wherein yellow coupler I ($\text{R} = \text{substituent}; \text{Z} = 6\text{- or 7-membered ring residue}; \text{R}' = \text{substituent}; n = \text{integer } 0-4; \text{X} = \text{H, hydrogen}; \text{A} = \text{H, leaving group}$). The photog. paper shows good storageability and provides images of good storageability.

IT 840524-02-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (yellow coupler in silver halide photog. paper)
 RN 840524-02-9 CAPLUS
 CN Benzonic acid, 4-[2-(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy-, methyl ester (9CI) (CA INDEX NAME)

RN 849336-68-1 CAPLUS
 CN 2-Quinazolineacetamide, N-[2-chloro-5-[(dioctylamino)sulfonyl]phenyl]-3,4-dihydro-4-oxo-3-phenyl-a-1H-1,2-triazol-1-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:286870 CAPLUS
DOCUMENT NUMBER: 143:26556

TITLE: Synthetic studies on 3-arylquinazolin-4-ones: Intramolecular nucleophilic aromatic substitution reaction of 2-carboxamido-3-aryquinazolin-4-ones and its application to the synthesis of secondary aryl amines

AUTHOR(S): Fuwa, Haruhiko; Kobayashi, Toshitake; Tokito, Takashi; Torii, Yukiko; Matsugari, Hideaki

CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan

SOURCE: Tetrahedron (2005), 61(17), 4297-4312


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:26556





GI




AB 2-Carboxamido-3-aryquinazolin-4-ones were prepared via acylation of aromatic amines, cyclodehydration, transesterification, and amidation. A novel intramol. nucleophilic aromatic substitution (SNAr) reaction of 2-carboxamido-3-aryquinazolin-4-ones, a potentially useful scaffold in the field of medicinal chemical, is described. E.g., treatment of 2-carboxamido-3-aryquinazolin-4-ones I (X = 4-CF3, o-CO2Me, 4-CN, etc.; R = CH2Ph, Ph, Bu) with NaH in DMF gave migrated products II. The synthetic utility of the SNAr reaction as a tool for the synthesis of secondary aryl amines, including diaryl amines, is also demonstrated. Thus, reaction of the 2-ethoxycarbonyl-3-aryquinazolin-4-ones and primary amines in the presence of a base induced a cascade process comprised of amide formation, intramol. SNAr reaction, and cleavage of the resultant tertiary amide to yield (in one-pot) secondary aryl amines.

IT 830324-73-7 830324-74-8P 830324-75-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intramol. nucleophilic aromatic substitution (SNAr) reaction of 2-carboxamido-3-aryquinazolin-4-ones)
RN 830324-73-7 CAPLUS
CN 2-Quinazolinonecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 830324-74-8 CAPLUS
CN 2-Quinazolinonecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)RN 830324-75-9 CAPLUS
CN 2-Quinazolinonecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-(4-trifluoromethylphenyl)- (9CI) (CA INDEX NAME)RN 830324-83-9 CAPLUS
CN 2-Quinazolinonecarboxamide, 3,4-dihydro-4-oxo-N-phenyl-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 830324-87-3 CAPLUS
CN Benzoic acid, 2-[4-oxo-2-[(phenylamino)carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:281059 CAPLUS

DOCUMENT NUMBER: 142:345089

TITLE: Color photographic films showing fine color

INVENTOR(S): Iwamoto, Ryoei; Sugino, Motoaki; Sugita, Shuichi
PATENT ASSIGNEE(S): Konica Minolta Photo Imaging, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 116 pp.

CODEN: JPOKA

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005084074	A2	20050331	JP 2003-312415	20030904
PRIORITY APPLN. INFO.:			JP 2003-312415	20030904

OTHER SOURCE(S): MARPAT 142:345089

GI



AB The films have blue-, green-, and red-sensitive emulsion layers on supports and contain yellow couplers I (R = substituent; X = aryl, heterocycle; Z = 6-membered ring; L = H or group leaving upon reaction with oxidized developers) and z1 of HOCGH3-n1(o-R10)(o'-R11)R12n1 [R10, R11 = alkyl; R12 = alkyl, NHR13, SR13 (R13 = monovalent organic group),

CO2R14 (R14 = H, monovalent organic group); n1 = 0-3], II (R21 = H, OH, oxy radical, SO2R27, SO2R27 (R27 = alkyl, aryl), alk(en)y1, alkyne1, COR28 (R28 = H, monovalent organic group); R22-R24 = alkyl, R25, R26 = H, OCOR29 (R29 = monovalent organic group); n2 = 0-4), C6OR31R32R33R34A3R5R36 [R31 = alkyl, trialkylsilyl; R32-R36 = H, alkyl(oxyl), etc.), C6(OH)R41R42R43R44 [R41-R44 = H, alkyl(oxyl), etc.], III (R53 = aryl, heterocycle; 254, 255 = Cl-3-alkylene satisfying total C number 3-6; n5 = 1, 2), or prescribed high-b.p. solvents (Markushes given) in one or more of the blue-sensitive layers.


IT 848650-81-7

RL: TEM (Technical or engineered material use); USES (Uses) (blue-sensitive emulsion layers; color photog. films containing sp. yellow

L4 ANSWER 14 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
couplers and dye fixers and showing good color reprodn. and lightfastness)

RN 848650-81-7 CAPLUS

CN 2-Quinazolinoneacetamide, N-[5-[(2-[2,5-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl)amino]-6,8-dichloro-a-(2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:258905 CAPLUS

DOCUMENT NUMBER: 142:345078

TITLE: Silver halide color photographic material showing excellent pressure-resistance, sticking-resistance, and color fading-resistance for color proof application

INVENTOR(S): Nakamura, Takeshi
PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JPOKA

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005077961	A2	20050324	JP 2003-310811	20030903
PRIORITY APPLN. INFO.:			JP 2003-310811	20030903

OTHER SOURCE(S): MARPAT 142:345078

GI



AB The title color photog. material contains a surface active agent represented by I [R1, R2 = alkyl; R3-5 = H, substituent; X1, X2, Z = connection group, single bond; M+ = cationic group; Y- = anion; m = 0, 1] or R(CF3)=CHCH2Y1N+(R1)(R2)(R3)-X- [R = H, F; m = 3-16; Y = S, SO2, O; L = divalent group having 2-4 carbons; R1-3 = H, alkyl; X- = anion] and a yellow coupler represented by II [R = substituent; Z = atoms for forming N-containing 6- or 7-membered ring; R' = substituent; n = 0-4].


X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent in a photog. emulsion layer.

IT 848408-90-2
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses) (yellow coupler in silver halide color photog. material showing excellent pressure-resistance, sticking-resistance, and color fading-resistance for color proof application)

RN 848408-90-2 CAPLUS


CN Benzoic acid, 4-[(2-butoxyphenyl)amino]-1-(3-[(dodecyloxy)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethoxy-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 16 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:238530 CAPLUS
 DOCUMENT NUMBER: 142:306367
 TITLE: Silver halide photographic paper showing improved yellow color reproducibility and image formation method from digital image data for color proof
 INVENTOR(S): Tanaka, Shigeo; Ishida, Hiroshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 99 pp.
 CODEN: JPOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005070685	A2	20050317	JP 2003-303814	20030828
PRIORITY APPLN. INFO.:			JP 2003-303814	20030828
OTHER SOURCE(S):	MARPAT	142:306367		
GI				



AB The title photog. paper contains a yellow coupler represented by I [B, R = substituent; Z = atoms for forming N-containing 6- or 7-member ring; A = H, group capable of leaving upon coupling with oxidized color development agent] and a high boiling organic solvent(s) selected from RaOC(CH₂)_mCOORb [Ra, Rb = C₄-10-alkyl; m = 2-10], RaCOOC(CnH₂n-2)COORd [Rc, Rd = C₄-10-alkyl; n = 2-10], RaCOOC(CH₂)_pOCRh [Re, Rf = C₃-24-alkyl; p = 2-10], C(Rg)(Rh)OH [Rg = alkyl, alkenyl; Rh, Ri = H, alkyl, alkenyl], X-[C(H₂)_qOCRj]r [X = 5- to 7-member saturated hydrocarbon ring; Rj = C₄-16-alkyl; q = 0-2; r = 1-3], Rk-OCH₂-CH(OH)-Rm [Rk = aliphatic, aromatic; Rm = H, aliphatic], RlOCO-C(R2)-COO(-R3-OOC-R2-COO)gR4 [R1, R4 = alkyl, alkenyl, cycloalkyl, aryl, heterocyclic; R2, R3 = alkylene, alkenylene, cycloalkylene; g = 1-20], and R50-R6-(OOC-R7-COO-R6-)tOr8 [R6, R7 = alkylene, alkenylene, cycloalkylene; R5, R8 = acyl, phosphonyl; t = 1-20] in a photosensitive emulsion layer(s).
 IT 840524-02-9
 RI: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (yellow coupler; silver halide photog. paper showing improved yellow color reproducibility and image formation method from digital image data for color proof)


RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NAME)




L4 ANSWER 17 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:235516 CAPLUS
 DOCUMENT NUMBER: 142:325823
 TITLE: Silver halide color photographic material containing yellow coupler
 INVENTOR(S): Okuyama, Masato
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
 CODEN: JPOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005070576	A2	20050317	JP 2003-302270	20030827
PRIORITY APPLN. INFO.:			JP 2003-302270	20030827
OTHER SOURCE(S):	MARPAT	142:325823		
GI				




AB Disclosed is a Ag color photog. material comprising a yellow photosensitive Ag halide emulsion layer, a magenta photosensitive Ag halide emulsion layer, and a cyan photosensitive Ag halide emulsion layer on a reflective support, wherein a dye-forming coupler in the yellow photosensitive Ag halide emulsion layer is represented by I [R = substituent; Z = atomic group forming ring; R' = substituent; n = 0-4; X = H, substituent; and A = leaving group], said coupler is dispersed in a hydrophilic colloid solution after dissolving in a high- or low-b.p. solvent, and said soluble contains a low-b.p. solvent 2-10%.
 IT 840524-02-9
 RI: NUU (Other use, unclassified); USES (Uses)
 (silver halide color photog. material containing yellow coupler)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 18 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:216177 CAPLUS
 DOCUMENT NUMBER: 142:306362
 TITLE: Silver halide color photographic paper showing excellent yellow color reproducibility suitable for digital color proof and its manufacture
 INVENTOR(S): Aoki, Atsushi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
 CODEN: JOKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062585	A2	20050310	JP 2003-294128	20030818
PRIORITY APPLN. INFO.:			JP 2003-294128	20030818
OTHER SOURCE(S):	MARPAT 142:306362			
GI				




L4 ANSWER 18 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title color photog. paper contains a yellow coupler represented by I (R = substituent; Z = atoms for forming 6- or 7-member ring; R' = substituent; n = 0-4; X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent) and a high boiling solvent represented by R21-(O)p-PO(O)-R23)-(O)q-R22 (R21-23 = aliphatic, aromatic; p, q, r = 0, 1) in a photog. emulsion layer.
 IT 840524-02-9
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler: silver halide color photog. paper showing excellent yellow color reproducibility suitable for digital color proof and its manufacture)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:216166 CAPLUS
 DOCUMENT NUMBER: 142:306361
 TITLE: Color photographic paper
 INVENTOR(S): Nakamura, Takeshi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
 CODEN: JOKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062498	A2	20050310	JP 2003-292835	20030813
PRIORITY APPLN. INFO.:			JP 2003-292835	20030813
OTHER SOURCE(S):	MARPAT 142:306361			
GI				



L4 ANSWER 19 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title photog. paper has light-sensitive layers containing photog. emulsion
 on a reflective support, wherein surfactant Ra-CON(Rb)-L-D(Ra = C26 alkylene; Rb = H, alkyl, aryl; D = -SO3M, -COOM, M = H, metal cation) is added in the photog. paper, and wherein photog. coupler I (Z = 6-7-membered ring residue; R' = substituent; n = integer 0-4; X = H, substituent; A = H, leaving group) is added in at least one of light-sensitive layers. The photog. paper shows good pressure-resistance and good image storagability.
 IT 840524-02-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (photog. couplers in color photog. paper)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:209982 CAPLUS
 DOCUMENT NUMBER: 142:287748
 TITLE: Silver halide color photographic paper showing improved storage stability suitable for digital color proof and image formation method using the same
 INVENTOR(S): Tanabe, Junichi
 PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
 Jpn. Kokai Tokkyo Koho, 49 pp.
 SOURCE: CODEN: JICCAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005062586	A2	20050310	JP 2003-294129	20030818
PRIORITY APPLN. INFO.:			JP 2003-294129	20030818
OTHER SOURCE(S):	MARPAT	142:287748		

GI



AB The title color photog. paper contains a yellow coupler represented by I (R = substituent; Z = atoms for forming 6- or 7-member ring; R' = substituent; n = 0-4; X = H, substituent; A = H, group capable of leaving upon coupling with oxidized color development agent) and a photog. emulsion stabilizer(s) selected from R11-SO2S-M11, R21-SO2-M21, and R31-S-S-R32 [R11, R21 = aliphatic, aromatic, heterocyclic; M11, M21 = cationic; R31, R32 = aliphatic, aromatic; R31 joining together with R32 may form ring]; in a photog. emulsion layer.
 IT 840524-02-9
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler; silver halide color photog. paper showing improved storage stability suitable for digital color proof and image formation method using the same)
 RN 840524-02-9 CAPLUS
 CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:160815 CAPLUS
 DOCUMENT NUMBER: 142:233323
 TITLE: Methods of inhibiting immune responses stimulated by an endogenous factor by administering phosphoinositide 3-kinase δ selective inhibitors
 INVENTOR(S): Douangpanya, Jason; Haylick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 27 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043239	A1	20050224	US 2004-918803	20040813
PRIORITY APPLN. INFO.:			US 2003-495370P	P 20030814
			US 2004-540090P	P 20040128


OTHER SOURCE(S): MARPAT 142:233323
 AB The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods of inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase delta (PI3Kδ) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.

IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474013-01-9
 845527-52-8 845527-53-9 845527-54-0
 845527-57-3 845527-58-4 845527-59-5
 845527-60-8 845527-61-9 845527-62-0
 845527-63-1 845527-64-2 845527-65-3
 845527-66-4 845527-67-5 845527-68-6
 845527-69-7 845527-70-0 845527-71-1
 845527-73-3 845527-74-4 845618-66-8


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (a) PI3Kδ selective inhibitor; phosphoinositide 3-kinase δ selective inhibitors for inhibiting immune responses stimulated by endogenous factor)

RN 371243-12-8 CAPLUS
 CN 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-13-9 CAPLUS
 CN 4-(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[[((2-amino-1H-purin-6-yl)amino)methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-[(2-fluoro-1H-purin-6-yl)amino]ethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-(1-(1H-purin-6-ylamino)ethyl)- (9CI) (CA INDEX NAME)



RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-(1-(1H-purin-6-ylamino)propyl)- (9CI) (CA INDEX NAME)


RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-[(2-fluoro-1H-purin-6-yl)amino]propyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

RN 474012-99-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(1-[(2-amino-1H-purin-6-yl)amino]propyl)-5-methyl-3-


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 845527-53-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-57-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-68-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[{(2-amino-1H-purin-6-yl)amino}methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[(2-diethylamino)ethyl]methylamino]phenyl]-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-70-0 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 845527-73-3 CAPLUS
 4(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-74-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 845618-66-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[{(2-fluoro-1H-purin-6-yl)amino}methyl]-5-methyl- (9CI) (CA INDEX NAME)

RN 845527-71-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:158543 CAPLUS
 DOCUMENT NUMBER: 142:233321
 TITLE: Methods of inhibiting leukocyte accumulation
 INVENTOR(S): Diacovo, Thomas G.; Haylick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): Icos Corporation, USA; Washington University
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016349	A1	20050224	WO 2004-US26834	20040813
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054614	A1	20050310	US 2004-918825	20040813
PRIORITY APPLN. INFO.:			US 2003-495370P	P 20030814
			US 2004-540036P	P 20040128

OTHER SOURCE(S): MARPAT 142:233321
 AB The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3K δ) activity in vascular endothelial cells. The adhesivity induced in these cells can result in temporary adhesion between the leukocytes and the endothelial cells, typically referred to as leukocyte tethering. Leukocyte tethering is generally mediated by interactions between selectin receptors including but not limited to E-selectin and P-selectin on endothelial cells and corresponding ligands present on leukocytes. The disclosed methods may be used to treat individuals having an inflammatory condition where leukocytes are accumulating at the site of insult or inflamed tissue. The disclosed methods may affect inflammatory conditions mediated by one or more components of the PI3K/Akt signal transduction pathway of endothelial cells.

IT 371243-12-8 371243-13-9 371243-14-0
 371243-15-1 371243-17-3 371243-22-0
 371243-23-1 474012-90-3 474012-93-6
 474012-96-9 474012-98-1 474013-01-9
 845527-52-8 845527-53-9 845527-54-0
 845527-57-3 845527-58-4 845527-59-5
 845527-60-8 845527-61-9 845527-62-0
 845527-63-1 845527-64-2 845527-65-3
 845527-66-4 845527-67-5 845527-68-6
 845527-69-7 845527-70-0 845527-71-1
 845527-72-2 845527-73-3 845527-74-4


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of leukocyte accumulation response to inflammatory mediator by inhibiting phosphoinositide 3-kinase and signal transduction of vascular endothelium to treat inflammatory conditions)
 RN 371243-12-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

RN 371243-14-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-15-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-22-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474012-93-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474012-98-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1H-purin-6-

Habte


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-53-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-57-3 CAPLUS

08/08/2006

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-60-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-62-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 845527-65-3 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-67-5 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]-

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-[2-[(2-(diethylamino)ethyl)methylamino]phenyl]-5-methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)




RN 845527-70-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-72-2 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4 (3H)-Quinazolinone, 2-[(1-[(2-amino-1H-purin-6-yl)amino]ethyl)-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 845527-73-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 845527-74-4 CAPLUS
 Habte

08/08/2006

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:158542 CAPLUS
 DOCUMENT NUMBER: 142:254586
 TITLE: Method using a phosphoinositide 3-kinase δ inhibitor for inhibiting immune responses stimulated by an endogenous factor
 INVENTOR(S): Dousangpanya, Jason; Haylick, Joel S.; Puri, Kamal D.
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXMD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200502248	A1	20050224	WO 2004-US26436	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RV: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SW, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CH, GA, GN, GQ, GW, ML, MR, NZ, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2003-495370P	P	20030814
		US 2004-540090P	P	20040128

OTHER SOURCE(S): MARPAT 142:254586

AB The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods for inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase δ (PI3K δ) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.

IT 371243-12-8 371243-13-9 371243-14-0

371243-15-1 371243-17-3 371243-22-0

371243-23-1 474012-90-0 474012-93-6

474012-96-9 474012-98-1 474013-01-9

845527-52-8 845527-53-9 845527-54-0

845527-57-3 845527-58-4 845527-59-5

845527-60-8 845527-61-9 845527-62-0

845527-63-1 845527-64-2 845527-65-3


845527-66-4 845527-67-5 845527-68-6

845527-69-7 845527-70-0 845527-71-1


845527-72-2 845527-73-3 845527-74-4

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (phosphoinositide 3-kinase inhibitor for inhibiting immune responses stimulated by endogenous factor)
 RN 371243-12-8 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-yl)amino]methyl- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-yl)amino]methyl- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 371243-22-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]ethyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-yl)amino]ethyl- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]ethyl-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-93-6 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474013-01-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-52-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-53-9 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-54-0 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-(2-fluorophenyl)-2-[1-[(2-fluoro-1H-purin-6-




RN 845527-57-3 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-chloro-3-(3,5-difluorophenyl)-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-58-4 CAPLUS
 CN 4 (3H)-Quinazolinone, 3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-59-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-60-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2,6-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)propyl]- (9CI) (CA INDEX NAME)




RN 845527-61-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 845527-62-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3,5-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-63-1 CAPLUS
CN 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-64-2 CAPLUS


L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 3-(2,3-difluorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-65-3 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 845527-66-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(3-chlorophenyl)-5-methyl-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 845527-67-5 CAPLUS
CN 4(3H)-Quinazolinone, 5-methyl-3-phenyl-2-[1-(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[{[(2-amino-1H-purin-6-yl)amino]methyl}-3-(3,5-difluorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 845527-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[2-[(2-diethylamino)ethyl]methylamino]phenyl]-5-

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-70-0 CAPLUS
CN 4-(3H)-Quinazolinone, 5-chloro-3-(2-fluorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-71-1 CAPLUS
CN 4-(3H)-Quinazolinone, 5-chloro-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 845527-72-2 CAPLUS
CN 4-(3H)-Quinazolinone, 5-chloro-3-(2-chlorophenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 845527-73-3 CAPLUS
CN 4-(3H)-Quinazolinone, 6-fluoro-3-(3-fluorophenyl)-2-[(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 845527-74-4 CAPLUS
CN 4-(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]ethyl-5-chloro-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005140199 CAPLUS
DOCUMENT NUMBER: 142-228609
TITLE: Silver halide color photographic material containing specific yellow coupler
INVENTOR(S): Muramatsu, Yasuhiro
PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005043530	A2	20050217	JP 2003-201442	20030725
PRIORITY APPLN. INFO.:			JP 2003-201442	20030725
OTHER SOURCE(S):	MARPAT 142:228609			
GI				



AB The material with short-side length ≥ 400 μm has each ≥ 1 yellow, magenta, and cyan color-forming light-sensitive emulsion layer on a reflecting support, in which the yellow color-forming light-sensitive layer contains a coupler I or II (R = substituent; Z = atoms required to form N-containing 6- or 7-membered ring with C:ONC:N; R' = substituent; n = 0-4; X = H, substituent; A = H, group to be released when coupled with color developer oxidation product). The material shows improved storage stability after development, and is useful for color proof.
IT 839711-63-6 839711-66-9
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide color photog. material containing pyrimidone derivative yellow coupler)
RN 839711-63-6 CAPLUS
CN 2-Quinazolineacetamide, N-[5-[(2-[5-his(1,1-dimethylpropyl)phenyl]-1-oxooctyl)amino]-2-(1-methylethoxy)phenyl]-3-cyclohexyl-a-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 839711-66-9 CAPLUS

CN Benzoic acid, 4-[2-[(5-chloro-2-(dodecyloxy)phenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:138433 CAPLUS

DOCUMENT NUMBER: 142:228608

TITLE: Silver halide photographic emulsion containing metal complex and yellow coupler

INVENTOR(S): Tanaka, Shigeo; Ishidai, Hiroshi

PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan; Konica Minolta Photo Imaging, Inc.

SOURCE: Jpn. Kokai Tokkyo Koho, 91 pp.

CODEN: JPOKAFT


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005043529	A2	20050217	JP 2003-201441	20030725
PRIORITY APPLN. INFO.:		JP 2003-201441		20030725
OTHER SOURCE(S):	MARPAT 142:228608	GI		



AB The material has ≥ 1 emulsion layer with $\text{AgCl} \approx 95$ mol%, containing (a) an emulsion containing an Ir complex and a metal complex having a central metal of group VB to VIII elements except Ir in a periodic table and a nitrosoyl or thionitrosoyl ligand and (b) the yellow coupler I (B = substituent; Z = atoms required to form N-containing 6- or 7-membered ring with N: A = H, group to be released when coupled with color developer oxidation product). The material prevents sensitivity change in storage under high-temperature conditions.


IT RL: TEM (Technical or engineered material use); USES (Uses) (yellow coupler; silver halide photog. emulsion containing metal complex and yellow coupler)

RN 840524-02-9 CAPLUS

CN Benzoic acid, 4-[2-[(2-butoxyphenyl)amino]-1-[3-(4-dodecylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1062614 CAPLUS

DOCUMENT NUMBER: 142:155910

TITLE: Intramolecular nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-ones and its application to the synthesis of secondary aryl amines

AUTHOR(S): Fuwa, Haruhiko; Kobayashi, Toshitake; Tokitoh, Takashi; Torii, Yukiko; Nataguri, Hideaki

CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033, Japan

SOURCE: Synlett (2004), (14), 2497-2500

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:155910

AB A novel intramol. nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-one derivs. induced by base treatment and its application to the expedited synthesis of secondary aryl amines, including diaryl amines, are described.


IT 830324-73-7 830324-87-3 830324-75-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of secondary aryl amines and diaryl amines via intramol. nucleophilic aromatic substitution reaction of 2-carboxamido-3-arylquinazolin-4-one derivs.)


RN 830324-73-7 CAPLUS

CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-phenyl)- (9CI) (CA INDEX NAME)




RN 830324-74-8 CAPLUS

CN 2-Quinazolinecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 830324-75-9 CAPLUS


L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Quinazolininecarboxamide, 3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 830324-83-9 CAPLUS
 CN 2-Quinazolininecarboxamide, 3,4-dihydro-4-oxo-N-phenyl-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 830324-87-3 CAPLUS
 CN Benzoic acid, 2-[4-oxo-2-[(phenylamino)carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 830324-88-4 CAPLUS
 CN Benzoic acid, 2-[4-oxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-3(4H)-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:902341 CAPLUS
 DOCUMENT NUMBER: 141:379919
 TITLE: Preparation of (iso)thiazole benzenesulfonamides and other heterocycles as inhibitors of fungal invasion
 INVENTOR(S): Talley, John Jeffrey; Fretzen, Angelika; Zimmerman, Craig; Barden, Timothy; Yang, Jing Jing; Martinez, Eduardo; Milne, G. Todd; Etchell, A. Cordero; Christine, M. Pierce; Houman, Fariba; Busby, Robert; Summers, Eric F.; Antonelli, Stephen; Lee, Peter; Farwell, Michael; Mayorga, Maria; O'Leary, Jessica
 PATENT ASSIGNEE(S): Microbia, Inc., USA
 SOURCE: PCT Int. Appl., 179 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092123	A2	20041028	WO 2004-US11187	20040412
WO 2004092123	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, N2, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, U2, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, S2, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:	US 2003-461727P	P	20030410	
	US 2003-469286P	P	20030509	
	US 2003-485678P	P	20030709	

OTHER SOURCE(S): MARPAT 141:379919
 GI

L4 ANSWER 27 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 logarithmic phase growth, title compds. showed IC50's of as low as 0.0005 μ M.
 IT 313067-40-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses);
 (preparation of (iso)thiazole benzenesulfonamides and other heterocycles
 as
 inhibitors of fungal invasion)
 RN 313067-40-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(phenylamino)methyl]-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




AB Title compds. e.g. [I]: R1 = (substituted) alkyl, alkoxy; R2 = H, halo; R3 = H, CHO, Ac, (substituted) alkyl; R4 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkylamino, Ph, heteroaryl, were prepared. Thus, 4-bromo-2-fluoro-N-(5-methylthiazol-2-yl)benzenesulfonamide, 4-fluorobenzenesboronic acid, Pd(PPh3)4, and K2CO3 were stirred in PhMe/Me2CHOH/H2O to give 15% 2,4'-difluoro-N-(5-methylthiazol-2-yl)-1,1'-biphenyl-4-sulfonamide. In a screen for inhibition of *Candida albicans*.

Habte


08/08/2006

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:167291 CAPLUS
 DOCUMENT NUMBER: 141:325173
 TITLE: Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivatives
 AUTHOR(S): Watkins, William J.; Lemoine, Remy C.; Chong, Lee; Cho, Aesop; Renau, Thomas E.; Kuo, Bonnie Wong; Vickie, Ludvikov; Marin, Garizi; Negar; Iqbal, Nadeem; Barnard, John; Janikowska, Renata; Singh, Rajeshwar; Madsen, Deidre; Lolans, Karen; Lomovskaya, Olga; Oza, Uma; Dudley, Michael N.
 CORPORATE SOURCE: Essential Therapeutics, Inc., Mountain View, CA, 94043, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20): 5133-5137
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:325173
 AB Structure-activity relationships of a novel series of fungal efflux pump inhibitors with respect to potentiation of the activity of fluconazole against strains of *Candida albicans* and *Candida glabrata* over-expressing ABC-type efflux pumps are systematically explored.
 IT 562835-78-3P 562835-83-OP 562835-84-1P
 562835-85-2P 562835-87-4P 562835-90-9P
 562835-91-0P 562835-92-1P 562835-94-3P
 562836-06-0P 562836-07-1P 562836-26-4P
 626245-88-3P 770746-52-6P 770746-53-7P
 770746-54-8P 770746-55-9P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 CW: Vito, structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors
 RN 562835-78-3 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562835-87-4 CAPLUS
 CN Benzenesulfonamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-90-9 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 562835-83-0 CAPLUS
 CN Urea, N'-(2-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-84-1 CAPLUS
 CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-85-2 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562835-91-0 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 562835-92-1 CAPLUS
 CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-94-3 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562836-06-0 CAPLUS
CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-07-1 CAPLUS
CN Benzanide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-26-4 CAPLUS
CN (4R)-Quinazolinone, 2-[1-((2,4-dimethoxyphenyl)amino)ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 626245-88-3 CAPLUS
CN Urea, N'-(6-chloro-3-pyridazinyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-52-6 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 770746-53-7 CAPLUS
CN Urea, N'-(3-cyanophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 770746-54-8 CAPLUS
CN Urea, N'-2-benzothiazolyl-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-55-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)carbonyl]- (9CI) (CA INDEX NAME)




IT 626245-93-0 626245-96-3 626246-00-2
626246-07-9 626246-13-7 626246-16-0
626246-22-8 626246-28-4 626246-31-9
626246-43-3 626246-48-8 626246-51-3
626246-54-6 626246-56-8 626246-64-8
633307-22-9 770746-58-2 770746-59-3
770746-60-6 770746-61-7 770746-62-8
770746-63-9 770746-64-0 770746-65-1
770746-66-2 770746-67-3 770746-68-4
770746-69-5 770746-70-8 770746-73-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors)

RN 626245-93-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(4-fluorophenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626245-96-3 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 626246-00-2 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-07-9 CAPLUS
CN Urea, N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-13-7 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-16-0 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-22-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)


L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626246-28-4 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-(1-oxopropoxy)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-31-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-43-3 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-48-8 CAPLUS
CN Urea, N-[1-[7-cyano-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-51-3 CAPLUS
CN 7-Quinazolinecarboxylic acid, 2-(1-[(4-fluorophenyl)amino]carbonyl)aminoethyl-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 626246-54-6 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-(7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 626246-56-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-56-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-hydroxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 633307-22-9 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-(7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 770746-58-2 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 770746-59-3 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-60-6 CAPIUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-61-7 CAPIUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-62-8 CAPIUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770746-63-9 CAPIUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(2,4-dimethylphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-64-0 CAPIUS
CN Urea, N-[2,4-bis(cyclopropylmethoxy)phenyl]-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-65-1 CAPIUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxy-3-pyridinyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-66-2 CAPIUS
CN Urea, N-[1-[5-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 770746-67-3 CAPIUS
CN Acetamide, 2-[[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quinazolinyl-oxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 770746-68-4 CAPLUS
 CN Methanesulfonamide, N-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quiazolinyl]- (9CI) (CA INDEX NAME)




RN 770746-69-5 CAPLUS
 CN Acetamide, N-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quiazolinyl]- (9CI) (CA INDEX NAME)




RN 770746-70-8 CAPLUS
 CN 7-Quinazolinecarboxylic acid, 2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 770746-73-1 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N-[(1R)-1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-6-quiazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 633305-75-6P 849751-99-1P 849752-46-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in vitro structure-activity relationships of (N-methylpiperazinyl)-containing derivs. of quinazolinone, fungal efflux pump inhibitors)


RN 633305-75-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 849751-99-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2,4-difluorophenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 849752-46-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(1R)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004-767290 CAPLUS
 DOCUMENT NUMBER: 141:325172
 TITLE: Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant *Candida* spp.

AUTHOR(S): Lemoine, Remy C.; Glinka, Tomasz W.; Watkins, William J.; Cho, Aesop; Yang, Jessie; Iqbal, Nadeem; Singh, Rajeshwar; Madsen, Deidre; Lolans, Karen; Lomovskaya, Olga; Oza, Umar; Dudley, Michael N.

CORPORATE SOURCE: Essential Therapeutics, Inc., Mountain View, CA, 94043, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5127-5131

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:325172

AB The discovery of a series of quinazolinone-based fungal efflux pump inhibitors by high-throughput screening for potentiation of fluconazole in *C. albicans* is described. Attempts to improve the aqueous solubility of screening

hits led to the discovery of an analog with greatly improved phys. properties and activity against clin.-relevant *Candida* spp.


IT 562835-78-3P 770743-57-2P 770743-58-3P

770743-59-4P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PNEP (Preparation); USES (Uses)


(N-methylpiperazine-containing quinazolinone derivative, efflux pump inhibitors in clin. relevant *Candida* spp.)

RN 562835-78-3 CAPLUS


CN Urea, N'-(3-chlorophenyl)-N-[(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quiazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 770743-57-2 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quiazolinyl)methyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770743-58-3 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]-1-methylethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 770743-59-4 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 770743-60-7
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-methylpiperazine-containing quinazolinone derivative, efflux pump inhibitors
in clin. relevant Candida spp.)
RN 770743-60-7 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[(1R)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 562836-26-4P 633305-74-5P 633305-75-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(N-methylpiperazine-containing quinazolinone derivative, efflux pump inhibitors
in clin. relevant Candida spp.)
RN 562836-26-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 633305-74-5 CAPLUS
CN Benzenesulfonamide, N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-2,4-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633305-75-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 30 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004-609430 CAPLUS
 DOCUMENT NUMBER: 141:164773
 TITLE: Processing of silver halide color photographic material containing yellow coupler and color imaging method to improve yellow color reproducibility
 INVENTOR(S): Ishida, Hiroshi; Tanaka, Shigeo
 PATENT ASSIGNEE(S): Konica Minolta MG K. K., Japan; Konica Minolta Photo Imaging K. K.
 SOURCE: Jpn Kokai Tokkyo Koho, 91 pp.
 CODEN: JKOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004212936	A2	20040729	JP 2003-291105	20030911
JP 2004246316	A2	20040902	JP 2003-201438	20030725
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			JP 2002-368028	A 20021219
MARPAT 141:164773 G1				




I

AB A silver halide color photog. material containing a yellow coupler represented by Alm-G-NH-O-R2 (R1 = aliphatic, aromatic, heterocyclyl, alkoxy, aryloxy, amino, -C(=O)-, -C(=O)NH-, -C(=O)NH-C(=O)-, -PO-, -SO-, -SO2-, R2 = R1 or is processed by a processing solution containing a compound represented by I (R11, R12 = H, substituent; R13, R14 = H, alkyl, aryl; R15, R16 = -(C(A)2)f-Og-(C(A)2)h-Oi-(C(A)2j)-Ok-H; Rv = H, -(C(A)2)f-Og-(C(A)2j)-Ok-H, -CH2CHG2603M; M = H, alkali metal, alkaline earth metal, ammonium pyridinium; A = H, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl; f, h, i = 1, 2; g, j, k = 0, 1). The color photog. material is especially suitable for color proof applications.
 IT 728032-91-5 728032-92-6


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003-971729 CAPLUS
 DOCUMENT NUMBER: 140:27843
 TITLE: Preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors
 INVENTOR(S): Watkins, Will J.; Lemoine, Remy; Cho, Aesop; Palme, Monica
 PATENT ASSIGNEE(S): Essential Therapeutics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Pat. Appl. 2003 220,338.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003229097	A1	20031211	US 2002-334755	20021230
US 6689782	B2	20040210		
US 6569723	B1	20030722	US 2001-906864	20010716
US 2003220338	A1	20031127	US 2002-243074	20020912
WO 2004024140	A1	20040325	WO 2003-US5184	20030221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KZ, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GV, ML, MR, NE, SN, TD, TG				
AU 2003215343	A1	20040430	AU 2003-215343	20030221
PRIORITY APPLN. INFO.:			US 2001-906864	A2 20010716
			US 2002-243074	A2 20020912
			US 2002-334755	A 20021230
OTHER SOURCE(S):	MARPAT 140:27843		WO 2003-US5184	W 20030221
GI				




I

L4 ANSWER 30 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: DEV (Device component use); USES (Uses)
 (yellow coupler); processing of silver halide color photog. material contg. yellow coupler and color imaging method to improve yellow color reproducibility
 RN 728032-91-5 CAPLUS
 CN Benzoic acid, 3-[[3-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)(5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-4-(1-methylethoxy)-, tetradecyl ester (9CI) (CA INDEX NAME)




RN 728032-92-6 CAPLUS
 2-Quinazolinacetamids, α -chloro-N-[5-chloro-2-(octadecyloxy)phenyl]-3,4-dihydro-4-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB The title compds. [I; Al = C, N (provided that when Al = N, R5 does not exist); R2, R3 = H, halo, alkoxy; R4, R6 = H, halo, alkoxy, OCF3, OC2H5(cycloalkyl); R5 = [1,2,3]triazol-2-yl; R7, R8 = H, halo, CN, alkoxy, OCH2, OCF3, or taken together form OCH2O; R1 = alkyl, cycloalkyl, CH2[alkyl], etc.; R2 = H, alkyl] and, particularly I wherein the compound is in S absolute configuration at the started carbon, that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism, were claimed. The general methods for the synthesis of the racemic and the enantiomERICALLY enhanced compds. I are given. E.g., a S-Asp synthesis of I [Al = C; R1 = Me; R2, R3, R5, R6, R7 = H; R4, R8 = OMe, R9 = CN] (starting from anthranilic acid and propionic anhydride), was presented. The activity of the compds. I in combination with an antifungal agent [fluconazole] were assessed using a checkerboard assay and the broth microdilution protocol. Data presented in tables show potentiation of anti-fungal, as manifested by a reduction in the MIC of the anti-fungal in the presence, as contrasted to the absence, of an efflux pump inhibitor I. The compds. I, most of which are shown to have little or no intrinsic anti-fungal activity, are tested at concns. of 4-32 μ g/mL. Pharmaceutical composition comprising the compound I and an antifungal agent is claimed.


IT 633305-97-2 CAPLUS
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)
 RW 633305-97-2 CAPLUS
 CN Piperazine, 1-[(2-aminoacyclopentyl)carbonyl]-4-[2-[(1-(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)



RN 633306-05-5 CAPLUS
 CN Piperazine, 1-(6-chloro-2-[(1-(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl)amino]ethyl)-4-oxo-3(4H)-quinazolinyl-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




IT 633305-78-9P 633305-79-0P 633305-80-3P
 633305-81-4P 633305-82-5P 633305-83-6P
 633305-84-7P 633305-86-9P 633305-87-0P
 633305-88-1P 633305-89-2P 633305-90-5P
 633305-91-6P 633305-92-7P 633305-93-8P
 633305-94-9P 633305-95-0P 633305-96-1P
 633305-98-3P 633305-99-4P 633306-00-0P
 633306-01-1P 633306-03-3P 633306-04-4P
 633306-06-6P 633306-07-7P 633306-08-8P
 633306-10-2P 633306-11-3P 633306-12-4P
 633306-13-5P 633306-14-6P 633306-15-7P
 633306-16-8P 633306-17-9P 633306-18-0P
 633306-19-1P 633306-20-4P 633306-21-5P
 633306-22-6P 633306-23-7P 633306-24-8P
 633306-25-9P 633306-26-0P 633306-27-1P
 633306-28-2P 633306-29-3P 633306-30-6P
 633306-31-7P 633306-32-8P 633306-33-9P
 633306-34-0P 633306-35-1P 633306-36-2P
 633306-37-3P 633306-38-4P 633306-39-5P
 633306-40-8P 633306-41-9P 633306-42-0P
 633306-43-1P 633306-44-2P 633306-45-3P
 633306-46-4P 633306-47-5P 633306-48-6P
 633306-49-7P 633306-50-0P 633306-52-2P
 633306-53-3P 633306-54-4P 633306-55-5P
 633306-56-6P 633306-57-7P 633306-58-8P
 633306-59-9P 633306-60-2P 633306-61-3P
 633306-62-4P 633306-63-5P 633306-64-6P
 633306-65-7P 633306-66-8P 633306-67-9P
 633306-68-0P 633306-69-1P 633306-70-4P
 633306-71-5P 633306-72-6P 633306-73-7P
 633306-74-8P 633306-75-9P 633306-76-0P
 633306-77-1P 633306-78-2P 633306-79-3P
 633306-80-6P 633306-81-7P 633306-82-8P
 633306-83-9P 633306-84-0P 633306-85-1P
 633306-86-2P 633306-87-3P 633306-88-4P
 633306-89-5P 633306-90-6P 633306-91-7P
 633306-92-0P 633306-93-1P 633306-94-2P

L4 ANSWER 31 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)

633306-95-3P 633306-96-4P 633306-97-5P
 633306-98-6P 633306-99-7P 633307-00-3P
 633307-01-4P 633307-02-5P 633307-03-6P
 633307-04-7P 633307-05-8P 633307-06-9P
 633307-07-0P 633307-08-1P 633307-09-2P
 633307-10-5P 633307-11-6P 633307-12-7P
 633307-13-8P 633307-14-9P 633307-15-0P
 633307-16-1P 633307-17-2P 633307-18-3P
 633307-19-4P 633307-20-5P 633307-21-6P
 633307-22-9P 633307-24-1P 633307-26-3P
 633307-28-5P 633307-30-9P 633307-32-1P
 633307-34-3P 633307-36-5P 633307-38-7P
 633307-39-8P 633307-40-1P 633307-41-2P
 633307-42-3P 633307-43-4P 633307-44-5P
 633307-45-6P 633307-46-7P 633307-47-8P
 633307-48-9P 633307-49-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepns. of quinazolinylmethyl ureas as fungal efflux pump inhibitors)

RN 633305-78-9 CAPIUS
 CN Urea, N'-(4-cyanophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-79-0 CAPIUS
 CN Urea, N'-(4-(difluoromethoxy)phenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633305-80-3 CAPIUS
 CN Urea, N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-81-4 CAPIUS
 CN Urea, N'-(4-methylphenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 31 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633305-82-5 CAPIUS
 CN Urea, N'-(4-cyanophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-83-6 CAPIUS
 CN Urea, N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-84-7 CAPIUS
 CN Urea, N'-1,3-benzodioxol-5-yl-N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-86-9 CAPLUS
CN Urea, N-[1-(3-chlorophenyl)-N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-87-0 CAPLUS
CN Urea, N-[1-(6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 633305-88-1 CAPLUS
CN Urea, N-[1-(7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-89-2 CAPLUS
CN Urea, N-[1-(7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)



RN 633305-90-5 CAPLUS
CN Urea, N-[1-(6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-91-6 CAPLUS
CN Urea, N-[1-(7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-(difluoromethoxy)phenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-92-7 CAPLUS



Habte




RN 633305-93-8 CAPLUS
CN Urea, N-[1-(7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-cyano phenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-94-9 CAPLUS
CN Urea, N-[1-(7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 633305-95-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-4-oxo-3-[4-(1,3,4-thiadiazol-2-yl)-1-piperazinyl]-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 633305-96-1 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)-N-[1-[3-(4-formyl-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 633305-98-3 CAPLUS
CN Carbamic acid, [2-[4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]carbonyl]cyclopentyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633305-99-4 CAPLUS
CN Piperazine, 1-[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-00-0 CAPLUS
CN Carbamic acid, [1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]carbonyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633306-01-1 CAPLUS
CN Carbamic acid, [(3R)-1-[(4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633306-03-3 CAPLUS
CN Carbamic acid, [(3S)-1-[(4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl)carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-04-4 CAPLUS
CN Carbamic acid, [(3S)-1-[(4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)carbonyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 633306-06-6 CAPLUS
 CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 633306-07-7 CAPLUS
 CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-08-8 CAPLUS
 CN Piperazine, 1-[3-aminopyrazinyl]carbonyl]-4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633306-10-2 CAPLUS
 CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(2-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-11-3 CAPLUS
 CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(2-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 633306-12-4 CAPLUS
 CN 1-Pyrrolidinocarboxylic acid, 2-[(4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-13-5 CAPLUS
 CN Piperazine, 1-[(2S)-1-cyclopropyl-2-pyrrolidinyl]carbonyl]-4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-14-6 CAPLUS
 CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-1-methyl-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-15-7 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(tetrahydro-2-furanyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 633306-16-8 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(1-methylsulfonyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 633306-17-9 CAPLUS

CN 1-Pyrorolidinecarboxylic acid, 3-[[4-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633306-18-0 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(1-methylsulfonyl)-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 633306-19-1 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(1-dimethylamino)sulfonyl]-3-pyrrolidinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 633306-20-4 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(5-methyl-3-isoxazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 633306-21-5 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-(3-morpholinyl)carbonyl- (9CI) (CA INDEX NAME)



RN 633306-22-6 CAPLUS


CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-(3-piperidinyl)carbonyl- (9CI) (CA INDEX NAME)



RN 633306-23-7 CAPLUS

CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4S,5R)-5-methyl-2-oxo-4-oxazolidinyl]carbonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-24-8 CAPLUS


CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4S,5R)-5-methyl-2-oxo-4-oxazolidinyl]carbonyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633306-25-9 CAPLUS


CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(5-isoxazolyl)carbonyl] - (9CI) (CA INDEX NAME)



RN 633306-26-0 CAPLUS

CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-27-1 CAPLUS

CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-28-2 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-5-oxo-2-pyrrolidinyl]carbonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-29-3 CAPLUS

CN Carboxylic acid, [(1S,2R)-1-[(4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-30-6 CAPLUS


CN Acetamide, N-[(1S,2R)-1-[(4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-hydroxypropyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-31-7 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[6-chloro-2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-32-8 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[7-chloro-2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-33-9 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[6-chloro-2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-34-0 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-35-1 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-36-2 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[6-chloro-2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-37-3 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[7-chloro-2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633306-38-4 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[2-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino)ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-39-5 CAPLUS

CN Carbamic acid, [(1S,2R)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-40-8 CAPLUS

CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S,3R)-3-hydroxy-2-(methylsulfonyl)amino]-1-oxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-43-1 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-44-2 CAPLUS

CN Acetamide, N-[(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-41-9 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(H-imidazol-4-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-42-0 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-3-(methylsulfonyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-45-3 CAPLUS

CN Carbamic acid, [(1S)-2-[4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(hydroxymethyl)-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-46-4 CAPLUS


CN Carbamic acid, [(1S)-1-[(4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-47-5 CAPLUS
CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[2-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-48-6 CAPLUS
CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[6-chloro-2-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 633306-50-0 CAPLUS
CN Piperazine, 1-[(2S)-2-amino-1-oxobutyl]-4-[2-[(2,4-dimethoxyphenyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-56-6 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[6-chloro-2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-57-7 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[7-chloro-2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-58-8 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-7-fluoro-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-59-9 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-60-2 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-61-3 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-methylpropyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-62-4 CAPLUS

CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-methylpropyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-63-5 CAPLUS


CN Carbamic acid, [(1S)-1-[(4-[2-{1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-methylpropyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-64-6 CAPIUS
 CN Carbamic acid, [(1R)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-65-7 CAPIUS
 CN Carbamic acid, [(1S)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-66-8 CAPIUS
 CN Carbamic acid, [(1S)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl)methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-67-9 CAPIUS
 CN Carbamic acid, [(1S)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl)methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-68-0 CAPIUS
 CN Carbamic acid, [(1S)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-69-1 CAPIUS
 CN Carbamic acid, [(1S)-2-[4-{2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-70-4 CAPIUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-71-5 CAPIUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-72-6 CAPLUS
CN Piperazine, 1-[{(2S)-2-amino-1-oxopropyl]-4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-73-7 CAPLUS
CN Piperazine, 1-[{(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-74-B CAPLUS
CN Carbamic acid, [(1S)-2-[4-[2-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-75-9 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-76-0 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[2-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-methoxy-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-77-1 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633306-78-2 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[2-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-79-3 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[2-1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-80-6 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633306-81-7 CAPLUS
CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[2-(dimethylamino)-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-82-8 CAPLUS
CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[2R]-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633306-83-9 CAPLUS
CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-4-[2S]-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 633306-84-0 CAPLUS
CN Piperazine, 1-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[2S]-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 633306-85-1 CAPLUS
CN Piperazine, 1-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[2S]-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-86-2 CAPLUS
CN Piperazine, 1-[2-amino-4-thiazolyl]acetyl]-4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633306-87-3 CAPLUS
CN Carbamic acid, [3-[4-[(2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl)-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-88-4 CAPLUS
CN Carbamic acid, [3-{4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 633306-88-5 CAPLUS
CN Carbamic acid, {3-[4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl}-3-oxopropyl-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-90-8 CAPLUS
CN Carbamic acid, {2-[4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl}-2-oxoethylmethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 633306-91-9 CAPLUS
CN Carbamic acid, {2-[4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl}-2-oxoethylmethyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 633306-92-0 CAPLUS
CN Carbamic acid, {2-[4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl}-2-oxoethyl-, .methyl ester (9CI) (CA INDEX NAME)




RN 633306-93-1 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(methylsulfonyl)amino]acetyl- (9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633306-94-2 CAPLUS
CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-95-3 CAPLUS
CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl){(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-96-4 CAPLUS
CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[7-chloro-2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-97-5 CAPLUS
CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-98-6 CAPLUS
CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[2-[1-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633306-99-7 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-1-piperazinyl-1,1-dimethyl-2-oxoethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 633307-00-3 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-1-piperazinyl-1,1-dimethyl-2-oxoethyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 633307-01-4 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl-1-piperazinyl-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633307-02-5 CAPLUS
CN Carbamic acid, [2-[4-[6-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-1-piperazinyl-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 633307-03-6 CAPLUS
CN Carbamic acid, [2-[4-[7-chloro-2-[(2,4-dimethoxyphenyl)][(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-1-piperazinyl-1,1-dimethyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-04-7 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 633307-05-8 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-06-9 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethyl-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 633307-07-0 CAPLUS
CN Carbamic acid, [2-[4-[6-chloro-2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-08-1 CAPLUS
CN Carbamic acid, [2-[4-[7-chloro-2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethyl-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 633307-09-2 CAPLUS
CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 633307-10-5 CAPLUS
CN Carbamic acid, [1-{[4-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl}-1-piperazinyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 633307-11-6 CAPLUS
CN Carbamic acid, [1-{[4-[2-[(2,4-bis(cyclopropylmethoxy)phenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl}-1-piperazinyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

||


O

RN 633307-12-7 CAPLUS
 CN Piperazine, 1-[3-amino-1-pyrrolidinyl]carbonyl]-4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 633307-15-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633307-16-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[(2-[4-bis(cyclopropylmethoxy)phenyl][(4-fluorophenyl)amino]carbonyl]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-17-2 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[[2-1-[[{(4-fluorophenyl)amino}carbonyl]3-(2H-1,2,3-triazol-2-yl)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-

L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 633307-13-8 CAPLUS
 CN Piperazine, 1-[2-{[2-(cyclopropylmethoxy)phenyl][{[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-14-9 CAPLUS
 CN Piperazine, 1-[2-{[4-(cyclopropylmethoxy)phenyl][{[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 633307-18-3 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(4-fluoro-2-methoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 633307-18-3 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(4-fluoro-2-methoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633307-19-4 CAPLUS
 CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[[{(4-fluorophenyl)amino}carbonyl][2-(trifluoromethoxy)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)



RN 633307-20-7 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(2-(cyclopropylmethoxy)phenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633307-21-8 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(2-ethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 633307-22-9 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[(1S)-1-(7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-24-1 CAPLUS
CN Urea, N-[(1S)-1-(3,4-dihydro-4-oxo-3-[4-(1,3,4-thiadiazol-2-yl)-1-piperazinyl]-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-26-3 CAPLUS
CN 1-Pyrrolidinocarboxylic acid, 2-[[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-28-5 CAPLUS
CN Piperazine, 1-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-30-9 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[6-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-32-1 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[[4-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-34-3 CAPLUS
CN Carbamic acid, [(1S,2R)-1-[(4-[2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-36-5 CAPLUS
CN Carbamic acid, [(1S)-1-[(4-[2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-38-7 CAPLUS
CN Piperazine, 1-[(2S)-2-amino-1-oxopropyl]-4-[(7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-39-8 CAPLUS
CN Carbamic acid, [(1S)-2-[(4-[2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6,7-difluoro-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-40-1 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[6-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-41-2 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-42-3 CAPLUS
CN Carbamic acid, [(1S)-2-[(4-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-43-4 CAPLUS
CN Carbamic acid, [(1S)-2-[2-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-44-5 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-45-6 CAPLUS
 CN Piperazine, 1-(2-amino-2-methyl-1-oxopropyl)-4-[6-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-46-7 CAPLUS
 CN Carbamic acid, [2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-47-8 CAPLUS
 CN Carbamic acid, [2-[4-[7-chloro-2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-48-9 CAPLUS
 CN Carbamic acid, [2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633307-49-0 CAPLUS
 CN Carbamic acid, [2-[4-[2-[(1S)-1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 562835-90-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)
 RN 562835-90-9 CAPLUS
 CN Urea, N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2-(4-dimethoxyphenyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 562836-26-4P 626245-65-6P 633305-74-5P
 633305-75-6P 633305-76-7P 633305-77-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinazolinylmethyl ureas as fungal efflux pump inhibitors)
 RN 562836-26-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 626245-65-6 CAPLUS
CN Urea, N-[1-(3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 633305-74-5 CAPLUS
CN Benzenesulfonamide, N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-2,4-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633305-75-6 CAPLUS
CN 4 (3H)-Quinazolinone, 2-[(1S)-1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633305-76-7 CAPLUS
CN Urea, N-[(1S)-1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 633305-77-8 CAPLUS
CN Urea, N-[(1S)-1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003-930975 CAPLUS
DOCUMENT NUMBER: 139:395945
TITLE: Preparation of quinazolinylmethyl urea derivatives as fungal efflux pump inhibitors
INVENTOR(S): Watkins, Will J.; Lemoine, Remy; Cho, Aesop; Palme, Monica
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 109 pp., Cont.-in-part of U.S. Ser. No. 906,864.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003220338	A1	20031127	US 2002-243074	20020912
US 6596723	B1	20030722	US 2001-906864	20010716
US 2003229097	A1	20031211	US 2002-334755	20021230
US 6689782	B2	20040210		
WO 2004024140	A1	20040325	WO 2003-US5184	20030221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, HK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RU: GH, GM, KE, LS, MW, MZ, SD, SI, S2, TZ, UG, ZM, ZV, AM, AZ, BY, XG, KZ, MD, RU, TJ, TM, AT, BZ, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003215343	A1	20040430	AU 2003-215343	20030221
PRIORITY APPLN. INFO.:			US 2001-906864	A2 20010716
			US 2002-243074	A2 20020912
			US 2002-334755	A 20021230
			WO 2003-US5184	W 20030221

OTHER SOURCE(S): MARPAT 139:395945
GI



I




II

AB This invention relates to compds. of formula I [A1-A6 = C, N; R1 = H, alkyl, cycloalkyl, CH2-cycloalkyl, etc.; R2 = alkyl; R3-R12 = H, alkyl, CF3, alkoxy, halo, OH, CN, etc.] that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism. Thus, II was prepared and showed a reduced MIC value against *Candida albicans* in the presence of fluconazole.


IT 562835-78-3P 626245-68-6P 626245-72-5P
626245-77-0P 626245-79-2P 626247-18-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)

RN 562835-78-3 CAPLUS


CN Urea, N'-(3-chlorophenyl)-N-{1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl}-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 626245-65-6 CAPLUS
CN Urea, N-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626245-72-5 CAPLUS
CN 1-Piperazinebutanoic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 626245-77-0 CAPLUS

CN 1-Pyridinedicarboxylic acid, 2-[[4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 626245-79-2 CAPLUS


CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 626247-18-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 626245-51-0P 626245-67-0P 626245-68-9P
626245-69-0P 626245-70-3P 626245-74-7P
626245-81-6P 626245-83-8P 626245-85-0P
626245-88-3P 626245-90-7P 626245-93-0P
626245-96-3P 626246-00-2P 626246-04-6P
626246-07-9P 626246-10-4P 626246-13-7P
626246-16-0P 626246-17-1P 626246-19-3P
626246-22-8P 626246-25-1P 626246-28-4P
626246-31-9P 626246-34-2P 626246-37-5P
626246-40-4P 626246-43-3P 626246-45-5P
626246-48-8P 626246-51-3P 626246-54-6P
626246-56-8P 626246-60-4P 626246-64-8P
626246-67-1P 626246-69-3P 626246-71-7P
626246-72-8P 626246-74-0P 626246-75-1P
626246-76-2P 626246-81-9P 626246-84-2P
626246-89-7P 626246-91-1P 626246-92-2P
626246-93-3P 626246-94-4P 626246-95-5P

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

626246-97-7P 626246-99-9P 626247-01-6P
 626247-03-8P 626247-05-0P 626247-07-2P
 626247-09-4P 626247-11-8P 626247-13-0P
 626247-15-2P 626247-20-9P 626247-23-2P
 626247-25-4P 626247-27-6P 626247-30-1P
 626247-32-3P 626247-35-6P 626247-37-8P
 626247-49-1P 626247-51-6P 626247-54-9P
 626247-57-2P 626247-58-3P 626247-60-7P
 626247-61-8P 626247-62-9P 626247-63-0P
 626247-64-1P 626247-65-2P 626247-66-3P
 626247-67-4P 626247-68-5P 626247-69-6P
 626247-70-9P 626247-71-0P 626247-72-1P
 626247-73-2P 626247-74-3P 626247-75-4P
 626247-76-5P 626247-77-6P 626247-78-7P
 626247-79-8P 626247-80-1P 626247-81-2P
 626247-82-3P 626247-83-4P 626247-84-5P
 626247-85-6P 626247-86-7P 626247-87-8P
 626247-88-9P 626247-89-0P 626247-90-3P
 626247-91-4P 626247-92-5P 626247-93-6P
 626247-94-7P 626247-95-8P 626247-96-9P
 626247-97-0P 626247-98-1P 626247-99-2P
 626248-00-3P 626248-01-9P 626248-02-0P
 626248-03-1P 626248-04-2P 626248-05-3P
 626248-06-4P 626248-07-5P 626248-08-6P
 626248-09-7P 626248-10-8P 626248-11-1P
 626248-12-2P 626248-13-3P 626248-14-4P
 626248-15-5P 626248-16-6P 626248-17-7P
 626248-18-8P 626248-19-9P 626248-20-2P
 626248-21-3P 626248-22-4P 626248-23-5P
 626248-24-6P 626248-25-7P 626248-26-8P
 626248-27-9P 626248-28-0P 626248-29-1P
 626248-30-1P 626248-31-5P 626248-32-6P
 626248-33-7P 626248-34-8P 626248-35-9P
 626248-36-0P 626248-37-1P 626248-38-2P
 626248-39-3P 626248-40-4P 626248-41-7P
 626248-42-8P 626248-43-9P 626248-46-2P
 626249-06-7P


RE: PAC (Pharmacological activity); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prep. of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)

RN 626245-51-0 CAPLUS
 CN Urea, N'-(3-chlorophenyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-, monomethanesulfonate (SC1) (CA INDEX NAME)

CH 1

CN 562835-78-3
 CHF C30 H33 Cl N6 O4


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2
 CRN 75-75-2
 CHF C H4 O3 S




RN 626245-67-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 626245-68-9 CAPLUS
 CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 626245-69-0 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 626245-70-3 CAPLUS
 CN Pyridinium, 1-[2-{4-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl}-1-piperazinyl]-2-oxethyl]-, chloride (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● Cl-

RN 626245-74-7 CAPLUS
 CN 1-Piperazinebutanoic acid, 4-[2-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626245-81-6 CAPLUS
 CN Carboxic acid, {2-[4-{2-[1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)amino}carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl}-1-piperazinyl]-2-oxethyl}-, 1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626245-83-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-, 2-(4-oxo-1(4H)-pyridinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626245-85-0 CAPLUS

CN Morpholine, 4-[(2-[1-[(2,4-dimethoxyphenyl)amino]carbonyl]amino)ethyl]-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 626245-88-3 CAPLUS

CN Urea, N'-(6-chloro-3-pyridazinyl)-N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626245-90-7 CAPLUS

CN Urea, N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 626245-93-0 CAPLUS

CN Urea, N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626245-96-3 CAPLUS

CN Urea, N-[1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-00-2 CAPLUS

Habte




RN 626246-04-6 CAPLUS

CN Urea, N-(3,4-dimethoxyphenyl)-N-[1-(5-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-07-9 CAPLUS


CN Urea, N-[1-(6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-10-4 CAPLUS
CN Urea, N-(4-chlorophenyl)-N-[1-[6,7-difluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-11-7 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-16-0 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-17-1 CAPLUS
CN Urea, N-(2,4-difluorophenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-19-3 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-22-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-25-1 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 626246-28-4 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-(1-oxopropoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 626246-31-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-34-2 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 626246-37-5 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-(trifluoromethyl)phenyl)- (9CI)
(CA INDEX NAME)




RN 626246-40-0 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 626246-43-3 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-45-5 CAPLUS
CN Urea, N-[1-[7-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 626246-48-8 CAPLUS
CN Urea, N-[1-[7-cyano-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 626246-51-3 CAPLUS
7-Quinazolinecarboxylic acid, 2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-, methyl ester (9CI)
(CA INDEX NAME)




RN 626246-54-6 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[7-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-56-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-60-4 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-8-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 626246-64-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-6-hydroxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626246-67-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-69-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[[[(3-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-71-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-72-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-74-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(3-fluorophenyl)amino]carbonyl]aminoethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-75-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-difluorophenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl]-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-76-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-chloro-2-[1-[[{(3-chlorophenyl)amino]carbonyl}(2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 626246-81-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-chloro-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-84-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626246-89-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[7-cyano-2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-92-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[[{(4-chlorophenyl)amino]carbonyl}(2,4-dimethoxyphenyl)amino]ethyl]-8-methoxy-4-oxo-3(4H)-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 626246-93-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1H-imidazol-1-yl)ethyl ester (9CI) (CA INDEX NAME)




RN 626246-94-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626246-95-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(3-hydroxy-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626246-97-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1-piperidinyl)ethyl ester (9CI) (CA INDEX NAME)





RN 626246-99-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-01-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(4-methyl-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-03-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(4-thiomorpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-07-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1,3,4-thiadiazol-2-ylthio)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-09-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-, 2-(1H-imidazol-2-ylthio)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-11-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl ester (9CI) (CA INDEX NAME)




RN 626247-13-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-2-(2,5-dioxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-15-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-2-(1,3,4-thiadiazol-2-ylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 626247-20-9 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626247-23-2 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]acetyl] - (9CI) (CA INDEX NAME)




RN 626247-25-4 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperidinyl]acetyl] - (9CI) (CA INDEX NAME)




RN 626247-27-6 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[[{(4-fluorophenyl)amino]carbonyl}(4-methoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]acetyl] - (9CI) (CA INDEX NAME)




RN 626247-30-1 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[[{(3-chlorophenyl)amino]carbonyl}(2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]acetyl] - (9CI) (CA INDEX NAME)




RN 626247-32-3 CAPLUS
CN Morphinoline, 4-[(4-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)- (9CI) (CA INDEX NAME)




RN 626247-35-6 CAPLUS
CN Pyrrolidine, 1-[(4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)- (9CI) (CA INDEX NAME)




RN 626247-37-8 CAPLUS
CN Piperidine, 1-[(4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)- (9CI) (CA INDEX NAME)




RN 626247-40-3 CAPLUS
CN Thiomorpholine, 4-[(4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)- (9CI) (CA INDEX NAME)




RN 626247-43-6 CAPLUS
CN Piperazine, 1-[(2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 626247-45-0 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 626247-48-1 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino]ethyl)-6-fluoro-4-oxo-3(4H)-quinazolinyl-1-piperazinyl]acetyl)- (9CI) (CA INDEX NAME)




RN 626247-51-6 CAPLUS
CN Urea, N-(3-chlorophenyl)-N-[1-[3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 626247-54-9 CAPLUS
 CN Piperazine, 1-[2-[1-[(3-chlorophenyl)amino]carbonyl](2,4-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl-4-(methylsulfonyl)-(9CI) (CA INDEX NAME)





RN 626247-57-2 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)-(9CI) (CA INDEX NAME)




RN 626247-58-3 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[(phenylamino)carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-60-7 CAPLUS
 CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[(6-fluoro-3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl)ethyl]-N'-(4-fluorophenyl)-(9CI) (CA INDEX NAME)




RN 626247-61-8 CAPLUS
 CN Urea, N-[1-(3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl-(9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-62-9 CAPLUS
 CN Urea, N-[1-(3,4-dihydro-4-oxo-3-(1-piperazinyl)-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)-(9CI) (CA INDEX NAME)




RN 626247-63-0 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(methylsulfonyl)-(9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 626247-64-1 CAPLUS
 CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-(4-morpholinylacetyl)-(9CI) (CA INDEX NAME)




RN 626247-65-2 CAPLUS
 CN Piperidine, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-(4-methyl-1-piperazinyl)acetyl-(9CI) (CA INDEX NAME)




RN 626247-66-3 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)-(9CI) (CA INDEX NAME)




RN 626247-67-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 626247-68-5 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 626247-69-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 626247-70-9 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-71-0 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-methyl-1-piperazinyl)acetyl)- (9CI) (CA INDEX NAME)




RN 626247-72-1 CAPLUS
CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-73-2 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-74-3 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1H-imidazol-1-ylacetyl)- (9CI) (CA INDEX NAME)




RN 626247-75-4 CAPLUS
CN Piperazine, 1-(cyanoacetyl)-4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626247-76-5 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperidinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-77-6 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(3-hydroxy-1-piperidinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-78-7 CAPLUS
CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperidinyl)acetyl] - (9CI) (CA INDEX NAME)






RN 626247-79-8 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-thiomorpholinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-80-1 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-hydroxy-1-piperidinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-81-2 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-oxo-1(4H)-pyridinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-83-4 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}aminoethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2,5-dioxo-1-pyrrolidinyl)acetyl] - (9CI) (CA INDEX NAME)




RN 626247-84-5 CAPLUS
CN 1-Piperazinebutanamide, 4-[2-[1-[[{(4-chlorophenyl)amino]carbonyl}(2,6-dimethoxyphenyl)amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-N-(methylsulfonyl) - (9CI) (CA INDEX NAME)




RN 626247-85-6 CAPLUS
CN Piperazine, 1-[2-{1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)acetyl]}- (9CI) (CA INDEX NAME)




RN 626247-86-7 CAPLUS
CN Piperazine, 1-[2-{1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)acetyl]}- (9CI) (CA INDEX NAME)



RN 626247-87-8 CAPLUS
CN Piperazine, 1-[2-{1-[(2,6-dimethoxy-3-pyridinyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2-methoxyethoxy)acetyl]}- (9CI) (CA INDEX NAME)




RN 626247-88-9 CAPLUS
CN Piperazine, 1-[2-{1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(1H-imidazol-4-ylacetyl)}- (9CI) (CA INDEX NAME)




RN 626247-89-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[{4-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperidinyl}carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 626247-90-3 CAPLUS
CN Piperazine, 1-[2-{1-[(2,6-dimethoxy-3-pyridinyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 626247-91-4 CAPLUS
CN Piperazine, 1-[2-{1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-6,7-difluoro-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 626247-92-5 CAPLUS
CN Piperazine, 1-[2-{1-[(2,4-dimethoxyphenyl){[{(4-fluorophenyl)aminocarbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2R)-2-pyrrolidinylcarbonyl]}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-93-6 CAPLUS
 CN Piperazine, 4-[2-[1-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 626247-94-7 CAPLUS
 CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-7-fluoro-4-oxo-3(4H)-quinazolinyl]-4-[1H-imidazol-4-ylacetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-95-8 CAPLUS
 CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[1-methyl-1H-imidazol-4-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 626247-96-9 CAPLUS
 CN Carbamic acid, [3-[4-[2-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626247-97-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626247-98-1 CAPLUS
 CN Carbamic acid, [(1S)-2-[4-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-(hydroxymethyl)-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626247-99-2 CAPLUS
 CN Carbamic acid, [2-[4-[2-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-00-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[2-[4-[(2,4-dimethoxyphenyl){{(4-fluorophenyl)amino}carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-2-oxoethyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-01-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[{2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl}-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-02-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl}-4-oxo-3(4H)-quinazolinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-03-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl}-4-oxo-3(4H)-quinazolinyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 626248-04-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl}-4-oxo-3(4H)-quinazolinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-05-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl}-4-oxo-3(4H)-quinazolinyl]-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 626248-06-4 CAPLUS
CN Urea, N-[1-[3-[4-(4,5-dihydro-2-oxazolyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626248-07-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-[2-[1-[[{(3-chlorophenyl)amino]carbonyl}(2,4-dimethoxyphenyl)amino]ethyl}-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-08-6 CAPLUS
CN Piperazine, 1-[2-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl]aminoethyl]-4-oxo-3(4H)-quinazolinyl]- (ethenylsulfonyl)ethyl- (9CI) (CA INDEX NAME)




RN 626248-09-7 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(1-methyl-4-piperidinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

14 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-10-0 CAPIUS
CN 1-Piperidinecarboxylic acid, 4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 626248-11-1 CAPIUS
CN Piperidine, 4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-1-[(2-methoxyethoxy)acetyl] - (9CI) (CA INDEX NAME)

14 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-12-2 CAPIUS
CN 1-Piperazinebutanamide, 4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-N-(phenylsulfonyl) - (9CI) (CA INDEX NAME)




RN 626248-13-3 CAPIUS
CN 1-Piperazinebutanamide, 4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]amino}ethyl}-4-oxo-3(4H)-quinazolinyl]-N-(methylsulfonyl) - (9CI) (CA INDEX NAME)

14 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-14-4 CAPIUS
CN 1-Piperazinebutanamide, N-cyano-4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl] - (9CI) (CA INDEX NAME)




RN 626248-15-5 CAPIUS
CN 1-Piperazinebutanamide, 4-[2-{1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-N-((trifluoromethyl)sulfonyl) - (9CI) (CA INDEX NAME)

14 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-16-6 CAPIUS
CN Piperazine, 1-[2-{1-[(1S)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-17-7 CAPIUS
CN Piperazine, 1-[2-{1-[(1R)-1-[(2,4-dimethoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl}-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-18-8 CAPIUS
CN Piperazine, 1-[{3-aminoacetyl}-4-{2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl}-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626248-19-9 CAPIUS
CN Piperazine, 1-[{3-amino-1-oxopropyl}-4-{2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl}-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-20-2 CAPIUS
CN Piperazine, 1-[{2-amino-1-oxopropyl}-4-{2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl}-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-21-3 CAPIUS
CN Piperazine, 1-[{(2S)-2-amino-3-hydroxy-1-oxopropyl}-4-{2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl}-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 626248-22-4 CAPIUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(methylamino)acetyl]- (9CI) (CA INDEX NAME)




RN 626248-23-5 CAPIUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(25S)-2-pyrrolidinylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 32 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 626248-24-6 CAPIUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(4-formyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 626248-25-7 CAPIUS
CN Carbamic acid, 2-[4-(2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino}carbonyl]amino]ethyl)-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl-2-oxoethyl methyl ester (9CI) (CA INDEX NAME)




RN 626248-26-9 CAPLUS
CN Carbamic acid, [(1S)-2-[4-[2-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-methyl-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-27-9 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2-(1-pyrrolidinyl)ethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 626248-28-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-4-oxo-3-(4-piperidinyl)-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 626248-29-1 CAPLUS
CN Pyrrolidine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 626248-30-4 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 626248-31-5 CAPLUS
CN Piperazine, 1-[2-[1-[(2,6-dimethoxy-3-pyridinyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2R)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-32-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[2-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]carbonyl]-, 1,1-dimethyl-1-oxoethyl ester (9CI) (CA INDEX NAME)




RN 626248-33-7 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl)[{[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 626248-34-8 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-dimethoxyphenyl){[(5-fluoro-2-pyridinyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)



RN 626248-35-9 CAPLUS
CN Morpholine, 4-[(4-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl)-4-oxo-3(4H)-quinazolinyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 626248-36-0 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(4-fluorophenyl)amino]carbonyl][3-[(methylsulfonyl)amino]phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 626248-37-1 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[2-[1-[(4-fluorophenyl)amino]carbonyl][3-(2H-1,2,3-triazol-2-yl)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 626248-38-2 CAPLUS
CN Piperazine, 1-[2-[1-[(2,4-bis(cyclopropylmethoxy)phenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl)-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 626248-39-3 CAPLUS
CN Piperazine, 1-[2-[1-[(5-acetyl-2-methoxyphenyl){[(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-(cyclopropylcarbonyl)- (9CI) (CA INDEX NAME)




RN 626248-40-6 CAPLUS
CN Piperazine, 1-[2-[1-[(4-fluorophenyl)amino]carbonyl][3-(2H-1,2,3-triazol-2-yl)phenyl]amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626248-41-7 CAPLUS
CN Urea, N-[1-[3-[4-(cyclopropylmethyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 626248-42-8 CAPLUS
CN Piperazine, 1-[(3-amino-1-pyrrolidinyl)carbonyl]-4-[2-{1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 626248-43-9 CAPLUS
CN Piperazine, 1-[(4-amino-1-piperidinyl)carbonyl]-4-[2-{1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 626248-46-2 CAPLUS
CN Piperazine, 1-[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]-4-[2-{1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 626249-06-7 CAPLUS
CN Morpholine, 4-[(4-[2-{1-[(2,6-dimethoxy-3-pyridinyl)[(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl)-1-piperazinyl]carbonyl- (9CI) (CA INDEX NAME)




IT 562835-90-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)
RN 562835-90-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 562836-26-4P 626245-57-6P 626245-59-8P
626245-61-2P 626245-63-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinylmethyl urea derivs. as fungal efflux pump inhibitors)
RN 562836-26-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)





RN 626245-57-6 CAPLUS
CN 1-Piperazinacetic acid, 4-[2-{1-[(2,4-dimethoxyphenyl)[(4-fluorophenyl)amino]carbonyl]amino}ethyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 626245-59-8 CAPLUS

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Urea, N-[2-(4-dimethoxyphenyl)-N-[1-[3-[4-[2-[2,5-dioxo-1-pyrrolidinyl]oxy]-2-oxoethyl]-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 626245-61-2 CAPLUS
 CN Piperazine, 1-(chloroacetyl)-4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 626245-63-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[1-[(2,4-dimethoxyphenyl)[{(4-fluorophenyl)amino]carbonyl}amino]ethyl]-4-oxo-3(4H)-quinazolinyl]-2-bromoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 2003:867291 CAPLUS
 DOCUMENT NUMBER: 140:156722
 TITLE: Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors
 AUTHOR(S): Kumar, Ashok; Sharma, Shalabh; Archana; Bajaj, Kiran; Sharma, Shipra; Panwar, Hemant; Singh, Tripti; Srivastava, V. K.
 CORPORATE SOURCE: Department of Pharmacology, Medicinal Chemistry Division, L.L.R.M Medical College, Meerut (U.P.), 250004, India
 SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(23), 5293-5299
 PUBLISHER: CODEN: BMCECP; ISSN: 0968-0896
 DOCUMENT TYPE: Elsevier Ltd.
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 GI: CASREACT 140:156722




I

AB Various 2-(substitutedphenylmethylenimino)aminoacetylmethylen-3-(2'-substitutedindol-3'-yl)-halosubstituted-4(3H)quinazolinones and 2-(substituted phenylaminomethyleneacetyl-4'-oxo-1'-thiazolidinyl-3-(2''-substitutedindol-3''-yl) 4(3H)-quinazolinones have been synthesized in the present studies. The structure of these compds. have been elucidated by elemental (C, H, N) and spectral (IR, 1H NMR and mass) anal. Furthermore, above said compds. were evaluated for their anti-inflammatory, analgesic, ulcerogenic activities and acute toxicity study. Compound I was found to be most potent. Compound I exhibiting less ulcerogenic liability and LD₅₀ >2000 mg/kg po.


IT 655250-10-1P 655250-41-2P 655250-42-3P
 655250-43-4P 655250-44-5P 655250-45-6P
 655250-46-7P 655250-47-8P 655250-48-9P
 NL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses); (trisubstituted quinazolinones as anti-inflammatory and analgesic COX-II inhibitors)

RN 655250-40-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[(2-(2-methoxyphenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 655250-41-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[(2-(4-methoxyphenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 655250-42-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[3-[(2-(2-chlorophenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 655250-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(1H-indol-3-yl)-6-iodo-2-[3-[(2-(2-methoxyphenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 655250-44-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(1H-indol-3-yl)-6-iodo-2-[3-[(2-(4-methoxyphenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]- (9CI) (CA INDEX NAME)




RN 655250-45-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[3-[(2-(4-chlorophenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(1H-indol-3-yl)-6-iodo- (9CI) (CA INDEX NAME)




RN 655250-46-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[3-[(2-(2-methoxyphenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)

RN 655250-47-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[3-[(2-(4-(dimethylamino)phenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 655250-48-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-2-[3-[(2-(2-chlorophenyl)-4-oxo-3-thiazolidinyl)amino]-2-oxopropyl]-3-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 20031563066 CAPLUS
DOCUMENT NUMBER: 139:117435
TITLE: Preparation of 3,4-dihydroquinazolin-4-one derivatives as fungal efflux pump inhibitors
INVENTOR(S): Watkins, Will J.; Lemoine, Remy; Cho, Aesop; Renau, Thomas E.
PATENT ASSIGNEE(S): Essential Therapeutics, Inc., USA
SOURCE: U.S., 29 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6596723	B1	20030722	US 2001-906864	20010716
US 2003220338	A1	20031127	US 2002-243074	20020912
US 2003220597	A1	20031211	US 2002-334755	20021230
US 6699782	B2	20040210		
PRIORITY APPLN. INFO.:			US 2001-906864	A2 20010716
OTHER SOURCE(S):			US 2002-243074	A2 20020912
G1			HARPAT 139:117435	




AB This invention relates to compds. represented by general formula [I]: $\text{I} = \text{a single bond, Cl-4 alkylene; R1 = (un)substituted C3-7 heterocyclic containing 1 nitrogen atom or 2 to 2 annl. heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, -C(=NH)(CH3), -C(=NH)C(CH3)2, -C(=NH)C(CH3)=O, -C(=NH)C(CH3)=S, -C(=NH)C(CH3)OC(=O)R1, -C(=NH)C(CH3)OC(=O)R2, -C(=NH)C(CH3)OC(=O)R3, -C(=NH)C(CH3)OC(=O)R4, -C(=NH)C(CH3)OC(=O)R5, -C(=NH)C(CH3)OC(=O)R6, -C(=NH)C(CH3)OC(=O)R7, -C(=NH)C(CH3)OC(=O)R8, -C(=NH)C(CH3)OC(=O)R9, -C(=NH)C(CH3)OC(=O)R10, -C(=NH)C(CH3)OC(=O)R11, -C(=NH)C(CH3)OC(=O)R12, -C(=NH)C(CH3)OC(=O)R13, -C(=NH)C(CH3)OC(=O)R14, -C(=NH)C(CH3)OC(=O)R15, -C(=NH)C(CH3)OC(=O)R16, -C(=NH)C(CH3)OC(=O)R17, -C(=NH)C(CH3)OC(=O)R18, -C(=NH)C(CH3)OC(=O)R19, -C(=NH)C(CH3)OC(=O)R20, -C(=NH)C(CH3)OC(=O)R21, -C(=NH)C(CH3)OC(=O)R22, -C(=NH)C(CH3)OC(=O)R23, -C(=NH)C(CH3)OC(=O)R24, -C(=NH)C(CH3)OC(=O)R25, -C(=NH)C(CH3)OC(=O)R26, -C(=NH)C(CH3)OC(=O)R27, -C(=NH)C(CH3)OC(=O)R28, -C(=NH)C(CH3)OC(=O)R29, -C(=NH)C(CH3)OC(=O)R30, -C(=NH)C(CH3)OC(=O)R31, -C(=NH)C(CH3)OC(=O)R32, -C(=NH)C(CH3)OC(=O)R33, -C(=NH)C(CH3)OC(=O)R34, -C(=NH)C(CH3)OC(=O)R35, -C(=NH)C(CH3)OC(=O)R36, -C(=NH)C(CH3)OC(=O)R37, -C(=NH)C(CH3)OC(=O)R38, -C(=NH)C(CH3)OC(=O)R39, -C(=NH)C(CH3)OC(=O)R40, -C(=NH)C(CH3)OC(=O)R41, -C(=NH)C(CH3)OC(=O)R42, -C(=NH)C(CH3)OC(=O)R43, -C(=NH)C(CH3)OC(=O)R44, -C(=NH)C(CH3)OC(=O)R45, -C(=NH)C(CH3)OC(=O)R46, -C(=NH)C(CH3)OC(=O)R47, -C(=NH)C(CH3)OC(=O)R48, -C(=NH)C(CH3)OC(=O)R49, -C(=NH)C(CH3)OC(=O)R50, -C(=NH)C(CH3)OC(=O)R51, -C(=NH)C(CH3)OC(=O)R52, -C(=NH)C(CH3)OC(=O)R53, -C(=NH)C(CH3)OC(=O)R54, -C(=NH)C(CH3)OC(=O)R55, -C(=NH)C(CH3)OC(=O)R56, -C(=NH)C(CH3)OC(=O)R57, -C(=NH)C(CH3)OC(=O)R58, -C(=NH)C(CH3)OC(=O)R59, -C(=NH)C(CH3)OC(=O)R60, -C(=NH)C(CH3)OC(=O)R61, -C(=NH)C(CH3)OC(=O)R62, -C(=NH)C(CH3)OC(=O)R63, -C(=NH)C(CH3)OC(=O)R64, -C(=NH)C(CH3)OC(=O)R65, -C(=NH)C(CH3)OC(=O)R66, -C(=NH)C(CH3)OC(=O)R67, -C(=NH)C(CH3)OC(=O)R68, -C(=NH)C(CH3)OC(=O)R69, -C(=NH)C(CH3)OC(=O)R70, -C(=NH)C(CH3)OC(=O)R71, -C(=NH)C(CH3)OC(=O)R72, -C(=NH)C(CH3)OC(=O)R73, -C(=NH)C(CH3)OC(=O)R74, -C(=NH)C(CH3)OC(=O)R75, -C(=NH)C(CH3)OC(=O)R76, -C(=NH)C(CH3)OC(=O)R77, -C(=NH)C(CH3)OC(=O)R78, -C(=NH)C(CH3)OC(=O)R79, -C(=NH)C(CH3)OC(=O)R80, -C(=NH)C(CH3)OC(=O)R81, -C(=NH)C(CH3)OC(=O)R82, -C(=NH)C(CH3)OC(=O)R83, -C(=NH)C(CH3)OC(=O)R84, -C(=NH)C(CH3)OC(=O)R85, -C(=NH)C(CH3)OC(=O)R86, -C(=NH)C(CH3)OC(=O)R87, -C(=NH)C(CH3)OC(=O)R88, -C(=NH)C(CH3)OC(=O)R89, -C(=NH)C(CH3)OC(=O)R90, -C(=NH)C(CH3)OC(=O)R91, -C(=NH)C(CH3)OC(=O)R92, -C(=NH)C(CH3)OC(=O)R93, -C(=NH)C(CH3)OC(=O)R94, -C(=NH)C(CH3)OC(=O)R95, -C(=NH)C(CH3)OC(=O)R96, -C(=NH)C(CH3)OC(=O)R97, -C(=NH)C(CH3)OC(=O)R98, -C(=NH)C(CH3)OC(=O)R99, -C(=NH)C(CH3)OC(=O)R100, -C(=NH)C(CH3)OC(=O)R101, -C(=NH)C(CH3)OC(=O)R102, -C(=NH)C(CH3)OC(=O)R103, -C(=NH)C(CH3)OC(=O)R104, -C(=NH)C(CH3)OC(=O)R105, -C(=NH)C(CH3)OC(=O)R106, -C(=NH)C(CH3)OC(=O)R107, -C(=NH)C(CH3)OC(=O)R108, -C(=NH)C(CH3)OC(=O)R109, -C(=NH)C(CH3)OC(=O)R110, -C(=NH)C(CH3)OC(=O)R111, -C(=NH)C(CH3)OC(=O)R112, -C(=NH)C(CH3)OC(=O)R113, -C(=NH)C(CH3)OC(=O)R114, -C(=NH)C(CH3)OC(=O)R115, -C(=NH)C(CH3)OC(=O)R116, -C(=NH)C(CH3)OC(=O)R117, -C(=NH)C(CH3)OC(=O)R118, -C(=NH)C(CH3)OC(=O)R119, -C(=NH)C(CH3)OC(=O)R120, -C(=NH)C(CH3)OC(=O)R121, -C(=NH)C(CH3)OC(=O)R122, -C(=NH)C(CH3)OC(=O)R123, -C(=NH)C(CH3)OC(=O)R124, -C(=NH)C(CH3)OC(=O)R125, -C(=NH)C(CH3)OC(=O)R126, -C(=NH)C(CH3)OC(=O)R127, -C(=NH)C(CH3)OC(=O)R128, -C(=NH)C(CH3)OC(=O)R129, -C(=NH)C(CH3)OC(=O)R130, -C(=NH)C(CH3)OC(=O)R131, -C(=NH)C(CH3)OC(=O)R132, -C(=NH)C(CH3)OC(=O)R133, -C(=NH)C(CH3)OC(=O)R134, -C(=NH)C(CH3)OC(=O)R135, -C(=NH)C(CH3)OC(=O)R136, -C(=NH)C(CH3)OC(=O)R137, -C(=NH)C(CH3)OC(=O)R138, -C(=NH)C(CH3)OC(=O)R139, -C(=NH)C(CH3)OC(=O)R140, -C(=NH)C(CH3)OC(=O)R141, -C(=NH)C(CH3)OC(=O)R142, -C(=NH)C(CH3)OC(=O)R143, -C(=NH)C(CH3)OC(=O)R144, -C(=NH)C(CH3)OC(=O)R145, -C(=NH)C(CH3)OC(=O)R146, -C(=NH)C(CH3)OC(=O)R147, -C(=NH)C(CH3)OC(=O)R148, -C(=NH)C(CH3)OC(=O)R149, -C(=NH)C(CH3)OC(=O)R150, -C(=NH)C(CH3)OC(=O)R151, -C(=NH)C(CH3)OC(=O)R152, -C(=NH)C(CH3)OC(=O)R153, -C(=NH)C(CH3)OC(=O)R154, -C(=NH)C(CH3)OC(=O)R155, -C(=NH)C(CH3)OC(=O)R156, -C(=NH)C(CH3)OC(=O)R157, -C(=NH)C(CH3)OC(=O)R158, -C(=NH)C(CH3)OC(=O)R159, -C(=NH)C(CH3)OC(=O)R160, -C(=NH)C(CH3)OC(=O)R161, -C(=NH)C(CH3)OC(=O)R162, -C(=NH)C(CH3)OC(=O)R163, -C(=NH)C(CH3)OC(=O)R164, -C(=NH)C(CH3)OC(=O)R165, -C(=NH)C(CH3)OC(=O)R166, -C(=NH)C(CH3)OC(=O)R167, -C(=NH)C(CH3)OC(=O)R168, -C(=NH)C(CH3)OC(=O)R169, -C(=NH)C(CH3)OC(=O)R170, -C(=NH)C(CH3)OC(=O)R171, -C(=NH)C(CH3)OC(=O)R172, -C(=NH)C(CH3)OC(=O)R173, -C(=NH)C(CH3)OC(=O)R174, -C(=NH)C(CH3)OC(=O)R175, -C(=NH)C(CH3)OC(=O)R176, -C(=NH)C(CH3)OC(=O)R177, -C(=NH)C(CH3)OC(=O)R178, -C(=NH)C(CH3)OC(=O)R179, -C(=NH)C(CH3)OC(=O)R180, -C(=NH)C(CH3)OC(=O)R181, -C(=NH)C(CH3)OC(=O)R182, -C(=NH)C(CH3)OC(=O)R183, -C(=NH)C(CH3)OC(=O)R184, -C(=NH)C(CH3)OC(=O)R185, -C(=NH)C(CH3)OC(=O)R186, -C(=NH)C(CH3)OC(=O)R187, -C(=NH)C(CH3)OC(=O)R188, -C(=NH)C(CH3)OC(=O)R189, -C(=NH)C(CH3)OC(=O)R190, -C(=NH)C(CH3)OC(=O)R191, -C(=NH)C(CH3)OC(=O)R192, -C(=NH)C(CH3)OC(=O)R193, -C(=NH)C(CH3)OC(=O)R194, -C(=NH)C(CH3)OC(=O)R195, -C(=NH)C(CH3)OC(=O)R196, -C(=NH)C(CH3)OC(=O)R197, -C(=NH)C(CH3)OC(=O)R198, -C(=NH)C(CH3)OC(=O)R199, -C(=NH)C(CH3)OC(=O)R200, -C(=NH)C(CH3)OC(=O)R201, -C(=NH)C(CH3)OC(=O)R202, -C(=NH)C(CH3)OC(=O)R203, -C(=NH)C(CH3)OC(=O)R204, -C(=NH)C(CH3)OC(=O)R205, -C(=NH)C(CH3)OC(=O)R206, -C(=NH)C(CH3)OC(=O)R207, -C(=NH)C(CH3)OC(=O)R208, -C(=NH)C(CH3)OC(=O)R209, -C(=NH)C(CH3)OC(=O)R210, -C(=NH)C(CH3)OC(=O)R211, -C(=NH)C(CH3)OC(=O)R212, -C(=NH)C(CH3)OC(=O)R213, -C(=NH)C(CH3)OC(=O)R214, -C(=NH)C(CH3)OC(=O)R215, -C(=NH)C(CH3)OC(=O)R216, -C(=NH)C(CH3)OC(=O)R217, -C(=NH)C(CH3)OC(=O)R218, -C(=NH)C(CH3)OC(=O)R219, -C(=NH)C(CH3)OC(=O)R220, -C(=NH)C(CH3)OC(=O)R221, -C(=NH)C(CH3)OC(=O)R222, -C(=NH)C(CH3)OC(=O)R223, -C(=NH)C(CH3)OC(=O)R224, -C(=NH)C(CH3)OC(=O)R225, -C(=NH)C(CH3)OC(=O)R226, -C(=NH)C(CH3)OC(=O)R227, -C(=NH)C(CH3)OC(=O)R228, -C(=NH)C(CH3)OC(=O)R229, -C(=NH)C(CH3)OC(=O)R230, -C(=NH)C(CH3)OC(=O)R231, -C(=NH)C(CH3)OC(=O)R232, -C(=NH)C(CH3)OC(=O)R233, -C(=NH)C(CH3)OC(=O)R234, -C(=NH)C(CH3)OC(=O)R235, -C(=NH)C(CH3)OC(=O)R236, -C(=NH)C(CH3)OC(=O)R237, -C(=NH)C(CH3)OC(=O)R238, -C(=NH)C(CH3)OC(=O)R239, -C(=NH)C(CH3)OC(=O)R240, -C(=NH)C(CH3)OC(=O)R241, -C(=NH)C(CH3)OC(=O)R242, -C(=NH)C(CH3)OC(=O)R243, -C(=NH)C(CH3)OC(=O)R244, -C(=NH)C(CH3)OC(=O)R245, -C(=NH)C(CH3)OC(=O)R246, -C(=NH)C(CH3)OC(=O)R247, -C(=NH)C(CH3)OC(=O)R248, -C(=NH)C(CH3)OC(=O)R249, -C(=NH)C(CH3)OC(=O)R250, -C(=NH)C(CH3)OC(=O)R251, -C(=NH)C(CH3)OC(=O)R252, -C(=NH)C(CH3)OC(=O)R253, -C(=NH)C(CH3)OC(=O)R254, -C(=NH)C(CH3)OC(=O)R255, -C(=NH)C(CH3)OC(=O)R256, -C(=NH)C(CH3)OC(=O)R257, -C(=NH)C(CH3)OC(=O)R258, -C(=NH)C(CH3)OC(=O)R259, -C(=NH)C(CH3)OC(=O)R260, -C(=NH)C(CH3)OC(=O)R261, -C(=NH)C(CH3)OC(=O)R262, -C(=NH)C(CH3)OC(=O)R263, -C(=NH)C(CH3)OC(=O)R264, -C(=NH)C(CH3)OC(=O)R265, -C(=NH)C(CH3)OC(=O)R266, -C(=NH)C(CH3)OC(=O)R267, -C(=NH)C(CH3)OC(=O)R268, -C(=NH)C(CH3)OC(=O)R269, -C(=NH)C(CH3)OC(=O)R270, -C(=NH)C(CH3)OC(=O)R271, -C(=NH)C(CH3)OC(=O)R272, -C(=NH)C(CH3)OC(=O)R273, -C(=NH)C(CH3)OC(=O)R274, -C(=NH)C(CH3)OC(=O)R275, -C(=NH)C(CH3)OC(=O)R276, -C(=NH)C(CH3)OC(=O)R277, -C(=NH)C(CH3)OC(=O)R278, -C(=NH)C(CH3)OC(=O)R279, -C(=NH)C(CH3)OC(=O)R280, -C(=NH)C(CH3)OC(=O)R281, -C(=NH)C(CH3)OC(=O)R282, -C(=NH)C(CH3)OC(=O)R283, -C(=NH)C(CH3)OC(=O)R284, -C(=NH)C(CH3)OC(=O)R285, -C(=NH)C(CH3)OC(=O)R286, -C(=NH)C(CH3)OC(=O)R287, -C(=NH)C(CH3)OC(=O)R288, -C(=NH)C(CH3)OC(=O)R289, -C(=NH)C(CH3)OC(=O)R290, -C(=NH)C(CH3)OC(=O)R291, -C(=NH)C(CH3)OC(=O)R292, -C(=NH)C(CH3)OC(=O)R293, -C(=NH)C(CH3)OC(=O)R294, -C(=NH)C(CH3)OC(=O)R295, -C(=NH)C(CH3)OC(=O)R296, -C(=NH)C(CH3)OC(=O)R297, -C(=NH)C(CH3)OC(=O)R298, -C(=NH)C(CH3)OC(=O)R299, -C(=NH)C(CH3)OC(=O)R300, -C(=NH)C(CH3)OC(=O)R301, -C(=NH)C(CH3)OC(=O)R302, -C(=NH)C(CH3)OC(=O)R303, -C(=NH)C(CH3)OC(=O)R304, -C(=NH)C(CH3)OC(=O)R305, -C(=NH)C(CH3)OC(=O)R306, -C(=NH)C(CH3)OC(=O)R307, -C(=NH)C(CH3)OC(=O)R308, -C(=NH)C(CH3)OC(=O)R309, -C(=NH)C(CH3)OC(=O)R310, -C(=NH)C(CH3)OC(=O)R311, -C(=NH)C(CH3)OC(=O)R312, -C(=NH)C(CH3)OC(=O)R313, -C(=NH)C(CH3)OC(=O)R314, -C(=NH)C(CH3)OC(=O)R315, -C(=NH)C(CH3)OC(=O)R316, -C(=NH)C(CH3)OC(=O)R317, -C(=NH)C(CH3)OC(=O)R318, -C(=NH)C(CH3)OC(=O)R319, -C(=NH)C(CH3)OC(=O)R320, -C(=NH)C(CH3)OC(=O)R321, -C(=NH)C(CH3)OC(=O)R322, -C(=NH)C(CH3)OC(=O)R323, -C(=NH)C(CH3)OC(=O)R324, -C(=NH)C(CH3)OC(=O)R325, -C(=NH)C(CH3)OC(=O)R326, -C(=NH)C(CH3)OC(=O)R327, -C(=NH)C(CH3)OC(=O)R328, -C(=NH)C(CH3)OC(=O)R329, -C(=NH)C(CH3)OC(=O)R330, -C(=NH)C(CH3)OC(=O)R331, -C(=NH)C(CH3)OC(=O)R332, -C(=NH)C(CH3)OC(=O)R333, -C(=NH)C(CH3)OC(=O)R334, -C(=NH)C(CH3)OC(=O)R335, -C(=NH)C(CH3)OC(=O)R336, -C(=NH)C(CH3)OC(=O)R337, -C(=NH)C(CH3)OC(=O)R338, -C(=NH)C(CH3)OC(=O)R339, -C(=NH)C(CH3)OC(=O)R340, -C(=NH)C(CH3)OC(=O)R341, -C(=NH)C(CH3)OC(=O)R342, -C(=NH)C(CH3)OC(=O)R343, -C(=NH)C(CH3)OC(=O)R344, -C(=NH)C(CH3)OC(=O)R345, -C(=NH)C(CH3)OC(=O)R346, -C(=NH)C(CH3)OC(=O)R347, -C(=NH)C(CH3)OC(=O)R348, -C(=NH)C(CH3)OC(=O)R349, -C(=NH)C(CH3)OC(=O)R350, -C(=NH)C(CH3)OC(=O)R351, -C(=NH)C(CH3)OC(=O)R352, -C(=NH)C(CH3)OC(=O)R353, -C(=NH)C(CH3)OC(=O)R354, -C(=NH)C(CH3)OC(=O)R355, -C(=NH)C(CH3)OC(=O)R356, -C(=NH)C(CH3)OC(=O)R357, -C(=NH)C(CH3)OC(=O)R358, -C(=NH)C(CH3)OC(=O)R359, -C(=NH)C(CH3)OC(=O)R360, -C(=NH)C(CH3)OC(=O)R361, -C(=NH)C(CH3)OC(=O)R362, -C(=NH)C(CH3)OC(=O)R363, -C(=NH)C(CH3)OC(=O)R364, -C(=NH)C(CH3)OC(=O)R365, -C(=NH)C(CH3)OC(=O)R366, -C(=NH)C(CH3)OC(=O)R367, -C(=NH)C(CH3)OC(=O)R368, -C(=NH)C(CH3)OC(=O)R369, -C(=NH)C(CH3)OC(=O)R370, -C(=NH)C(CH3)OC(=O)R371, -C(=NH)C(CH3)OC(=O)R372, -C(=NH)C(CH3)OC(=O)R373, -C(=NH)C(CH3)OC(=O)R374, -C(=NH)C(CH3)OC(=O)R375, -C(=NH)C(CH3)OC(=O)R376, -C(=NH)C(CH3)OC(=O)R377, -C(=NH)C(CH3)OC(=O)R378, -C(=NH)C(CH3)OC(=O)R379, -C(=NH)C(CH3)OC(=O)R380, -C(=NH)C(CH3)OC(=O)R381, -C(=NH)C(CH3)OC(=O)R382, -C(=NH)C(CH3)OC(=O)R383, -C(=NH)C(CH3)OC(=O)R384, -C(=NH)C(CH3)OC(=O)R385, -C(=NH)C(CH3)OC(=O)R386, -C(=NH)C(CH3)OC(=O)R387, -C(=NH)C(CH3)OC(=O)R388, -C(=NH)C(CH3)OC(=O)R389, -C(=NH)C(CH3)OC(=O)R390, -C(=NH)C(CH3)OC(=O)R391, -C(=NH)C(CH3)OC(=O)R392, -C(=NH)C(CH3)OC(=O)R393, -C(=NH)C(CH3)OC(=O)R394, -C(=NH)C(CH3)OC(=O)R395, -C(=NH)C(CH3)OC(=O)R396, -C(=NH)C(CH3)OC(=O)R397, -C(=NH)C(CH3)OC(=O)R398, -C(=NH)C(CH3)OC(=O)R399, -C(=NH)C(CH3)OC(=O)R400, -C(=NH)C(CH3)OC(=O)R401, -C(=NH)C(CH3)OC(=O)R402, -C(=NH)C(CH3)OC(=O)R403, -C(=NH)C(CH3)OC(=O)R404, -C(=NH)C(CH3)OC(=O)R405, -C(=NH)C(CH3)OC(=O)R406, -C(=NH)C(CH3)OC(=O)R407, -C(=NH)C(CH3)OC(=O)R408, -C(=NH)C(CH3)OC(=O)R409, -C(=NH)C(CH3)OC(=O)R410, -C(=NH)C(CH3)OC(=O)R411, -C(=NH)C(CH3)OC(=O)R412, -C(=NH)C(CH3)OC(=O)R413, -C(=NH)C(CH3)OC(=O)R414, -C(=NH)C(CH3)OC(=O)R415, -C(=NH)C(CH3)OC(=O)R416, -C(=NH)C(CH3)OC(=O)R417, -C(=NH)C(CH3)OC(=O)R418, -C(=NH)C(CH3)OC(=O)R419, -C(=NH)C(CH3)OC(=O)R420, -C(=NH)C(CH3)OC(=O)R421, -C(=NH)C(CH3)OC(=O)R422, -C(=NH)C(CH3)OC(=O)R423, -C(=NH)C(CH3)OC(=O)R424, -C(=NH)C(CH3)OC(=O)R425, -C(=NH)C(CH3)OC(=O)R426, -C(=NH)C(CH3)OC(=O)R427, -C(=NH)C(CH3)OC(=O)R428, -C(=NH)C(CH3)OC(=O)R429, -C(=NH)C(CH3)OC(=O)R430, -C(=NH)C(CH3)OC(=O)R431, -C(=NH)C(CH3)OC(=O)R432, -C(=NH)C(CH3)OC(=O)R433, -C(=NH)C(CH3)OC(=O)R434, -C(=NH)C(CH3)OC(=O)R435, -C(=NH)C(CH3)OC(=O)R436, -C(=NH)C(CH3)OC(=O)R437, -C(=NH)C(CH3)OC(=O)R438, -C(=NH)C(CH3)OC(=O)R439, -C(=NH)C(CH3)OC(=O)R440, -C(=NH)C(CH3)OC(=O)R441, -C(=NH)C(CH3)OC(=O)R442, -C(=NH)C(CH3)OC(=O)R443, -C(=NH)C(CH3)OC(=O)R444, -C(=NH)C(CH3)OC(=O)R445, -C(=NH)C(CH3)OC(=O)R446, -C(=NH)C(CH3)OC(=O)R447, -C(=NH)C(CH3)OC(=O)R448, -C(=NH)C(CH3)OC$

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pthalimidooethyl)-3,4-dihydroquinazolin-4-one (III). III (0.71 g) and 0.26 g 2,4-dimethoxyaniline were dissolved in 20 ml DMF, treated with freshly crushed K2CO3, and stirred at 80° for 16 h to give 2-[1-(3,4-dimethoxyphenyl)ethyl]-6-chloro-3-(2-phthalimidooethyl)-3,4-dihydroquinazolin-4-one which (0.46 g) was dissolved in 5 ml 1,2-dichloroethane, treated with 0.12 ml Ph isocyanate, and stirred at 40° for 16 h to give 66% N-[1-(6-Chloro-3-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethyl]-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenylurea (IV). IV showed MPC8 (concen. of efflux pump inhibitor necessary to reduce the fluconazole MIC 8-fold) of 50.03 µg/mL against C. albicans vs. MIC (concen. of fluconazole alone that causes a 80% inhibition the growth/proliferation of fungal cells) of 16 µg/mL.


IT 562835-78-3P, N-(3-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-79-4P, Acetic acid 2-[2-[1-[N-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)ureido]ethyl]-4-oxo-4H-quinazolin-3-yl)piperazine-1-yl]ethyl ester 562835-81-8P, N-(3-Chlorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562835-82-9P, N-(3-Chlorophenyl)-N-(4-methoxy-2-methylphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-83-0P, N-(2-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-84-1P, N-(4-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-85-2P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-N'-phenylurea
 562835-86-3P, N-(2,4-Dimethoxyphenyl)-N-[2-(3-methoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-87-4P, 4-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562835-88-5P, 4-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzenesulfonamide 562835-88-5P, (2,4-Dimethoxyphenyl)-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamic acid phenyl ester 562835-89-6P, N-(4-Chlorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562835-90-9P, N-(2,4-Dimethoxyphenyl)-N-[1-(4-fluorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562835-91-0P, N-(2,4-Dimethoxyphenyl)-N-[1-(3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea 562835-92-1P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562835-93-2P, 2-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzenesulfonamide 562835-94-3P, (2,4-Dimethoxyphenyl)-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamic acid 4-chlorophenyl ester 562835-95-5P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-N'-phenylurea 562835-96-5P, N-Benzol[1,3]dioxol-5-yl-N-(3-chlorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562835-98-7P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-N'-m-tolylurea

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 562835-99-8P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-00-4P, N-[1-(3-Chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-[1-[3-(1-methylpiperidin-4-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-01-5P, N-[1-[6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-02-6P, N-[1-[6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-03-7P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea
 562836-04-8P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzamide
 562836-05-9P, N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzamide
 562836-06-0P, 4-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzamide
 562836-07-1P, 2-Chloro-N-(2,4-dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzamide
 562836-08-2P, N-(2,4-Dimethoxyphenyl)-4-methoxy-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]benzamide
 562836-09-3P, N-Benzol[1,3]dioxol-5-yl-N-(4-chlorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-10-6P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea
 562836-11-7P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-N-[3,(4,5-trimethoxyphenyl)]urea
 562836-12-8P, N-Benzol[1,3]dioxol-5-yl-N-(4-methoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 562836-13-9P, N-[1-(6-Chloro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea
 562836-14-0P, (2,4-Dimethoxyphenyl)[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamic acid
 562836-15-1P, (2,4-Dimethoxyphenyl)[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]carbamic acid
 562836-16-2P, N-(4-Chlorophenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562836-18-4P,
 N-(2,4-Dimethoxyphenyl)-N-[1-[3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea 562836-19-5P, N-[1-[3-(4-(2-Chloroethyl)piperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]urea
 562836-20-8P, N-(2,4-Dimethoxyphenyl)-N-[1-[6-fluoro-3-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]urea
 RL PAF (Pharmacological use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of 3,4-dihydroquinazolin-4-one derivs. as fungal efflux pump inhibitors and potentiators of antifungal agents for treating infections caused by fungi employing efflux pump resistance mechanism)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 562835-78-3 CAPLUS
 CN Urea, N-[1-[3-(4-[2-(acetoxyethyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-79-4 CAPLUS
 CN Urea, N-[1-[3-(4-[2-(acetoxyethyl)-1-piperazinyl]-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-80-7 CAPLUS
 CN Urea, N-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-(2-hydroxyethyl)-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-81-8 CAPLUS
 CN Urea, N-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-82-9 CAPLUS
 CN Urea, N-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 562835-83-0 CAPLUS
 CN Urea, N-(2-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-84-1 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-85-2 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)





L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562835-86-3 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-87-4 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-88-5 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, phenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-89-6 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-90-9 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562835-91-0 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 562835-92-1 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562835-93-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562835-94-3 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562835-96-5 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562835-97-6 CAPLUS
CN Carbamic acid, [1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 562835-98-7 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562835-99-8 CAPLUS
CN Urea, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-00-4 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(1-methyl-4-piperidinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562836-01-5 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(3-chlorophenyl)-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-02-6 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 562836-03-7 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-04-8 CAPLUS
CN Benzamide, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 562836-05-9 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-06-0 CAPLUS
CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-07-1 CAPLUS
CN Benzamide, 2-chloro-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)





RN 562836-08-2 CAPLUS

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-4-methoxy- (9CI) (CA INDEX NAME)


RN 562836-09-3 CAPLUS
CN Urea, N-1,3-benzodioxol-5-yl-N'-(4-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 562836-10-6 CAPLUS
CN Urea, N-[1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(2,4-dimethoxyphenyl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 562836-11-7 CAPLUS
CN Urea, N'-(3-chlorophenyl)-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

RN 562836-12-8 CAPLUS
CN Urea, N-1,3-benzodioxol-5-yl-N-[1-[3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562836-13-9 CAPLUS
CN Carbamic acid, [1-[6-chloro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl](2,4-dimethoxyphenyl)-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-14-0 CAPLUS
CN Carbamic acid, [1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl](2,4-dimethoxyphenyl)-, 2-chlorophenyl ester (9CI) (CA INDEX NAME)




RN 562836-15-1 CAPLUS
CN Carbamic acid, [1-(3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl](2,4-dimethoxyphenyl)-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562836-16-2 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-(2,4-dimethoxyphenyl)-N-(1-[6-fluoro-3,4-dihydro-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl)- (9CI) (CA INDEX NAME)




RN 562836-18-4 CAPLUS
CN Urea, N-[1-(3,4-dihydro-3-[4-(2-hydroxyethyl)-1-piperazinyl]-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562836-19-5 CAPLUS
CN Urea, N-[1-(4-(2-chloroethyl)-1-piperazinyl)-3,4-dihydro-4-oxo-2-quinazolinyl]N-(2,4-dimethoxyphenyl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-20-8 CAPLUS
CN Urea, N-(2,4-dimethoxyphenyl)-N-[1-[6-fluoro-3,4-dihydro-3-(4-(2-hydroxyethyl)-1-piperazinyl)-4-oxo-2-quinazolinyl]ethyl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562836-22-0 CAPLUS

Habte


L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Urea, N-[1-(3,4-dihydro-6-methyl-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)

RN 562836-23-1 CAPLUS
CN Urea, N-[1-(3,4-dihydro-6-methoxy-3-(4-methyl-1-piperazinyl)-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethoxyphenyl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 562836-24-2
RN: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3,4-dihydroquinazolin-4-one derivs. as fungal efflux pump inhibitors and potentiators of antifungal agents for treating infections caused by fungi employing efflux pump resistance mechanism)
RN 562836-24-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[1-[(2,4-dimethoxyphenyl)amino]ethyl]-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002-833514 CAPLUS
 DOCUMENT NUMBER: 137:337912
 TITLE: Preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): ICOS Corp., USA
 SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of U.S. Ser. No. 841,341.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PARENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161014	A1	20021031	US 2001-27591	20011019
US 6667300	B2	20031223		
US 6516277	B1	20030211	US 2001-841341	20010424
CA 2463294	AA	20030501	CA 2002-2463294	20020827
WO 2003035075	A1	20030501	WO 2002-U527240	20020827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW R: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1438052	A1	20040721	EP 2002-757407	20020827
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SI			
CN 1606444	A	20050413	CN 2002-825687	20020827
JP 2005509635	T2	20050414	JP 2003-537642	20020827
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
US 2003195211	A1	20031016	US 2003-337192	20030106
US 6800620	B2	20041005		
US 2004266780	A1	20041230	US 2003-697912	20031030
US 6949535	B2	20050927		
US 2005261317	A1	20051124	US 2005-110204	20050420
PRIORITY APPLN. INFO.:			US 2000-199655P	P 20000425
			US 2000-238057P	P 20001005
			US 2001-841341	A2 20010424
			US 2001-27591	A 20011019
			WO 2002-U527240	W 20020827
			US 2003-697912	A1 20031030

OTHER SOURCE(S): HARPAT 137:337912
G1

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB A method of disrupting leukocyte function comprises administration of title compds. [I]: X = C(R)2, CR2CRb, CH:CRb; R = H, alky1, heteroalkyl, aryl, heteroaryl, aralkyl, etc.; Y = null, S, SO, SO2, NH, O, CO, CO2, NHCOCH2S; R, R1 = H, alkyl, aryl, heteroaryl, halo, etc.; RR1 = atoms to form a 3- membered alkylene, alkenylene chain; R2 = H, (substituted) alkyl, cycloalkyl, heterocycloalkyl, alklenecycloalkyl, alkenyl, alklenesilyl, aryl, heteroaryl, etc.; A = (substituted) mono- or bicyclic ring system containing ≥ 2 N atoms and in which 2¹ ring is aromatic]. Thus, dose-dependent decrease in histamine release from basophils.

when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; 5 connected to 6-position of purine ring, preparation given).


IT 371243-12-8, 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- 371243-13-9, 4-(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- 371243-14-0, 4-(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-ylamino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-15-1, 4-(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-ylamino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-17-37, 4-(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-ylamino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-22-0P, 4-(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-ylamino)methyl]-5-methyl-3-(2-methylphenyl)- 371243-23-1P, 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- 474012-90-3P, 474012-93-6P, 474012-96-1P, 474013-01-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of purinylquinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta)


RN 371243-12-8 CAPLUS

CN 4-(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-13-9 CAPLUS
 4-(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-14-0 CAPLUS
 CN 4-(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-ylamino)methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-yloamino)ethyl]- (9CI) (CA INDEX NAME)




RN 474012-90-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474012-93-6 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-yloamino)propyl]- (9CI) (CA INDEX NAME)




RN 474012-96-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]propyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474012-98-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-amino-1H-purin-6-yl)amino]propyl]-5-methyl-3-

L4 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474013-01-9 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[2-(phenylmethoxy)-1-(1H-purin-6-yloamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:813938 CAPLUS
DOCUMENT NUMBER: 137:337907

TITLE: Preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions
INVENTOR(S): Medina, Julio C.; Johnson, Michael G.; Li, An-Rong; Liu, Jiven; Huang, Alan X.; Zhu, Liusheng; Marcus, Andrew P.
PATENT ASSIGNEE(S): Tularic Inc., USA
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083143	A1	20021024	WO 2001-US47850	20011211
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, MR, NE, SN, TD, TG				
CA 2431553	AA	20021024	CA 2001-2431553	20011211
US 2002169159	A1	20021114	US 2001-15532	20011211
US 6964967	B2	20051115		
EP 1343505	A1	20030917	EP 2001-273533	20011211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR				
JP 2004536796	T2	20041209	JP 2002-580947	20011211
CN 1575177	A	20050202	CN 2001-822596	20011211
BR 2001016096	A	20050108	BR 2001-16096	20011211
US 2003069234	A1	20030410	US 2002-164690	20020606
US 6794379	B2	20040921		
US 2003055054	A1	20030320	US 2002-231895	20020829
US 7053215	B2	20060530		
ZA 2003004342	A	20050509	ZA 2003-4342	20030603
NO 2003002612	A	20030805	NO 2003-2612	20030610
US 2005075333	A1	20050407	US 2004-946935	20040921
US 7067662	B2	20060627		
US 2006116388	A1	20060601	US 2006-332054	20060113
PRIORITY APPLN. INFO.:			US 2000-255211P	P 20001211
OTHER SOURCE(S):	MARPAT	137:337907	US 2001-296499P	P 20010606
G1			US 2001-15532	A1 20011211
			WO 2001-US47850	W 20011211
			US 2002-164690	A1 20020606
			US 2002-231895	A1 20020829


L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(CXCR3 antagonist; prep. of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473907-65-2 CAPLUS
CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-4-fluoro-N-4-piperidinyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 473719-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CXCR3 antagonist; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)



RN 473719-99-2 CAPLUS
CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-4-fluoro-N-(1-methyl-4-piperidinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 473720-98-8P 473720-99-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)


RN 473720-98-8 CAPLUS
CN 1-Piperidinacarboxylic acid, 4-[[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [wherein X = a bond, CO, CR5R6, CR5:, SO, SO2, or N: ; z = a bond, N:, O, S, NR17, or CR7: ; with the proviso that X and Z are not both a bond; L = CO-alkylene or (hetero)alkylene; Q = (hetero)alkylene, CO, OCO, NR10, CH2CO, CH2SO, or CH2SO2; or NR10 = heterocyclic; R1 and R2 = independently H, (hetero)alkyl, or (hetero)aryl; or CR1R2 = (hetero)cycl; or CR2L = heterocyclic; R3 = OH, alkoxy, NH2, (di)alkylamino, heteroalkyl, heterocyclyl, acylaminoamido, guanidino, ureido, CN, heteroaryl, carbamoyl, or carboxy; R4 = (hetero)alkyl, (hetero)aryl, or (hetero)acyl; or CR5R6 = a ring; R5 and R6 = independently H, (hetero)alkyl, or (hetero)aryl; Y1 and Y2 = independently H, (hetero)alkyl, or (hetero)aryl; Y3 = N or C, wherein C shares a double bond with either Z or Y4; Y4 = NR14, CR14; N, NR14CR15R16; R12 = H, halo, OH, NH2, (di)alkylamino, (hetero)alkyl, or (hetero)aryl, etc.; R14 = (hetero)alkyl, (hetero)aryl, etc.; R15 and R16 = independently H or (hetero)alkyl; R17 = H, (hetero)alkyl, (hetero)aryl, etc.; with provisos] were prepared as chemokine receptor modulators, in particular CXCR3 antagonists. For example, antranilic acid was acylated with propionyl chloride and the amide cyclized using acetic anhydride to give 2-ethylbenzod[1,3]oxazine-4-one. Treatment with 4-fluoroaniline, followed by ethylene glycol and NaOH afforded 2-ethyl-3-(4-fluorophenyl)-3H-quinazolin-4-one. Bromination and stepwise addition of 1-amino-2-methoxyethane and decanoyl chloride produced the decanoic acid (quinazolinylmethoxy) (methoxyethyl)amide II. Approx. one third of the 101 invention compds. tested in a CXCR3 binding assay displayed activity with IC50 values of < 1 μM. I are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, and type I diabetes (no data).
IT 473907-65-2, T 0913409
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation)

L4 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CN 473720-99-9 CAPLUS
CN 1-Piperidinacarboxylic acid, 4-[[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:769983 CAPLUS
 DOCUMENT NUMBER: 137:302093
 TITLE: Photographic color coupler, silver halide photographic material, and azomethine dye
 INVENTOR(S): Takeuchi, Kiyoshi; Ushira, Shigeo
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 54 pp.
 CODEN: JKOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002296741	A2	20021009	JP 2001-102698	20010330
US 2003064332	A1	20030403	US 2002-106192	20020327
US 6677110	B2	20040113		
US 2004096787	A1	20040520	US 2003-679495	20031007
PRIORITY APPLN. INFO.:			JP 2001-102538	A 20010330
			JP 2001-102698	A 20010330
			US 2002-106192	A3 20020327


OTHER SOURCE(S): MARPAT 137:302093
 GI



L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The invention relates to a photog. color coupler represented by I (Q = atoms for forming N-containing 6-membered ring, preferably 4-pyrimidone rings); R1 = aryl, heterocycl; X = aryl; Y = H, group capable of leaving upon coupling reaction with oxidized developing agent) and a photog. material containing the color coupler. The invention also relates to an azomethine dye represented by II (Q = atoms for forming N-containing 6-membered ring, preferably 4-pyrimidone ring; R1 = aryl, heterocycl; X = aryl; R5, R6, R7 = H, substituent; n = 0-4) formed by the above color coupler's coupling reaction. The photog. material shows excellent color hue, storage stability, color reproduction, and lightfastness.


IT 468730-22-5 468730-23-6 468730-24-7
 468730-25-8
 RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
 (azomethine dye; photog. color coupler forming azomethine dye for color photog. material showing improved color hue, storage stability, color reproduction, and lightfastness)
 RN 468730-22-5 CAPLUS
 CN Benzoic acid, 4-chloro-3-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl){(4-[ethyl[2-(methylsulfonyl)amino]ethyl]amino)-2-methylphenyl}imino]acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)




RN 468730-23-6 CAPLUS

CN Benzoic acid, 3-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl){(4-[ethyl[2-(methylsulfonyl)amino]ethyl]amino)-2-methylphenyl}imino]acetyl]amino)-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468730-24-7 CAPLUS
 CN 2-Quinazolineacetamide, N-[5-{2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl}amino]-2-methoxyphenyl]-6,8-dichloro-a-[(4-[ethyl[2-(methylsulfonyl)amino]ethyl]amino)-2-methylphenyl]imino]-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 468730-25-8 CAPLUS
 CN 2-Quinazolineacetamide, N-[2-chloro-5-[(dioctylamino)sulfonyl]phenyl]-a-[(4-[ethyl[2-(methylsulfonyl)ethyl]amino]-2-methylphenyl)imino]-3,4-dihydro-4-oxo-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-14-5P 468730-15-6P

RL: MOA (Modifier or additive use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (coupler preparation; photog. color coupler forming azomethine dye for color

photog. material showing improved color hue, storage stability, color reproduction, and lightfastness)

RN 468730-14-5 CAPLUS


CN Benzoic acid, 4-chloro-3-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)acetyl]amino)-dodecyl ester (9CI) (CA INDEX NAME)




RN 468730-15-6 CAPLUS

CN Benzoic acid, 3-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)acetyl]amino)-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-20-3P 468730-21-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (coupler; photog. color coupler forming azomethine dye for color reproduction, material showing improved color hue, storage stability, color reproduction, and lightfastness)
 RN 468730-20-3 CAPLUS
 CN Benzoic acid, 3-[[(bromo(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)acetyl)amino]-4-chloro-, dodecyl ester (9CI) (CA INDEX NAME)




RN 468730-21-4 CAPLUS
 CN Benzoic acid, 3-[[(bromo(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)acetyl)amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 468730-16-7 468730-17-8 468730-19-0
 RL: MOA (Modifier or additive use); USES (Uses)
 (coupler; photog. color coupler forming azomethine dye for color reproduction, material showing improved color hue, storage stability, color reproduction, and lightfastness)
 RN 468730-16-7 CAPLUS
 CN 2-Quinazolineacetamide, N-[5-[{2-(2,4-bis(1,1-dimethylpropyl)phenoxy)-1-oxobutyl}amino]-2-methoxyphenyl]-6,8-dichloro-a-[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 468730-17-8 CAPLUS
 CN 2-Quinazolineacetamide, N-[2-chloro-5-[(diethylamino)sulfonyl]phenyl]-3,4-dihydro-4-oxo-3-(4-pyridinyl)-a-1H-1,2,4-triazol-1-yl- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 468730-19-0 CAPLUS
 CN 2-Quinazolineacetamide, a-1H-benzotriazol-1-yl-3-(1,2-dihydro-2-oxo-4-pyridinyl)-N-[2-(hexadecyloxy)-5-[(1-oxopropyl)amino]sulfonyl]phenyl]-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 468730-13-4 CAPLUS
 RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (coupler; photog. color coupler forming azomethine dye for color reproduction, material showing improved color hue, storage stability, color reproduction, and lightfastness)
 RN 468730-13-4 CAPLUS
 CN Benzoic acid, 3-[[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)(5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)



IT 468730-12-3 468730-13-4P
 RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (coupler; photog. color coupler forming azomethine dye for color reproduction, material showing improved color hue, storage stability, color reproduction, and lightfastness)
 RN 468730-12-3 CAPLUS
 CN Benzoic acid, 4-chloro-3-[[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)(5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)acetyl]amino]-, dodecyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 38 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:291843 CAPLUS
 DOCUMENT NUMBER: 136:316838

TITLE: Color photographic paper comprising azomethine dye forming coupler
 INVENTOR(S): Uehira, Shigeki; Ogasawara, Jun; Takeuchi, Kiyoshi; Shimada, Yasuhiro; Deguchi, Yasuaki
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 101 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1197799	A1	20020417	EP 2001-122626	20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002107880	A2	20020410	JP 2000-294964	20000927
JP 2002174884	A2	20020621	JP 2001-101418	20010330
PRIORITY APPLN. INFO.:			JP 2000-294964	A 20000927
			JP 2000-297609	A 20000928
			JP 2001-101418	A 20010330

OTHER SOURCE(S): MARPAT 136:316838
 GI



AB Disclosed is a photog. dye-forming coupler of the formula I (E = aryl, heterocyclic, -C(=O)W group, in which W = nitrogen-containing heterocyclic group; Z = aryl, heterocyclic; X, Y = O, S, N-R, in which R is a substituent, with the proviso that when E = aryl or heterocyclic group, X and Y are O, and when E = -C(=O)W group, Z is aryl). Also disclosed are a silver halide photog. paper that contains at least one dye-forming coupler of the formula I and a method for producing an azomethine dye using a compound of the formula I.

IT 411241-90-2

RL: PNU (Preparation, unclassified); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (azomethine dye, silver halide photog. light-sensitive material comprising dye-forming coupler and method for producing azomethine dye)

RN 411241-90-2 CAPLUS


CN Benzilic acid, 3-[(3-cyclohexyl-3,4-dihydro-4-oxo-2-quinazolinyl)][4-[ethyl[2-(methylsulfonyl)amino]ethyl]amino]-2-[methylphenyl]imino]acetyl]amino-4-methoxy-, tetradecyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:798224 CAPLUS
 DOCUMENT NUMBER: 135:357937


TITLE: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta
 INVENTOR(S): Sadhu, Chanchal; Dick, Kent; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy
 PATENT ASSIGNEE(S): Icos Corporation, USA
 SOURCE: PCT Int. Appl., 278 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081346	A2	20011101	WO 2001-US13315	20010424
WO 2001081346	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DX, DM, OZ, EE, ES, FI, GB, GD, GE, GH, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SO, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MV, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BI, CG, CL, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406278	AA	20011101	CA 2001-2406278	20010424
EP 1278749	A2	20030129	EP 2001-928855	20010424
R: AT, BE, CH, DE, DK, ES, FI, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, RO, MK, CY, AL, TR				
BR 2001010371	A	20030617	BR 2001-10371	20010424
JP 2003531209	T2	20031021	JP 2001-578436	20010424
MZ 522076	A	20050826	MZ 2001-522076	20010424
NO 2002005104	A	20021210	NO 2002-5104	20021024
ZA 2002008698	A	20031010	ZA 2002-8698	20021028
PRIORITY APPLN. INFO.:			US 2000-199659P	P 20000425
			US 2000-230057P	P 20001005
			WO 2001-US13315	W 20010424

OTHER SOURCE(S): MARPAT 135:357937
 GI



L4 ANSWER 38 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K plays a role in leukocyte function are claimed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compds. are provided that inhibit PI3K activity, including compds. that selectively inhibit PI3Kδ activity. The compds. claimed are all quinazolin-1-one derivs., including I [Y = null, S, NH, R, H, halo, OH, OMe, Me, CF3; R1 = H, OMe, halo, RAV] together with C-6 and C-7 of quinazolin-1-one ring optically containing 1-O, N or S; R2 = 5- or 6-membered aromatic ring optically containing 1-O, N or S; R3 = C1-6 alkyl, Ph, alkoxyphenyl, alkylphenyl, biphenyl, PhCH2, pyridinyl, 4-methylpiperazinyl, CO2Et, morpholinyl, R2 = NH2, halo, C1-3 alkyl, S(C1-3 alkyl), OH(NH(C1-3 alkyl)), N(C1-3 alkyl)2, NH(C1-3 alkylphenenyl)] q = 1, 2; and pharmaceutically acceptable salts and solvates thereof. Methods of using PI3Kδ inhibitory compds. to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compds. to inhibit PI3Kδ-mediated processes *in vitro* and *in vivo*. Thus, in an example, dose-dependent decrease in histamine release from basophils when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, RI = H, R2 = 2-C10H4, R3 = H; S connected to 6-position of purine ring; preparation given).

IT 371243-12-87 371243-13-9 371243-14-0P


371243-15-1P 371243-17-3P 371243-22-0P

371243-23-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPA (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and inhibition of human phosphatidylinositol kinase by)

IT 371243-12-8 CAPLUS


CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)




RN 371243-13-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-14-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 371243-15-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-17-3 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 371243-22-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 371243-23-1 CAPLUS
 CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methoxyphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:290354 CAPLUS
 DOCUMENT NUMBER: 135:76844
 TITLE: Quinazolin-4-one α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure-Activity Relationship of the C-2 Side Chain Tether
 AUTHOR(S): Chenard, Bertrand L.; Welch, Willard M.; Blake, James F.; Butler, Todd W.; Reinhold, Anthony; Ewing, Frank E.; Menniti, Frank S.; Pagnozzi, Martin J.
 CORPORATE SOURCE: Global Research and Development Groton Laboratories, Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: Journal of Medicinal Chemistry (2001), 44(11), 1710-1717
 PUBLISHER: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: American Chemical Society
 LANGUAGE: Journal English
 GI



AB A series of 6-fluoro-3-(2-chlorophenyl)quinazolin-4-ones has been prepared, which contains a 2-fluorophenyl ring attached to C-2 by a variety of two-atom tethers. These compounds were used to probe the structure-activity relationship (SAR) for AMPA receptor inhibition. The relative potencies of the new compounds, ranging from 11 nM to greater than 10 μ M. The differential activity of the compounds was rationalized on the basis of alterations of the 2-fluorophenyl positioning (planar and radial) relative to the quinazolin-4-one ring based on computational methods. From this effort, new AMPA receptor antagonists I [R = 2-F, 2-CN, 3-CN, 3-pyridolidinomethyl], containing the methylamino tether group, have been identified.
 IT 217942-71-7 CAPLUS
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)
 RN 217942-71-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 217942-52-4P 217942-64-0P 217942-66-0P
221152-63-2P 346700-93-4P 346700-94-5P
346700-95-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)

RN 217942-52-4 CAPLUS



CN Benzonitrile, 3-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-64-8 CAPLUS
CN Acetamide, N-[3-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-66-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(3-(1-pyrrolidinylmethyl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 221152-63-2 CAPLUS
CN Benzonitrile, 2-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 346700-93-4 CAPLUS
CN Acetamide, N-[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 346700-94-5 CAPLUS
CN 4(OH)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)methylamino]- (9CI) (CA INDEX NAME)



RN 346700-95-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(3-methylphenyl)amino)methyl]- (9CI) (CA INDEX NAME)




IT 346700-98-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-arylaminoethylquinazolinones as AMPA receptor antagonists)

Habte

08/08/2006


L4 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 346700-98-9 CAPLUS
CN Formamide, N-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]-N-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 242479-75-0 CAPLUS
 CN 2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,N-bis(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 242479-77-2 CAPLUS
 CN 2-Quinazolinecarboxamide, 3,4-dihydro-N,N-bis(4-methoxyphenyl)-8-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 242479-78-3 CAPLUS
 CN 2-Quinazolinecarboxamide, 3,4-dihydro-6,7-dimethoxy-N,N-bis(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 242479-79-4 CAPLUS
 CN 2-Quinazolinecarboxamide, N,N-bis[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:198895 CAPLUS
 DOCUMENT NUMBER: 130:311760
 TITLE: Synthesis and fungicidal activity of 3-aryl-2-(4'-aryl thiazol-2'-ylaminomethyl) quinazol-4 (3H)-ones
 AUTHOR(S): Pattanaik, J. M.; Pattanaik, M.; Bhatta, D.
 CORPORATE SOURCE: Department of Chemistry, Utkal University, Bhubaneswar, 751 004, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(12), 1304-1306
 PUBLISHER: CODEN: IJSCBD; ISSN: 0376-4699
 DOCUMENT TYPE: National Institute of Science Communication, CSIR
 LANGUAGE: Journal
 English
 AB A series of 3-aryl-2-(4-aryl-2-thiazolylaminomethyl) quinazol-4(3H)-ones was prepared by condensing 3-aryl-2-chloromethylquinazol-4(3H)-ones with 2-amino-4-substituted phenylthiazoles. Another group of 3-aryl-6,8-dibromo-2-(4-aryl-2-thiazolylaminomethyl)quinazol-4 (3H)-ones was also synthesized from 3-aryl-6,8-dibromo-2-chloromethylquinazol-4 (3H)-ones and 2-amino-4-substituted phenylthiazoles in the same manner. Their antifungal activity was determined.

IT 223590-50-5P 223590-49-6P 223590-50-9P
 223590-51-0P 223590-52-1P 223590-53-2P
 223590-54-3P 223590-55-4P 223590-56-5P
 223590-57-6P 223590-58-7P 223590-59-8P
 223590-60-7P 223590-61-2P 223590-62-3P
 223590-63-4P 223590-64-5P 223590-65-6P
 223590-66-7P 223590-67-8P 223590-68-9P
 223590-69-0P 223590-70-3P 223590-71-4P
 223590-72-5P 223590-73-6P 223590-74-7P
 223590-75-8P 223590-76-9P 223590-77-0P
 223590-78-1P 223590-79-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and fungicidal activity of [(arylthiazolyl)aminomethyl]quinazol-4(3H)-ones)

RN 223590-48-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-(4-methylphenyl)-2-thiazolyl]amino)methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 223590-49-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-50-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[4-(4-methylphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 223590-51-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-(4-chlorophenyl)-2-thiazolyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-52-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methoxyphenyl)-2-[[4-(4-methoxyphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
methylphenyl)-2-thiazolyl]amino)methyl]- (9CI) (CA INDEX NAME)



RN 223590-67-8 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-68-9 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-69-0 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 223590-70-3 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-chlorophenyl)-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-71-4 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-chlorophenyl)-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-72-5 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-methylphenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-73-6 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 223590-74-7 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 223590-75-8 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-[[[4-(4-methylphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 223590-76-9 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 223590-77-0 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-chlorophenyl)-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 223590-78-1 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(4-methoxyphenyl)-2-[[[4-(4-methoxyphenyl)-2-thiazolyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 223590-79-2 CAPIUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-2-[[[4-(4-chlorophenyl)-2-thiazolyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:175749 CAPLUS
 DOCUMENT NUMBER: 130:218317
 TITLE: AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
 INVENTOR(S): Chenard, Bertrand Leo; Menniti, Frank Samuel; Welch, Willard McKowan, Jr.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 22 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 900568	A2	19990310	EP 1998-307181	19980904
EP 900568	A3	20010502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11158072	A2	19990615	JP 1998-245269	19980831
JP 2001316267	A2	20011113	JP 2001-134816	19980831
AU 9883120	A1	19990318	AU 1998-83120	19980904
AU 736254	B2	20010726		
NZ 331741	A	20000825	NZ 1998-331741	19980904
US 6136812	A	20001024	US 1998-148974	19980904
ZA 9808139	A	20000322	ZA 1998-8139	19980907
CA 2246839	AA	19990305	CA 1998-2246839	19980908
CA 2246839	C	20021112		

PRIORITY APPLN. INFO.: US 1997-58098P P 19970905
 JP 1998-245269 A3 19980831

OTHER SOURCE(S): MARPAT 130:218317

AB The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease. One example compound of the 212 claimed was (S)-3-(2-chlorophenyl)-2-[2-(5-diethylaminomethyl-2-fluorophenyl)vinyl]-6-fluoro-3H-quinazolin-4-one.

IT 217942-51-3 217942-54-6 217942-55-7

217942-57-9 217942-58-0 217942-60-4

217942-62-6 217942-64-8 217942-66-0

217942-68-2 217942-69-3 217942-71-7

217942-72-8 217942-86-4 221152-54-1

221152-55-2 221152-56-3 221152-57-4

221152-58-5 221152-59-6 221152-60-9


221152-61-0 221152-62-1 221152-63-2

RL: THI (therapeutic use); BIOL (Biological study); USES (Uses)
 (AMPA antagonists for treatment of dyskinesias associated with dopamine agonist therapy)


RN 217942-51-3 CAPLUS

CN Benzonitrile, 2-[(3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-


quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-54-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[(3-((diethylamino)methyl)phenyl)amino]methyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 217942-55-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyrimidinylamino)methyl]- (9CI) (CA INDEX NAME)




RN 217942-57-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(3-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-66-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(3-(1-pyrrolidinylmethyl)phenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-68-2 CAPLUS
CN 3-Pyridinecarboxonitrile, 2-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-69-3 CAPLUS


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 217942-71-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-72-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(6-methyl-2-pyridinyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-86-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyridinylamino)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 221152-54-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[(3-(1-pyrrolidinylmethyl)phenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 221152-55-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chlorophenyl)-2-[(3-(1-pyrrolidinylmethyl)phenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 221152-56-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chlorophenyl)-2-[(3-(diethylamino)methyl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)




RN 221152-57-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-(2-chloro-3-pyridinyl)-2-[(3-(diethylamino)methyl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 221152-58-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-[(3-(diethylamino)methyl)phenyl]amino-3-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221152-59-6 CAPLUS
CN Benzonitrile, 2-[(3-(2-chloro-3-pyridinyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 221152-60-9 CAPLUS
CN Benzonitrile, 2-[(3,4-dihydro-3-(2-methyl-3-pyridinyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 221152-61-0 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[[6-fluoro-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 221152-62-1 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[[3-(2-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 221152-63-2 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 1999:3410 CAPLUS
 DOCUMENT NUMBER: 130:66507
 TITLE: Quinazolin-4-one AMPA antagonists
 INVENTOR(S): Chenard, Bertrand Leo; Reinhold, Anthony Ronald;
 Welch, Willard McKowan
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 884310	A1	19981216	EP 1998-304319	19980601
EP 884310	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6627755	B1	20030930	US 1998-79420	19980514
AT 303997	E	20050915	AT 1998-304319	19980601
ES 2245015	T3	20051216	ES 1998-304319	19980601
CA 2240138	AA	19981209	CA 1998-2240138	19980605
CA 2240138	C	20020820		
JP 11012255	A2	19990119	JP 1998-160821	19980609
JP 3415443	B2	20030609		
BR 9801808	A	20000321	BR 1998-1808	19980609
US 2004049039	A1	20040311	US 2003-640482	20030813
US 6921764	B2	20050726		
PRIORITY APPLN. INFO.:				
US 1997-49082P	P	19970609		
US 1997-53274P	P	19970721		
US 1997-50110P	P	19970613		
US 1998-79420	A3	19980514		

OTHER SOURCE(S): MARPAT 130:66507
 GI




AB Preparation of quinazolin-4-one derivs. I [A = benzo- or thieno-fused aromatic; B = Ph, pyridyl, pyrimidyl; X = N, CH; YZ = CH2NH, NHCH2; R1 = H, (C1-C6)alkyl optionally substituted with from one to three fluorine atoms, cyano, halo, amino, nitro and (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms; R2 = halo, cyano, (C1-C6)alkyl

Habte


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 optionally substituted with from one to three fluorine atoms, nitro, amino, (C1-C6)alkylthio, (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms, hydroxy, etc.; R3, R4 = H, (C1-C6)alkyl optionally substituted with from one to three fluorine atoms, halo, cyano, hydroxy (C1-C6)alkoxy optionally substituted with from one to three fluorine atoms, etc.; and the use of such compds. to treat neurodegenerative, psychotropic, and drug and alc. induced central and peripheral nervous system disorders (no data), are described. E.g., reaction of 2-(2-chloropyridin-3-yl)-6-fluoro-3,4-dihydroquinazolin-4-one-2-carbaldehyde with 2-anthranilonitrile gave an intermediate imine, which was reduced to give 2-[[3-(2-chloropyridin-3-yl)-6-fluoro-3,4-dihydroquinazolin-2-ylmethyl]amino]benzonitrile.

IT 217962-95-3P 217962-96-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
 Interpretation of quinazolinone as AMPA antagonists

RN 217962-05-3 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, (3R)- (9CI) (CA INDEX NAME)




RN 217962-96-4 CAPLUS
 CN Benzonitrile, 2-[[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, (3S)- (9CI) (CA INDEX NAME)




IT 217942-51-3P 217942-52-4P 217942-54-6P
 217942-55-7P 217942-57-9P 217942-59-0P
 217942-59-1P 217942-60-4P 217942-62-6P
 217942-64-8P 217942-66-0P 217942-68-2P
 217942-69-3P 217942-71-7P 217942-72-8P
 217942-86-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses);
 (prepn. of quinazolinone as AMPA antagonists)
 RN 217942-51-3 CAPLUS
 CN Benzonitrile, 2-[[3-(2-chloro-3-pyridinyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-52-4 CAPLUS
 CN Benzonitrile, 3-[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-54-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-[[3-[(diethylamino)methyl]phenyl]amino]methyl]-6-fluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 217942-55-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyrimidinylamino)methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-57-9 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[(3-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-58-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[(6-methyl-2-pyridinylamino)methyl]amino- (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 217942-59-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyridinylamino)methyl]amino- monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 217942-60-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chloro-3-pyridinyl)-6-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-62-6 CAPLUS
 CN 4(3H)-Quinazolinone, 6-fluoro-3-(2-methyl-3-pyridinyl)-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 217942-64-8 CAPLUS
 CN Acetamide, N-[(3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino-phenyl- (9CI) (CA INDEX NAME)




RN 217942-66-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)




RN 217942-68-2 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[[3-(2-chlorophenyl)-6-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 217942-69-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-71-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-fluorophenyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 217942-72-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(6-methyl-2-pyridinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 217942-86-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-6-fluoro-2-[(2-pyridinylamino)methyl]methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:233063 CAPLUS
DOCUMENT NUMBER: 125:10737
TITLE: Synthesis and reactions of 2-chloromethyl-3,1-benzoxazin-4-ones with amines
AUTHOR(S): Amin, M.A.; Osman, A.N.; Aziza, M.A.; El-Hakim, A.E.
CORPORATE SOURCE: Faculty of Pharmacy, Al-Azhar University, Egypt
SOURCE: Egyptian Journal of Chemistry (1995), 38(1), 113-23
CODEN: EGJC43; ISSN: 0367-0422
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB Benzoxazinones I (Y = H, Br) were prepared and reacted with amines. Thus, reaction with RNH₂ (R = 2-MeC₆H₄, 2-HOC₆H₄, 3-MeC₆H₄, etc.) gave quinazolinones II.
IT 177167-23-6P 177167-24-7P
RL: SRN (Synthetic preparation); PREP (Preparation)
(R) preparation and reaction of benzoxazinones with amines
RN 177167-23-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-phenyl-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 177167-24-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-(4-methylphenyl)-2-[(4-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:534062 CAPLUS
 DOCUMENT NUMBER: 121:134062
 TITLE: 4-(3H)-Quinazolones; 2-N-aryl/alkylaminomethyl/ethyl-3-p-hydroxyphenyl/p-anisyl/p-arylaminoacyloxyphenyl/p-N-arylcabamoylmethoxyphenyl-4-(3H)-quinazolones
 AUTHOR(S): Parasharya, P. M.; Soni, V. C.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1992), 64 (6), 238-41
 DOCUMENT TYPE: CODEN: JOICAA; ISSN: 0020-3254
 Journal
 LANGUAGE: English
 GI




AB Some new 4(3H)-quinazolone derivs., I and II, having N-arylaminoethyl/N-alkylaminomethyl/N-arylaminoethyl group at C(2) and p-hydroxyphenyl/p-anisyl/p-arylaminoacyloxyphenyl/p-(N-arylcabamoylmethoxy)phenyl group at C(3) were prepared I and II showed moderate antimicrobial activity (no data). Structures of I and II were confirmed by IR spectra and elemental anal.

IT 156672-31-0P 156672-32-1P 156672-33-2P
 156672-34-3P 156672-35-4P 156672-36-5P
 156672-37-6P 156672-38-7P 156672-39-8P
 156672-40-1P 156672-41-2P 156672-42-3P
 156672-43-4P 156672-44-5P 156672-45-6P
 156672-47-8P 156672-49-9P 156672-51-1P
 156672-53-6P 156672-54-7P 156672-55-8P
 156672-56-9P 156672-57-0P 156672-58-1P
 156672-59-2P 156672-60-5P 156672-61-6P
 156672-62-7P 156672-63-8P 156672-64-9P
 156672-65-0P 156672-66-1P 156672-70-7P
 156672-71-8P 156672-72-9P 156672-74-1P
 156672-76-3P 156672-77-4P 156703-84-3P
 156703-85-4P 156932-49-9P 156932-50-2P
 156932-52-4P 156932-53-5P 156932-54-6P
 156932-55-7P 156932-56-8P 156932-57-9P
 156932-58-0P 156932-59-1P 156932-60-4P
 156932-61-5P 156932-62-6P 156932-63-7P
 156932-64-8P 156932-65-9P 156932-66-0P
 156932-68-2P 156932-69-3P 156932-70-6P
 156932-73-9P 156932-74-0P 156932-75-1P
 156932-76-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prep. and antimicrobial activity of)
 RN 156672-31-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 156672-32-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[{(2-chlorophenyl)amino}methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-33-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[{(3-chlorophenyl)amino}methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-34-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[[{(2-methylphenyl)amino}methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156672-35-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(3-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-36-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-37-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-38-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 156672-39-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-40-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(3-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-41-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-42-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-hydroxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-43-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-44-5 CAPLUS
CN Benzoic acid, 4-[(3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 156672-45-6 CAPLUS
CN Benzoic acid, 4-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 156672-47-8 CAPLUS
CN Benzoic acid, 3-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 156672-49-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 156672-51-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-53-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



RN 156672-54-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-chlorophenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-55-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(3-chlorophenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-56-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-57-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 156672-58-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-59-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methylphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-60-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)

Habte


08/08/2006




RN 156672-61-6 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-62-7 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]methyl- (9CI) (CA INDEX NAME)





RN 156672-63-8 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-64-9 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(4-methoxyphenyl)amino]methyl-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 156672-65-0 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(2-hydroxyphenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156672-66-1 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(4-hydroxyphenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
RN 156672-70-7 CAPIUS
CN Benzoic acid, 4-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 156672-71-8 CAPIUS
CN Benzoic acid, 4-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino-, ethyl ester (9CI) (CA INDEX NAME)




RN 156672-72-9 CAPIUS
CN Benzoic acid, 3-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino-2-hydroxy- (9CI) (CA INDEX NAME)




RN 156672-74-1 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 156672-76-3 CAPIUS
CN Benzamide, N-[(5-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino)-1,3,4-thiadiazol-2-yl]methyl- (9CI) (CA INDEX NAME)



RN 156672-77-4 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 156703-84-3 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 156703-85-4 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156932-49-9 CAPLUS
CN Sulfamic acid, [4-[(3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 156932-50-2 CAPLUS
CN Benzamide, N-[[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-1,3,4-thiadiazol-2-yl]methyl] - (9CI) (CA INDEX NAME)




RN 156932-52-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(phenylamino)ethyl] - (9CI) (CA INDEX NAME)




L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(4-methylphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-58-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(2-methoxyphenylamino)ethyl] - (9CI) (CA INDEX NAME)



RN 156932-59-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(3-methoxyphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-60-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(4-methoxyphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-61-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(2-nitrophenylamino)ethyl] - (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 156932-53-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[(3-chlorophenyl)amino]ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)


RN 156932-54-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[(4-chlorophenyl)amino]ethyl]-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 156932-55-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(2-methylphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-56-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(3-methylphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-57-9 CAPLUS


L4 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156932-62-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-[(4-nitrophenyl)amino]ethyl] - (9CI) (CA INDEX NAME)



RN 156932-63-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(2-hydroxyphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-64-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[2-(4-hydroxyphenylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 156932-65-9 CAPLUS
CN Benzoic acid, 4-[[2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl]amino] - (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-66-0 CAPIUS
CN Benzoic acid, 4-[(2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 156932-68-2 CAPIUS
CN Sulfamic acid, [4-[(2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 156932-69-3 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-(2-(1-naphthalenylamino)ethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-70-6 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(2-(cyclohexylamino)ethyl)-3-(4-hydroxyphenyl)-] (9CI) (CA INDEX NAME)




RN 156932-73-9 CAPIUS
CN Benzoic acid, 2-[(2-[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]ethyl)amino]- (9CI) (CA INDEX NAME)




RN 156932-74-0 CAPIUS
CN 4(3H)-Quinazolinone, 2-[(2-[(4-bromophenyl)amino]ethyl)-3-(4-hydroxyphenyl)-] (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 156932-75-1 CAPIUS
CN Sulfamic acid, [4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 156932-76-2 CAPIUS
CN Carbamic acid, [4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 48 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:508675 CAPIUS
DOCUMENT NUMBER: 121:108675
TITLE: 4(3H)-Quinazolones. Part I: 2-Alkyl/arylaminoethyl-3-p-hydroxy/methoxyphenyl-4(3H)-quinazolones
AUTHOR(S): Parasharya, P. M.; Parikh, A. R.
CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
SOURCE: Journal of the Institution of Chemists (India) (1992), 64 (5), 184-5
DOCUMENT TYPE: CODEN: JOICA7; ISSN: 0020-3254
LANGUAGE: Journal
G1 English




AB The title compds. I (X = OH, OMe; R = alkyl, aryl) were prepared by amination of the 2-(bromomethyl) derive, and tested for antibacterial activity. Some I showed remarkable antibacterial activity.

IT 156672-31-0P 156672-32-1P 156672-33-2P
156672-34-3P 156672-35-4P 156672-36-5P
156672-37-6P 156672-38-7P 156672-39-8P
156672-40-1P 156672-41-2P 156672-42-3P
156672-43-4P 156672-44-5P 156672-45-6P
156672-47-8P 156672-49-0P 156672-50-3P
156672-51-4P 156672-53-6P 156672-54-7P
156672-55-8P 156672-56-9P 156672-57-0P
156672-58-1P 156672-59-2P 156672-60-5P
156672-61-6P 156672-62-7P 156672-63-8P
156672-64-9P 156672-65-0P 156672-66-1P
156672-67-2P 156672-69-4P 156672-70-7P
156672-71-8P 156672-72-9P 156672-73-0P
156672-74-1P 156672-76-3P 156672-77-4P
156703-84-3P 156703-85-4P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); (preparation and antibacterial activity of)

RN 156672-31-0 CAPIUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-32-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)-(9CI) (CA INDEX NAME)



RN 156672-33-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(3-chlorophenyl)amino]methyl]-3-(4-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 156672-34-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-methylphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-35-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(3-methylphenyl)amino]methyl-


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-39-8 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-40-1 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(3-nitrophenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-41-2 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-nitrophenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-42-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-hydroxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)

L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)

RN 156672-36-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-methylphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-37-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-38-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(3-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-43-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)



RN 156672-44-5 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-(9CI) (CA INDEX NAME)




RN 156672-45-6 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, ethyl ester (9CI) (CA INDEX NAME)




RN 156672-47-8 CAPLUS
 CN Benzoic acid, 3-[[3,4-dihydro-3-(4-hydroxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-2-hydroxy-(9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-49-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(1-naphthalenylamino)methyl]-(9CI) (CA INDEX NAME)



RN 156672-50-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(5-benzoyl-1,3,4-thiadiazol-2-yl)amino]methyl]-3-(4-hydroxyphenyl)-(9CI) (CA INDEX NAME)




RN 156672-51-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-hydroxyphenyl)-(9CI) (CA INDEX NAME)





L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-56-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 156672-57-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methylphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-58-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methylphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-59-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methylphenyl)amino]methyl-(9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-53-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(phenylamino)methyl]-(9CI) (CA INDEX NAME)



RN 156672-54-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 156672-55-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(3-chlorophenyl)amino]methyl]-3-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 156672-60-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(2-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)



RN 156672-61-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-62-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]methyl-(9CI) (CA INDEX NAME)




RN 156672-63-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(3-nitrophenyl)amino]methyl-(9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-64-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 156672-65-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-hydroxyphenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 156672-66-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-hydroxyphenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 156672-67-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-bromophenyl)amino]methyl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 156672-69-4 CAPLUS
CN Benzoic acid, 2-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 156672-70-7 CAPLUS
CN Benzoic acid, 4-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 156672-71-8 CAPLUS
CN Benzoic acid, 4-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 156672-72-9 CAPLUS
CN Benzoic acid, 3-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino-2-hydroxy- (9CI) (CA INDEX NAME)



RN 156672-73-0 CAPLUS
CN Benzenesulfonic acid, 4-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino- (9CI) (CA INDEX NAME)




RN 156672-74-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(1-naphthalenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 156672-76-3 CAPLUS
CN Benzamide, N-[15-[(3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl]amino]-1,3,4-thiadiazol-2-yl]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 156672-77-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 156703-84-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 156703-85-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(2-nitrophenyl)amino]methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 49 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:298578 CAPLUS
DOCUMENT NUMBER: 1201:298578
TITLE: Synthesis and some reactions of 4-oxo-3-phenyl-(1H,3H)-
quinalizine-2-thione
AUTHOR(S): El-Deen, I.M.; Mohamed, S.M.
CORPORATE SOURCE: Fac. Educ., El-Arish, Suez Canal Univ., Egypt
SOURCE: Indian Journal of Heterocyclic Chemistry (1993), 2(4),
233-6
CODEN: IJCHEI; ISSN: 0971-1627
DOCUMENT TYPE: Journal
LANGUAGE: English
GI





AB Room temperature treatment of 2-(3-phenylthioureido)benzoic acid with concentrated sulfuric acid led to 4-oxo-3-phenyl(1H,3H)quinazoline-2-thione (I) in generally very good yield. Ammonolysis, hydrazinolysis, and alkylation of I yielded 2-substituted 3-phenyl(1H,3H)quinazoline-4-one II ($R = NH_2$, $R_1 = Ph$, CH_2Ph , NH_2CH_2Ph , $NH_2C_6H_4CH_3$), 3-phenyl-1-(4-(1H,3H)quinazolinone-2-thio)glycolic acid II ($R = SCH_2CO_2H$) and ester III ($R = SCH_2CO_2Et$). II ($R = SCH_2CO_2H$) reacted with p-anisaldehyde to afford the B-(3-phenyl-4-(1H,3H)quinazoline-2-thio)-4-methoxystyrene II ($R = SCH_2CH_2CO_2Me$). Treatment of II ($R = SCH_2CO_2Et$) with anthranilic acid gave the corresponding 2-substituted 4H-3,1-benzoxazin-4-one. Hydrazinolysis and arylation of the latter under

Friedel-Crafts conditions affords N-substituted anti-
III ($R_1 = NH_2$) and N-2-(substituted) benzophenone
IT 146849-71-0P


RN 146849-71-0 CAPLUS
CN 2,4(1H,3H)-Quinazolininedione, 3-phenyl-, 2-(phenylhydrazone) (9CI) (CA INDEX NAME)




L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-67-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-methylphenyl)amino]methyl]-4-oxo-3(4H)-quiazolinyl- (SC1) (CA INDEX NAME)




RN 147766-68-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[(2-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quiazolinyl- (9CI) (CA INDEX NAME)




RN 147766-69-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quiazolinyl- (9C1) (CA INDEX NAME)

L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1993-449324 CAPLUS
 DOCUMENT NUMBER: 119-49324
 TITLE: 4-(3H)-quinazolones. Part III: Alkyl or
 arylaminoethyl/ substituted cinnamyl-3-p
 sulfonamidophenyl-4-(3H)-quinazolones
 AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1991),
 63(6), 219-20
 CODEN: JOICAT; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB	Title compds., including aminomethyl derivs. I (R = Ph, 2-MeC6H4, 3-MeC6H4-4-MeC6H4, 2-MeOC6H4, 3-MeOC6H4, 4-MeOC6H4, 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 2-C1ClC6H4, 3-C1ClC6H4, 4-C1ClC6H4, 4-BrC6H4, PhC6H4, 1-naphthyl, Me, Bu, octadecyl) and styryl derivs. II (R = 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 2-C1ClC6H4, 3-C1ClC6H4, 4-C1ClC6H4, 4-I-ClC6H4, 2-C1IIC6H4, 3-C1IIC6H4, 4-C1IIC6H4, 4-O2NC6H4-2-C1ClC6H4, 3-C1ClC6H4, 4-C1ClC6H4), several aminomethyl derivs., e.g., 1-(2-O2NC6H4)-2-O2NC6H4, 1-(2-O2NC6H4)-4-O2NC6H4, 2-C1ClC6H4, 3-C1ClC6H4, 4-C1ClC6H4, Bu, ester, cyclyl) showed bactericidal and fungicidal activity.
IT	147766-69-6 147766-67-4P 147766-68-5P 147766-69-6P 147766-70-9P 147766-71-0P 147766-72-1P 147766-72-2P 147766-74-3P 147766-76-5P 147766-77-6P 147766-78-7P 147766-79-8P 147766-80-1P 147766-81-2P 147766-82-3P 147766-83-4P 147792-99-2P 148472-79-1P 148472-80-4P 149411-85-8P
RL	SPB (Synthetic preparation); PREP (Preparation) (preparation of)
RN	147766-66-3 CAPIUS
CN	Benzeneponamidine, 4-[2-[{2-(2-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolin-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-70-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quiazolinyl- (9CI) (CA INDEX NAME)




RN 147766-71-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quiazolinyl- (9CI) (CA INDEX NAME)




RN 147766-72-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinoxalinolyl- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-73-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 147766-74-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 147766-76-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-bromophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-77-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[(1-naphthalenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 147766-78-7 CAPLUS
CN Benzoic acid, 4-[(3-[4-(aminosulfonyl)phenyl]amino)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 147766-79-8 CAPLUS
CN Benzoic acid, 4-[(3-[4-(aminosulfonyl)phenyl]amino)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-80-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[(2-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 147766-81-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 147766-82-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 147766-83-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[(cyclohexylamino)methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)



RN 147792-99-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[(2-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)





RN 148472-79-1 CAPLUS
CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 148472-80-4 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(2-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)




RN 149411-85-8 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(4-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,4(1H,3H)-Quinazolineone, 3-phenyl-, 2-(phenylhydrazone) (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:254854 CAPLUS
 DOCUMENT NUMBER: 118:254854
 TITLE: Synthesis and some reactions of 3-phenyl-(1H,3H)-quiazoline-2-thione-4-one
 AUTHOR(S): El-Deen, I. M.; El-Desoky, S.
 CORPORATE SOURCE: Fac. Educ., Suez Canal Univ., Egypt
 SOURCE: Journal of the Serbian Chemical Society (1992), 57(11), 719-23
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 118:254854
 GI




AB Room temperature treatment of 2-(3-Ph thioureido)-benzoic acid with concentrated sulfuric acid lead to the formation of 3-phenyl(1H,3H)-quinazoline-2-thione-4-one (I) in generally very good yield. Ammonolysis, hydrazinolysis and alkylation of I yielded 2-substituted-3-phenyl(1H,3H)-quinazoline-4-one II (R = NPh, NHCH₂Ph, NHNH₂, NHNHPH), 3-phenyl-4-(1H,3H)-quinazoline-2-thioglycolic acid III; R = SCH₂CO₂H and the ester II (R = SCH₂CO₂Z, resp. Compound II (R = SCH₂CO₂H) reacted with anisaldehyde to afford the β -[3-phenyl-4-(1H,3H)-quinazoline-2-yl-thio]-4-methoxystyrene. Treatment of compound II (R = SCH₂CO₂H) with anthranilic acid gave the corresponding 2-substituted-4H-3,1-benzoxazine-4-one III. Hydrazinolysis and acylation, under Friedel-Crafts conditions, of III affords N-substituted anthranilic acid hydrazide IV (R1 = NH₂NH₂) and N-2-(substituted)-benzophenone IV (R1 = C₆H₅Me₂-2,4), resp.


IT 146849-71-0
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 146849-71-0 CAPLUS

L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2,4(1H,3H)-Quinazolineone, 3-phenyl-, 2-(phenylhydrazone) (9CI) (CA INDEX NAME)


L4 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:656106 CAPLUS
 DOCUMENT NUMBER: 115:256106
 TITLE: 4-(3H)-quinazolones. Part II: 2-alkyl- or arylaminomethyl-substituted cinnamyl-1-3-p-(N-phenylthioureido)sulfonylphenyl)-4-(3H)-quinazolones
 AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.
 CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 SOURCE: Journal of the Institution of Chemists (India) (1991), 63(2), 66-8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Title compds. I (R = Ph, substituted Ph, furyl, naphthyl, octadecyl; R1 = CH₂NHR, CH₂CH₂Ph, CH₂CH₂H) were prepared from the sulfonamide II. I have bactericidal and fungicidal activity.
 IT 137205-41-5P 137205-42-6P 137205-43-7P
 137205-44-8P 137205-45-9P 137205-46-0P
 137205-47-1P 137205-48-2P 137205-49-3P
 137205-50-6P 137205-51-7P 137205-53-9P
 137205-54-0P 137205-55-1P 137205-56-2P
 137205-57-3P 137205-58-4P 137205-59-5P
 137205-60-8P 137205-92-6P 137205-93-7P
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 137205-41-5 CAPLUS
 CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-42-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-[(4-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-43-7 CAPIUS
CN Benzenesulfonamide, 4-[2-[(2-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-44-8 CAPIUS
CN Benzenesulfonamide, 4-[2-[(3-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-45-9 CAPIUS
CN Benzenesulfonamide, 4-[2-[(4-methoxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-46-0 CAPIUS
CN Benzenesulfonamide, 4-[2-[(2-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)





RN 137205-47-1 CAPIUS
CN Benzenesulfonamide, 4-[2-[(3-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-48-2 CAPIUS
CN Benzenesulfonamide, 4-[2-[(4-nitrophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-49-3 CAPIUS
CN Benzenesulfonamide, 4-[2-[(2-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-50-6 CAPIUS
CN Benzenesulfonamide, 4-[2-[(3-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-51-7 CAPIUS
CN Benzenesulfonamide, 4-[2-[(4-chlorophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-53-9 CAPIUS
CN Benzenesulfonamide, 4-[2-[(4-bromophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-54-0 CAPIUS
CN Benzenesulfonamide, 4-[2-[(1-naphthalenylamino)methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-55-1 CAPIUS
CN Benzoic acid, 4-[[[3,4-dihydro-4-oxo-3-[[4-[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]-2-quinazolinyl]methyl]amino-, ethyl ester (9CI) (CA INDEX NAME)




RN 137205-56-2 CAPLUS
CN Benzenesulfonamide, 4-[{[3,4-dihydro-4-oxo-3-[(4-[(phenylamino)thioxomethyl]amino)sulfonyl]phenyl}-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 137205-57-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[(2-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-58-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)





RN 137205-59-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-60-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[(cyclohexylamino)methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-62-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[(2-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-93-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1991:449604 CAPLUS
DOCUMENT NUMBER: 115:49604
TITLE: Synthesis and biological activity of some newer substituted 3-arylg-4(3H)-quinoxalinones
AUTHOR(S): Shukla, Jagdish S.; Fadayan, Hanoucheh
CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226 007, India
SOURCE: Indian Journal of Pharmaceutical Sciences (1989), S1(1), 5-6
CODEN: IJSIDW; ISSN: 0250-474X
DOCUMENT TYPE: Journal
LANGUAGE: English


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A number of [(arylmethylene)dihydrophenyloximidezolylphenylaminomethyl]quinoxalinones I (R = H, Iodo; R1 = NO₂, H, Cl, MeO; R2 = H, 4-OH, 2-OH, 4-CMe, 4-Cl, 3-NO₂) were prepared by reaction of phenyl(benzylidene)oxazolinones II with p-(H₂N)C₆H₄ and alkylation of the resulting (anilinophenyl)arylimidazolinones III with aryl(chloromethyl)quinoxalinones IV. I were screened for antihelmintic, virucidal, and bactericidal activity. All the compds. showed marked activity against *Bacillus subtilis* and *Staphylococcus aureus*.


IT 134989-51-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation) (preparation and bactericidal activity of)

RN 134989-51-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl-1-phenyl- (9CI) (CA INDEX NAME)




IT 134989-58-5P 134989-59-6P 134989-60-9P
134989-61-0P 134989-62-1P 134989-63-2P
RL: SPN (Synthetic preparation); PRP (Preparation) (preparation, antihelmintic and bactericidal activity of)


RN 134989-58-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl-6-iodo-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 134989-59-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-6-iodo-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 134989-60-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-4-[(2-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 134989-61-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-5-oxo-2-phenyl-4-(phenylmethylene)-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 134989-62-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[4-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 134989-63-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[4-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1991:449595 CAPLUS
DOCUMENT NUMBER: 115:49595
TITLE: Quinazolinylpyrazolines as antiinflammatory agents
AUTHOR(S): Kumar, Ashok; Verma, R. S.; Jaju, B. P.; Sinha, J. N.
CORPORATE SOURCE: Dep. Pharmacol. Pharm., LBM Med. Coll., Meerut, 250 004, India
SOURCE: Journal of the Indian Chemical Society (1990), 67(11), 920-1
DOCUMENT TYPE: JICSAH; ISSN: 0019-4522
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:49595
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB [(N-Acetylpyrazolyl)phenylamino]methyltolylquinazolinones I (R = r, - Br, - Cl, - 2-F, - 2-MeO, - 4-MeN, - 2-Cl, - H) were prepared from (bromomethyl)quinazolinones II (R2 = Br) and 2-AcGHNH2 via condensation of (acetylphenyl)amino[methyl]quinazolinones II (R2 = 2-MeCOCH4NH) with R1C6H4CHO and cyclodenaturation of the resulting cinnamoyl derivs. III with H2NNH2. Evaluation of the inflammation inhibiting activity of I, II (R2 = 2-AcGHNH) and III in albino rats at 50 mg/kg orally showed varying degree of protection (7.2-34%) against carrageen induced edema.

IT 134951-72-7 134951-84-18 134951-85-29
134951-86-39 134951-87-48 134951-88-59
134951-89-60 134951-90-91 134951-91-09
134951-92-12 134951-93-28 134951-63-89
RL SPN (Synthetic preparation); PREP (Preparation)
(preparation and inflammation inhibiting activity of)


RN 134951-72-7 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-84-1 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 134951-85-2 CAPLUS
CN 1H-Pyrazole, 1-acetyl-3-[2-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 134951-86-3 CAPLUS
CN 1H-Pyrazole, 1-acetyl-5-(2-chlorophenyl)-3-[2-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-87-4 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(4-(dimethylamino)phenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-88-5 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-89-6 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134951-90-9 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 134951-91-0 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(2-chlorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 134951-92-1 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-5-(4-(dimethylamino)phenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 134951-93-2 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[6-bromo-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)





RN 134981-63-8 CAPLUS
 CN 1H-Pyrazole, 1-acetyl-3-[2-[[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





IT 134951-70-5P 134951-73-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, antiinflammatory activity, and condensation of, with aromatic aldehydes)

RN 134951-70-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-acetylphenyl)amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-73-8 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[[(2-acetylphenyl)amino]methyl]-6-bromo-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




IT 134951-71-6P 134951-74-9P 134951-75-0P
 134951-76-1P 134951-77-2P 134951-78-3P

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 134951-79-4P 134951-80-7P 134951-81-8P
 134951-82-9P 134951-83-0P 134981-62-7P
 RL: SPN (Synthetic preparation), PREP (Preparation)
 (prepn., antiinflammatory activity, and cyclocondensation of, with
 hydrazine)

RN 134951-71-6 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[2-(3-(2-fluorophenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-74-9 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[2-(3-(2-methoxyphenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-75-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[2-(3-(4-methoxyphenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-78-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[2-(1-oxo-3-phenyl-2-
 propenyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 134951-79-4 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[2-(3-(2-fluorophenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-80-7 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[2-(3-(4-methoxyphenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 134951-76-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[2-(3-(4-dimethylamino)phenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 134951-77-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[2-(3-(2-chlorophenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 134951-81-8 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[2-(3-(4-dimethylamino)phenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 134951-82-9 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[[2-(3-(2-chlorophenyl)-1-oxo-2-
 propenyl)phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 134951-83-0 CAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[[2-(1-oxo-3-phenyl-2-
 propenyl)phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 134981-62-7 CAPLUS


08/08/2006

Habte

L4 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 6-bromo-2-[(2-(3-(2-methoxyphenyl)-1-oxo-2-propenyl)phenyl)amino]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 55 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 1991:122242 CAPLUS
 DOCUMENT NUMBER: 114:122242
 TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones
 AUTHOR(S): Faragly, Ahmed M.; Chabab, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.
 CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SOURCE: Alexandria Journal of Pharmaceutical Sciences (1990), 4(1), 52-6
 DOCUMENT TYPE: CODEN: AJPS6; ISSN: 1110-1792
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:122242
 GI




AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methanimino, ethenyl, imidomethyl, aminomethyl or methinehydrazino grouping. Thus, acetantranil (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.

IT 132111-60-5P
 RL: BA (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antiinflammatory activity of)
 RN 132111-60-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[(2-chlorophenyl)-2-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino]methyl]- (9CI) (CA INDEX NAME)



IT 132088-57-4P 132088-58-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)


L4 ANSWER 55 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of)
 RN 132088-57-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino]methyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 132088-58-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-bromophenyl)-2-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 56 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 1990:216839 CAPLUS
 DOCUMENT NUMBER: 112:216839
 TITLE: 2,3-Disubstituted quinazolinones and their antiparkinsonian activity
 AUTHOR(S): Naithani, Pankaj K.; Palit, Gautam; Srivastava, V. K.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Therapeut., King George's Med. Coll., Lucknow, 226 003, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1989), 28B(9), 745-50
 DOCUMENT TYPE: CODEN: IJSBD8; ISSN: 0376-4699
 LANGUAGE: Journal
 English
 OTHER SOURCE(S): CASREACT 112:216839
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
 AB Fifteen title compds., e.g. I and II, were prepared from arylmethyliquinazolinones, e.g., III. Of the compds. prepared, I showed the greatest antiparkinsonian activity with no toxicity.
 IT 126946-15-4P 126946-40-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiparkinson activity of)
 RN 126946-15-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1,2-bis[(4-chlorophenyl)amino]-2-(4-hydroxy-3-methoxyphenyl)ethyl]-6,8-dibromo-3-[4-(4-chlorophenyl)amino]-1-oxopropyl]phenyl]- (9CI) (CA INDEX NAME)




RN 126946-40-5 CAPLUS
 CN 4(3H)-Quinazolinone, 6,8-dibromo-3-[4-(4-chlorophenyl)amino]-1-oxopropyl]phenyl]-2-[2-(4-hydroxy-3-methoxyphenyl)-1,2-bis[(4-methoxyphenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 117664-22-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-iodo-3-(2-methylphenyl)-2-[(2-(2-(4-methylphenyl)-1H-indol-3-yl)-4-oxo-3-thiazolidinylamino)methyl] - (9CI) (CA INDEX NAME)




RN 117664-23-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[(4-oxo-2-(2-phenyl-1H-indol-3-yl)-3-thiazolidinylamino)methyl] - (9CI) (CA INDEX NAME)




RN 117664-24-1 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-(2-methylphenyl)-2-[(2-[2-(4-methylphenyl)-1H-indol-3-yl]-4-oxo-3-thiazolidinylamino)methyl] - (9CI) (CA INDEX NAME)



RN 117664-25-2 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methylphenyl)-2-[(4-oxo-2-(2-phenyl-1H-indol-3-yl)-3-thiazolidinylamino)methyl] - (9CI) (CA INDEX NAME)




RN 117664-26-3 CAPLUS
CN 4(3H)-Quinazolinone, 6,8-dibromo-3-(2-methylphenyl)-2-[(2-[2-(4-methylphenyl)-1H-indol-3-yl]-4-oxo-3-thiazolidinylamino)methyl] - (9CI) (CA INDEX NAME)



TITLE: Synthesis and pharmacological evaluation of N1-[p-[(3-aryl-4-oxoquinazolin-2-yl)methyl]amino]-N4-aryltiosemicarbazides and 2-(arylamino)-5-[p-[(3-aryl-4-oxoquinazolin-2-yl)methyl]amino]phenyl]-1,3,4-thiadiazoles/oxadiazoles as oral hypoglycemic agents

AUTHOR(S): Husain, M. I.; Jamali, Mohd Raghib
CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226 007, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1988), 27B(1), 43-6


DOCUMENT TYPE: CODEN: IJSCBD; ISSN: 0376-4699
LANGUAGE: Journal
OTHER SOURCE(S): English
G1




AB Thiosemicarbazides I (R1 = Me, OMe, O2N; R2 = H, Me, OMe, Cl, Br) were treated with concentrated H2SO4 at room temperature to give thiadiazoles II (Z = S). II (Z = O) were obtained by treatment of I with HgO in MeOH at reflux. A number of II exhibited hypoglycemic activity.

IT 116270-54-3P 116270-55-4P 116270-56-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and addition reaction of, with aryl isothiocyanates)


RN 116270-54-3 CAPLUS
CN Benzoic acid, 4-((3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino-, hydrazide (9CI) (CA INDEX NAME)



RN 116270-55-4 CAPLUS
CN Benzoic acid, 4-((3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl)amino-, hydrazide (9CI) (CA INDEX NAME)




RN 116270-58-5 CAPLUS
CN Benzoic acid, 4-((3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl)methyl)amino-, hydrazide (9CI) (CA INDEX NAME)




IT 116270-57-6P 116270-58-8P 116270-59-8P
116270-60-1P 116270-61-2P 116270-62-3P
116270-63-4P 116270-64-5P 116270-65-6P
116270-66-7P 116270-67-8P 116270-68-9P
116285-50-8P 116285-51-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization reactions of, thiadiazole and oxadiazole derivatives)

IT 116270-57-6 CAPLUS
CN Benzoic acid, 4-((3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl)methyl)amino-, 2-(phenylamino)thiokomethylhydrazide (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 116270-58-7 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)



RN 116270-59-8 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methylphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116270-60-1 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methylphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116270-61-2 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methoxyphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 116270-66-7 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-chlorophenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)



RN 116270-67-8 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-bromophenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116270-68-9 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-bromophenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116285-50-8 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-62-3 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methoxyphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)



RN 116270-63-4 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methoxyphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116270-64-5 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-chlorophenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)




RN 116270-65-6 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-chlorophenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116285-51-9 CAPLUS
 CN Benzoic acid, 4-[[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino-, 2-[(4-methylphenyl)amino]thioxomethyl hydrazide (9CI) (CA INDEX NAME)



IT 116270-69-0 P 116270-70-3P 116270-71-4P
 116270-72-5P 116270-73-6P 116270-74-7P
 116270-75-8P 116270-76-9P 116270-77-0P
 116270-78-1P 116270-79-2P 116270-80-5P
 116270-81-6P 116270-82-7P 116270-83-8P
 116270-84-9P 116270-85-0P 116270-86-1P
 116270-87-2P 116270-88-3P 116270-89-4P
 116270-90-7P 116270-91-8P 116270-92-9P
 116270-93-0P 116270-94-1P 116270-95-2P
 116285-52-0P


RN SPN (Synthetic preparation): PREP (Preparation)
 (Preparation cf., as hypoglycemic)

RN 116270-69-0 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[4-(5-(phenylamino)-1,3,4-thiadiazol-2-yl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)




RN 116270-70-3 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[4-(5-(phenylamino)-1,3,4-thiadiazol-2-yl)phenyl]amino]methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-71-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-nitrophenyl)-2-[(4-[5-(phenylamino)-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl - (9CI) (CA INDEX NAME)




RN 116270-72-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[(4-[5-(4-methylphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl - (9CI) (CA INDEX NAME)




RN 116270-73-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-[5-(4-methylphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl - (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116270-74-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-methylphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(4-nitrophenyl) - (9CI) (CA INDEX NAME)




RN 116270-75-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-methoxyphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(2-methylphenyl) - (9CI) (CA INDEX NAME)




L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 116270-76-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[(4-[5-(4-methoxyphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl - (9CI) (CA INDEX NAME)




RN 116270-77-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-methoxyphenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(4-nitrophenyl) - (9CI) (CA INDEX NAME)




RN 116270-78-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-chlorophenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(2-methylphenyl) - (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 116270-79-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-chlorophenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(4-methoxyphenyl) - (9CI) (CA INDEX NAME)




RN 116270-80-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-chlorophenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(4-nitrophenyl) - (9CI) (CA INDEX NAME)




RN 116270-81-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(4-[5-(4-bromophenyl)amino]-1,3,4-thiadiazol-2-yl]phenyl)amino]methyl-3-(2-methylphenyl) - (9CI) (CA INDEX NAME)




RN 116270-82-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-(4-bromophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116270-83-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-84-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-85-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-nitrophenyl)-2-[[[4-[5-(phenylamino)-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-86-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-(2-methylphenyl)-2-[[[4-[5-(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-87-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 116270-88-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-89-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 116270-90-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[[[4-[5-(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 116270-91-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-(4-chlorophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 116270-92-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[4-[5-(4-chlorophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino]methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116270-93-0 CAPLUS


08/08/2006

Habte

L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 2-[[4-[5-(4-chlorophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 116270-94-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-[5-(4-bromophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 116270-95-2 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-[5-(4-bromophenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino)methyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 116285-52-0 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[[4-[5-(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl]phenyl]amino)methyl]-3-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 59 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:575980 CAPLUS
 DOCUMENT NUMBER: 107:175980
 TITLE: Synthesis of some quinazolones
 AUTHOR(S): Srivastava, Vijai K.; Singh, I. P.; Singh, Shradha; Gupta, M. B.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Ther., King George's Med. Coll., Lucknow, 226 003, India
 SOURCE: Indian Journal of Pharmaceutical Sciences (1986), 48(5), 133-6
 CODEN: IJSPD; ISSN: 0250-474X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 107:175980
 GI




AB 4(3H)-Quinazolinones I (n = 1, 2; R1 = R2 = disubstituted amino, or R1 = Br and R2 = alkoxy; R3 = OMe, NMe₂; R4 = Br, Iodo; R5 = H, Br) were prepared, and they showed antiparkinsonian and anticonvulsant activity. Methylquinazolinones underwent a condensation reaction with the resp. 4-R₃C₆H₄CHO, and the products were converted to I.

IT 110818-25-2

R1: SPN (Synthetic preparation); PREP (Preparation) (preparation and antiparkinsonian activity of)


RN 110818-25-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1,2-bis(diphenylamino)-2-(4-methoxyphenyl)ethyl]-6,8-dibromo-3-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:207516 CAPLUS
 DOCUMENT NUMBER: 106:207516
 TITLE: Synthesis and anticonvulsant activity of some new 4(3H)-quinazolone derivatives
 AUTHOR(S): El-Nasser Ossman, Abdel Rahman; El-Sayed Barakat, Sabea
 CORPORATE SOURCE: Fac. Pharm., Al-Azhar Univ., Cairo, Egypt
 SOURCE: Archiv für Pharmazie und Chemie, Scientific Edition (1986), 14(2), 37-43
 CODEN: AVPCCS; ISSN: 0302-248X
 DOCUMENT TYPE: Journal
 LANGUAGE: English

GI



AB Some new 2,3-disubstituted-4(3H)-quinazolones (I, X and Y = H or Br, and R = H, Br, Cl or NO₂) as potential anticonvulsants were prepared by the N-bromosuccinimide bromination of 2-methyl-3-phenyl-4(3H)-quinazolones followed by the reaction of the resulting bromomethyl derivs. (II) with sulfonamide [63-74-1].

IT 108282-55-9P 108282-56-0P 108282-57-1P


108282-58-2P 108282-59-3P 108282-60-6P

108282-61-7P

R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses) (preparation and anticonvulsant activity of)


RN 108282-55-9 CAPLUS

CN Benzenesulfonamide, 4-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)methyl]amino)- (9CI) (CA INDEX NAME)




RN 108282-56-0 CAPLUS
 CN Benzenesulfonamide, 4-[(3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]amino)- (9CI) (CA INDEX NAME)


L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 108282-57-1 CAPLUS
CN Benzenesulfonamide, 4-[[[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 108282-58-2 CAPLUS
CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-nitrophenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 108282-59-3 CAPLUS
CN Benzenesulfonamide, 4-[[[6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 108282-60-6 CAPLUS
CN Benzenesulfonamide, 4-[[[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 108282-61-7 CAPLUS
CN Benzenesulfonamide, 4-[[[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 61 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:472082 CAPLUS

DOCUMENT NUMBER: 105:72082

TITLE: Thiadiazolyl quinazolones as potential CNS active agents

AUTHOR(S): Pandey, V. K.; Lohani, H. C.; Agarwal, Akhilesh K.

CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, 226007, India


SOURCE: Biological Memoirs (1985), 11(2), 197-200

CODEN: BMEMDK ISSN: 0379-8097

DOCUMENT TYPE: Journal


LANGUAGE: English

G1



L4 ANSWER 61 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 4(3H)-Quinazolinone, 2-[[[2-methoxyphenyl]amino]methyl]-3-[5-[(2-methoxyphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



AB Ten thiadiazolyl quinazolones (I; R = Ph, PhCH=CH etc.; R1 = (Me)2N, (Et2)N, morpholino, etc.) were evaluated for their central nervous system activities in mice. Some compds. had central stimulant activity. Compds. containing styryl groups at position 2 of the quinazolone nucleus showed central depressant activities. The compds. were nontoxic and their approx. LD50 values ranged from 316 mg/kg to <1000 mg/kg, i.p.

IT 74796-95-5 103537-64-0
R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
central nervous system response to)

RN 74796-95-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[[2-methylphenyl]amino]methyl]-3-[5-[(2-methylphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 103537-64-0 CAPLUS

Habte

08/08/2006

L4 ANSWER 62 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1983:405584 CAPIUS
 DOCUMENT NUMBER: 99:5584
 TITLE: Synthesis and biological activities of certain derivatives of 3-aryl-4(3H)-quinazolinones. Part I
 AUTHOR(S): Shankar, C; Ravi, Rao, A; Devendar, Reddy, B.
 CORPORATE SOURCE: Univ. Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009, India
 SOURCE: Journal of the Indian Chemical Society (1983), 60(1), 61-3
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 99:5584
 GI



AB Nine different 3-aryl-2-(N¹,N²-substituted aminomethyl)-4(3H)-quinazolinones have been synthesized by condensing 3-aryl-2-chloromethyl-4(3H)-quinazolinones with different secondary bases. Similarly, seven different 3-aryl-2-(N⁴-arylsulfonamidomethyl)-4(3H)-quinazolinones, e.g. I, have been obtained on reacting 3-aryl-2-chloromethyl-4(3H)-quinazolinones with various aryl sulfonamides. The antibacterial and antifungal activities of the compds. have been determined and the structure-activity relationships is discussed.


IT 86109-99-1P 86110-00-1P 86110-01-2P

86110-02-3P 86110-03-4P 86110-04-5P

RL: SPM (Synthetic preparation); PREP (Preparation)
 (preparation, bactericidal, and fungicidal activity of)

RN 86109-99-1 CAPIUS


CN Benzenesulfonamide, 4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)- (9CI) (CA INDEX NAME)




RN 86110-00-1 CAPIUS

CN Benzenesulfonamide, 4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-


L4 ANSWER 62 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 quinazolinyl)methyl)amino)-N-(2,6-dimethoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 86110-01-2 CAPIUS
 CN Benzenesulfonamide, 4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)-N-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 86110-02-3 CAPIUS
 CN Benzenesulfonamide, 4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 86110-03-4 CAPIUS
 CN Acetamide, N-[(4-((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)phenyl]sulfonyl- (9CI) (CA INDEX NAME)




RN 86110-04-5 CAPIUS

L4 ANSWER 62 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)-N-(2,6-dimethyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 86110-05-6 CAPIUS

CN Benzenesulfonamide, N-(aminoiminomethyl)-4-(((3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1982:533440 CAPIUS
 DOCUMENT NUMBER: 97:133440
 TITLE: Physicochemical properties and stabilities of afloquelone (HQ-495)
 AUTHOR(S): Shimizu, Reiji; Nakamura, Kouji; Yaku, Kouji;
 Shimaoka, Yukio; Matsuo, Masaaki
 CORPORATE SOURCE: Anal. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd.,
 Osaka, S32, Japan
 SOURCE: Iyakuhin Kenkyu (1982), 13(3), 688-701
 DOCUMENT TYPE: CODEN: IYKEOH; ISSN: 0287-0894
 LANGUAGE: Journal
 GI



AB The solubility, stability, partition coefficient, powder x-ray diffraction pattern,

UV, IR, NMR and mass spectra, etc. of HQ-495 (I) [56287-74-2] were determined.

I in solid state was stable to heat and moisture in the shade, but unstable to light. Decomposition of I by light was examined, the decomposition could

be avoided by keeping the material in an amber container. In aqueous solution, I

was unstable to light and heat. Impurities derived from synthetic process and decomposed products were determined by high-performance liquid chromatog. and

TLC. Formation pathways of the decomposition products were proposed from the chromatog. results .

IT 83038-91-9


RL: ANT (Analyte); ANST (Analytical study)
 (chromatog. of afloquelone stability in relation to)

RN 83038-91-9 CAPIUS

CN Benzamide, 5-(((6-amino-3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl)methyl)amino)-2-((fluoroacetyl)amino)-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 63 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN

(Continued)



L4 ANSWER 64 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:514437 CAPIUS

DOCUMENT NUMBER: 93:114437

TITLE:

Synthesis of possible antiparkinsonian compounds:

Part I. Synthesis of 2-aryl/alkyl-3-(2-aminomethyl-

1,3,4-thiadiazol-5-yl)quinazol-4(3H)-ones

AUTHOR(S): Pandey, V. K.; Lohani, H. C.

CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, India

SOURCE: Journal of the Indian Chemical Society (1979), 56(9), 915-16


CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 93:114437

G1



AB The thiadiazolylquinazoline I ($R = Ph$, $PhCH_2CH_3$, $\alpha\text{-MeC}_6\text{H}_4\text{NHCH}_2$, $p\text{-MeOC}_6\text{H}_4\text{NHCH}_2$; $R_1 = R_2 = Et$, Ph ; $R_1 = \alpha\text{-MeC}_6\text{H}_4$, $p\text{-MeOC}_6\text{H}_4$, $R_2 = H$, R_1R_2N = morpholine, piperazine) were prepared by reaction of the benzoxazines II ($R_3 = Me$, Ph , $PhCH_2CH_3$) with 2-amino-5-methyl-1,3,4-thiadiazole followed by bromination and reaction with amines.

IT 74796-95-5P 74796-96-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of)

RN 74796-95-5 CAPIUS

CN 4(3H)-Quinazolinone, 2-[(2-methylphenyl)amino]methyl-3-[5-[(2-methylphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 64 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 74796-96-6 CAPIUS

CN 4(3H)-Quinazolinone, 2-[(4-methoxyphenyl)amino]methyl-3-[5-[(4-methoxyphenyl)amino]methyl]-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 65 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:446577 CAPIUS

DOCUMENT NUMBER: 93:46577

TITLE: Synthesis of some quinazolone derivatives structurally related to certain sedatives, hypnotics and anticonvulsant agents

AUTHOR(S): El-Ashry, A. K.; Botros, S.; Khalifa, M.


CORPORATE SOURCE: Fac. Pharm., Univ. Cairo, Cairo, Egypt

SOURCE: Pharmazie (1979), 34(11), 753-4

DOCUMENT TYPE: Journal

LANGUAGE: English

G1



AB Quinazolones I ($R = Br$, Me , OEt ; $R_1 = 4\text{-OMe}$, $3,4\text{-OMe}_2$, 4-NMe_2 , 4-OH , 2-OH , H) were obtained in 50-69% yield by treating 2-methyl-3-arylquinazolines with benzaldehydes. II ($R_2 = NH_2$, NHC_6H_4Me-4 , NHC_6H_4Cl-4 , NHC_6H_4Br-4 , NHC_6H_4Cl-4 , succinimido, phthalimido, saccharino) were obtained in 65-80% yield by aminating II ($R_2 = Br$).

IT 72235-16-6P 72235-19-9P 74116-00-0P


IT 74116-01-1P 74116-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 72235-16-6 CAPIUS

CN 4(3H)-Quinazolinone, 3-phenyl-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 72235-19-9 CAPIUS


CN 4(3H)-Quinazolinone, 2-[(2-methylphenyl)amino]methyl-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 65 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 74116-00-0 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(4-methylphenyl)amino]methyl-3-phenyl- (9CI)
 (CA INDEX NAME)




RN 74116-01-1 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(4-bromophenyl)amino]methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 74116-02-2 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(4-chlorophenyl)amino]methyl-3-phenyl- (9CI)
 (CA INDEX NAME)



L4 ANSWER 66 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1980-22449 CAPIUS
 DOCUMENT NUMBER: 92-22449
 TITLE: Some reactions of nitrogen nucleophiles with 2-(bromomethyl)-3-phenyl-4(3H)-quinazolinone
 AUTHOR(S): Kirmani, M. Z.; Ahmed, Msc., S. R.
 CORPORATE SOURCE: Dep. Chem., Indian Inst. Technol., New Delhi, 110029, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1979), 18B(1), 22-4
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 92-22449
 GI




AB Treating quinazolinone I ($R = CH_2Br$), which does not undergo ring expansion, with pyridine, quinoline, or Et₃N gave the corresponding quaternary bromides, whereas using primary and secondary amines gave I [$R = CH_2R'$] ($R' = NH_2, NHCH_2CO_2Me-4, cyclohexylamino, piperidino, morpholino, NHCO_2Me-4, NHCO_2Me-2$). Also prepared were I ($R = CH:NOR, CH:NHPh$).
 IT 72235-16-6P 72235-17-7P 72235-18-8P
 72235-19-9P 72235-20-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 72235-16-6 CAPIUS
 CN 4(3H)-Quinazolinone, 3-phenyl-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 72235-17-7 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(4-methoxyphenyl)amino]methyl-3-phenyl- (9CI)
 (CA INDEX NAME)


L4 ANSWER 66 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)




RN 72235-18-8 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(4-ethoxyphenyl)amino]methyl-3-phenyl- (9CI)
 (CA INDEX NAME)



RN 72235-19-9 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(2-methylphenyl)amino]methyl-3-phenyl- (9CI)
 (CA INDEX NAME)




RN 72235-20-2 CAPIUS
 CN 4(3H)-Quinazolinone, 2-[(cyclohexylamino)methyl]-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 67 OF 72 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1976-523860 CAPIUS
 DOCUMENT NUMBER: 85-123860
 TITLE: Studies of 4-quinazolones. VII. Synthesis and properties of 2-[β -(acrylamido)propionyl]-3-phenyl-4-quinazolones
 AUTHOR(S): Kochnevnikov, Yu. V.
 CORPORATE SOURCE: USSR
 SOURCE: Nauch. Tr. Perm. Farmatsavt. In-t (1975), (8), 37-40
 Proc: Ref. Zh., Khim. 1976, Abstr. No. 112h313
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 85-123860


AB Title only translated.
 IT 55557-79-1P 55557-80-7P 55557-81-8P
 55557-82-9P 55557-84-1P 55557-85-2P
 55557-86-3P 55557-87-4P 55557-88-5P
 55557-90-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55557-79-4 CAPIUS
 CN 2-Quinazolinepropanamide, 3,4-dihydro-4-oxo-3-diphenyl- (9CI) (CA INDEX NAME)




RN 55557-80-7 CAPIUS
 CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(2-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-81-8 CAPIUS
 CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(3-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-82-9 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-84-1 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-85-2 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-86-3 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-87-4 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-88-5 CAPLUS
CN 2-Quinazolinepropanamide, N-cyclohexyl-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-90-9 CAPLUS
CN 2-Quinazolinepropanamide, N-(2-methoxyphenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:140064 CAPLUS
DOCUMENT NUMBER: 82:140064
TITLE: 4(3H)-quinolinone. 7. Synthesis and properties of 3-phenyl-4(3H)-quinolinone-2-arylamides of β-propionic acid
AUTHOR(S): Kozhevnikov, Yu. V.
CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR
SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1974), 17(12), 1877-8
CODEN: IVUKAR; ISSN: 0579-2991
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI: For diagram(s), see printed CA issue.
AB: The quinazolinepropanamides I (R = Ph, MeCH₂, PhCH₂, ClCH₂, BrCH₂, MeOCCH₂, Et₂NCH₂CH₃, cyclohexyl) were prepared by reaction of RN(MgX)₂ (X = halo) with the quinazolinepropanonide II and subsequent hydrolysis.
IT: 55557-79-4P 55557-80-7P 55557-81-8P
55557-82-9P 55557-84-1P 55557-85-2P
55557-86-3P 55557-87-4P 55557-88-5P
55557-90-9P
RL: SPN (synthetic preparation); PREP (Preparation)
(preparation of)
RN: 55557-79-4 CAPLUS
CN: 2-Quinazolinepropanamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)




RN 55557-80-7 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(2-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-81-8 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(3-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-82-9 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methylphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 55557-84-1 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(2-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-85-2 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-chlorophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-86-3 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(2-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 55557-87-4 CAPLUS
CN 2-Quinazolinepropanamide, N-(4-bromophenyl)-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 55557-88-5 CAPLUS
CN 2-Quinazolinepropanamide, 3,4-dihydro-N-(4-methoxyphenyl)-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 55557-90-9 CAPLUS
CN 2-Quinazolinepropanamide, N-cyclohexyl-3,4-dihydro-4-oxo-3-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 69 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:515526 CAPLUS
DOCUMENT NUMBER: 79:115526
TITLE: Vilsmeier-Haack reaction. V. Reaction of 2-methyl-4-quinazolone derivatives and a new synthesis of pyrazolo[5,1-b]quinazolones
AUTHOR(S): Pandit, R. S.; Seshadri, S.
CORPORATE SOURCE: Dep. Chem. Technol., Univ. Bombay, Bombay, India
SOURCE: Indian Journal of Chemistry (1973), 11(6), 532-7
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English

GI For diagram(s), see printed CA Issue.
AB 2-Methyl-3-phenyl-4-quinazolone underwent diformylation by the Vilsmeier reagent to give the dialdehyde I. I with RONHNH₂, R₂NNH₂, PhNNHNH₂ gave the related 3-phenyl-4-quinazolone derivs. with different heterocyclic systems in the 2-position. On treatment with polyphosphoric acid, I cyclized to give 12-oxoquino[2,1-b]quinazoline-6-carboxaldehyde (II). Vilsmeier-Haack reaction of 2-methyl-3-amino-4-quinazolone gave 3-formylpyrazolo[5,1-b]quinazolone (III). Various derivs. of III were prepared to investigate the fluorescence properties. Vilsmeier-Haack reaction on 2-methyl-3-acylamido-4-quinazolone also gave III with the loss of acyl residues. 2-Methyl-3-anilino-4-quinazolone reacts with the Vilsmeier reagent to give 1-phenylpyrazolo[5,1-b]quinazolone.


IT 49552-40-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 49552-40-1 CAPLUS
CN 2-Quinazolineacetaldehyde, 3,4-dihydro-4-oxo-3-phenyl-a-[(phenylamino)methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:76386 CAPLUS
DOCUMENT NUMBER: 74:76386
TITLE: Heterocyclic chemistry. LI. Reaction of ethoxacylalanthranil with amines
AUTHOR(S): Petyunin, F. A.; Chernykh, V. P.; Petyunin, G. P.; Kozhevnikov, Yu. V.
CORPORATE SOURCE: Khar'k. Farm. Inst., Kharkov, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), 11(1), 1575-8
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The title compound (I, Z = O) reacted with 28 aromatic amines (RNH₂) in DMF, yielding the corresponding I (Z = NR). The latter underwent amidation with NH₃, N₂H₄, and RICGH₄NH₂ (R₁ = H, 3-, 4-Br, 3-Me, 4-MeO), and saponification in the usual manner.
IT 30689-31-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30689-31-7 CAPLUS
CN 2-Quinazolinecarboxamide, 3,4-dihydro-4-oxo-N,3-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 71 OF 72 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:427405 CAPLUS
DOCUMENT NUMBER: 69:27405
TITLE: Drugs acting on the central nervous system. Syntheses of substituted quinazolinones and quinazolines and triazepino- and triazocinoquinazolinones
AUTHOR(S): Gupta, C. M.; Bhaduri, A. P.; Khanna, N. M.
CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, India
SOURCE: Journal of Medicinal Chemistry (1968), 11(2), 392-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 2,3-Disubstituted 4-quinazolinones, 2,4-disubstituted quinazolines, and 5H-2,3-disubstituted triazepino[1,4,5] [2,1-b]-quinazolin-11-ones (I) (R = 2-furyl, Ph, Me, and p-MeOC₆H₄) are prepared and tested for toxicity and anticonvulsant activity in mice. Of the 48 compds. prepared and tested, only 2-ethylthio-4-quinazolone and 2,4-bis[(dibenzylamino)quinazoline gave protection against maximum electroshock, 3 other compds. showed slight activity, and the remainder were inactive.
IT 19062-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19062-62-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(6-methyl-2-pyridyl)amino]methyl-3-phenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 72 OF 72 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1939:4026 CAPLUS
 DOCUMENT NUMBER: 33:4026
 ORIGINAL REFERENCE NO.: 33:624b-d
 TITLE: Attempts to synthesize methylenediquinazoline derivatives
 AUTHOR(S): Kassur, A.; Weil, S.
 SOURCE: Roczniki Chemii (1938), 18, 163-9 (in French) 168-9
 CODEN: ROCHAC; ISSN: 0035-7677
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB The authors tried to obtain a few derivs. of methylenediquinazoline by fusing anthranilic acid with aromatic amides of malonic acid, but they did not succeed. By fusion of the diamide or monophenylamide of malonic acid with anthranilic acid, $\text{CH}_2(\text{CONHPh})_2$ was obtained. From $p\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ and anthranilic acid, $\text{CH}_2(\text{CONHC}_6\text{H}_4\text{OMe})_2$ is formed. Condensation of $\text{o}\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ with anthranilic acid gives the derivative of monoketoquinazoline. Condensations of antifebrin and phenacetin with anthranilic acid by the aid of POCl_3 give the derivs. of monoketoquinazoline. By condensation of BzH with $\text{CH}_2(\text{CONHPh})_2$ the product containing 2 mols. of BzH and one of dianilide was obtained. $\text{o}\text{-HOCH}_2\text{C}_6\text{H}_4\text{CHO}$ condensed with $p\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ and with $p\text{-MeOC}_6\text{H}_4\text{NHCOCH}_2\text{CO}_2\text{Et}$ yields derivs. of coumarin.
 IT 858277-01-7, 2-Quinazolineaceto-o-toluide, 3-(o-carboxyphenyl)-3,4-dihydro-4-oxo-
 dihydro-4-oxo-
 (preparation of)
 RN 858277-01-7 CAPLUS
 CN 2-Quinazolineaceto-o-toluide, 3-(o-carboxyphenyl)-3,4-dihydro-4-oxo- (4CI)
 (CA INDEX NAME)

